

CITATION REPORT

List of articles citing

Angiogenesis in cancer and other diseases

DOI: 10.1038/35025220
Nature, 2000, 407, 249-57.

Source: <https://exaly.com/paper-pdf/31439082/citation-report.pdf>

Version: 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2284	Complementary Video.		
2283	Endoscopic Doppler optical coherence tomography and autofluorescence imaging of peripheral pulmonary nodules and vasculature. 2015 , 6, 4191		
2282	Endoscopic Doppler optical coherence tomography and autofluorescence imaging of peripheral pulmonary nodules and vasculature. 2015 , 6, 4191		
2281	In vivo volumetric imaging of subcutaneous microvasculature by photoacoustic microscopy. 2006 , 14, 9317		
2280	Inspiratory contrast for in vivo optical imaging. 2008 , 16, 19		
2279	Inspiratory contrast for in vivo optical imaging. 2008 , 16, 19		
2278	In vivo volumetric imaging of subcutaneous microvasculature by photoacoustic microscopy. 2006 , 14, 9317		
2277	Mechanics in Tumor Growth. 2007 , 263-321		15
2276	Surface-negative, slow-potential shift associated with conditioning in man. 1966 , 16, 771-771		134
2275	The effects of nitrous oxide on vascular endothelial growth factor (VEGF) and its soluble receptor 1 (VEGFR1) in patient undergoing urological surgery. 2014 , 30, 45-9		1
2274	Monoclonal IgM kappa antibody precipitating with chondroitin sulfate C from patients with axonal polyneuropathy and epidermolysis. 1983 , 33, 192-201		97
2273	Activation of Akt-mTOR-p70S6K pathway in angiogenesis in hepatocellular carcinoma. 1994 , 20, 713		4
2272	Developmental biology. One cell, two fates. <i>Nature</i> , 2000 , 408, 43, 45	50.4	53
2271	Nanotechnology. Flipping a molecular switch. <i>Nature</i> , 2000 , 408, 45-6	50.4	23
2270	Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood. 2000 , 97, 14608-13		528
2269	Clinical practice in the new era. A fusion of molecular biology and classical medicine is transforming the way we look at and treat diseases. 2001 , 2, 80-2		10
2268	The hemostatic system and angiogenesis in malignancy. 2001 , 3, 371-84		91

2267	Predominant role of endothelial nitric oxide synthase in vascular endothelial growth factor-induced angiogenesis and vascular permeability. 2001 , 98, 2604-9	789
2266	Sphingolipid mediators in cardiovascular cell biology and pathology. 2001 , 89, 957-68	143
2265	Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. 2001 , 17, 615-75	933
2264	Prospects for Antiangiogenic Therapies Based upon VEGF Inhibition. 2001 , 282-298	2
2263	Hypoxia promotes apoptosis of human neuroblastoma cell lines with enhanced N-myc expression. 2001 , 281, 272-6	16
2262	Heterotypic signaling between epithelial tumor cells and fibroblasts in carcinoma formation. 2001 , 264, 169-84	447
2261	Kinetics of placenta growth factor/vascular endothelial growth factor synergy in endothelial hydraulic conductivity and proliferation. 2001 , 61, 203-10	21
2260	Concurrent induction of lymphangiogenesis, angiogenesis, and macrophage recruitment by vascular endothelial growth factor-C in melanoma. 2001 , 159, 893-903	329
2259	Glomeruloid microvascular proliferation orchestrated by VPF/VEGF: a new world of angiogenesis research. 2001 , 158, 789-96	109
2258	Cell type specific expression of vascular endothelial growth factor and angiopoietin-1 and -2 suggests an important role of astrocytes in cerebellar vascularization. 2001 , 108, 45-57	103
2257	Inhibition of tumor angiogenesis by non-steroidal anti-inflammatory drugs: emerging mechanisms and therapeutic perspectives. 2001 , 4, 314-21	41
2256	Total synthesis and biological evaluation of the nakijiquinones. 2001 , 123, 11586-93	105
2255	Modeling pO(2) distributions in the bone marrow hematopoietic compartment. I. Krogh's model. 2001 , 81, 675-84	199
2254	[The mechanisms of angiogenesis. Medical and therapeutic applications]. 2001 , 22, 1064-82	8
2253	Antiangiogenic and antivasular therapy for cancer. 2001 , 1, 378-84	54
2252	Angiogenesis in dermatology. 2001 , 13, 183-192	
2251	Antiangiogenesis therapy. Current and future agents. 2001 , 15, 835-51, viii	18
2250	Protein kinase C inhibitors as novel anticancer drugs. 2001 , 10, 2117-40	149

2249	Liver organogenesis promoted by endothelial cells prior to vascular function. 2001 , 294, 559-63	706
2248	Plasmin-dependent and -independent effects of plasminogen activators and inhibitor-1 on ex vivo angiogenesis. 2001 , 281, H1784-92	49
2247	Tubes, Branches, and Pillars. 2001 , 89, 645-647	67
2246	Tissue Factor IIA Receptor Involved in the Control of Cellular Properties, Including Angiogenesis. 2001 , 86, 334-345	92
2245	Bioimmunotherapeutic targets on angiogenetic blood vessels in solid malignancies. 2001 , 6, D776-84	4
2244	Regulation of hypoxia-induced angiogenesis: a chaperone escorts VEGF to the dance. 2001 , 108, 39-40	120
2243	Angiopoietin-1, angiopoietin-2 and Tie-2 in tumour and non-tumour tissues during growth of experimental melanoma. 2001 , 11, 639-43	18
2242	Biotechnology Update. 2001 , 41, 771-773	
2241	Angiogenesis and antiangiogenic approaches to sarcomas. 2001 , 13, 261-9	29
2240	Dynamic contrast-enhanced magnetic resonance imaging in oncology. 2001 , 12, 301-8	125
2239	Combined genomic and antisense analysis reveals that the transcription factor Erg is implicated in endothelial cell differentiation. 2001 , 98, 3332-9	83
2238	Angiogenesis. 2001 , 66-73	12
2237	Matrix metalloproteinases as targets for therapy in Kaposi sarcoma. 2001 , 13, 368-73	14
2236	Evidence of increased endothelial cell turnover in brain arteriovenous malformations. 2001 , 49, 124-31; discussion 131-2	71
2235	Evidence of Increased Endothelial Cell Turnover in Brain Arteriovenous Malformations. 2001 , 49, 124-132	69
2234	The Emerging Role of the Bone Marrow-Derived Stem Cells in (Therapeutic) Angiogenesis. 2001 , 86, 289-297	88
2233	Measurement of physiological parameters in tumors in vivo using MPLSM. 2001 ,	2
2232	Angiogenesis in hematologic malignancies. 2001 , 80, 695-705	47

2231	Mechanistic insights on the inhibition of tumor angiogenesis. 2001 , 78, 663-72	49
2230	Vinblastine and hyperthermia target the neovasculature in BT(4)AN rat gliomas: therapeutic implications of the vascular phenotype. 2001 , 51, 535-44	20
2229	Evidence of a leading role for VEGF in Bartonella henselae-induced endothelial cell proliferations. 2001 , 3, 623-32	135
2228	Vascular endothelial growth factor expression correlates with tumour grade and vascularity in gliomas. 2001 , 39, 409-15	150
2227	Synthesis and biological evaluation of novel bisindolylmaleimides that inhibit vascular endothelial cell proliferation. 2001 , 11, 2701-3	9
2226	Decreased mRNA stability as a mechanism of glucocorticoid-mediated inhibition of vascular endothelial growth factor gene expression by cultured keratinocytes. 2001 , 117, 1581-7	39
2225	Lymphatic function, lymphangiogenesis, and cancer metastasis. 2001 , 55, 92-9	134
2224	Lymphangiogenesis and lymphangiodysplasia: from molecular to clinical lymphology. 2001 , 55, 122-45	165
2223	Mathematical modeling of capillary formation and development in tumor angiogenesis: penetration into the stroma. 2001 , 63, 801-63	185
2222	Structural and biophysical simulation of angiogenesis and vascular remodeling. 2001 , 220, 387-401	71
2221	Multiple angiogenesis stimulators in a single malignancy: implications for anti-angiogenic tumour therapy. 2001 , 4, 259-62	36
2220	CM101 stimulates cutaneous wound healing through an anti-angiogenic mechanism. 2001 , 4, 61-70	15
2219	Cancer and thrombosis revisited. 2001 , 15, 61-7	32
2218	The helical domain of GBP-1 mediates the inhibition of endothelial cell proliferation by inflammatory cytokines. 2001 , 20, 5568-77	144
2217	Pancreas microenvironment promotes VEGF expression and tumor growth: novel window models for pancreatic tumor angiogenesis and microcirculation. 2001 , 81, 1439-51	99
2216	RGD peptides and monoclonal antibodies, antagonists of alpha(v)-integrin, enter the cells by independent endocytic pathways. 2001 , 81, 1615-26	82
2215	Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. 2001 , 7, 192-8	1383
2214	The well-tempered vessel. 2001 , 7, 532-4	95

2213	Inhaled CO: deadly gas or novel therapeutic?. 2001 , 7, 534-5	27
2212	Hypoxia and Lou Gehrig. 2001 , 28, 107-8	19
2211	Clearing the smoke on nicotine and angiogenesis. 2001 , 7, 775-7	29
2210	Nicotine stimulates angiogenesis and promotes tumor growth and atherosclerosis. 2001 , 7, 833-9	622
2209	In vivo measurement of gene expression, angiogenesis and physiological function in tumors using multiphoton laser scanning microscopy. 2001 , 7, 864-8	528
2208	NSAIDs inhibit alpha V beta 3 integrin-mediated and Cdc42/Rac-dependent endothelial-cell spreading, migration and angiogenesis. 2001 , 7, 1041-7	250
2207	Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. 2001 , 7, 987-9	1686
2206	Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. 2001 , 7, 1194-201	1633
2205	Cell surface display of a lysosomal enzyme for extracellular gene-directed enzyme prodrug therapy. 2001 , 8, 1005-10	32
2204	The angiogenic factor midkine is aberrantly expressed in NF1-deficient Schwann cells and is a mitogen for neurofibroma-derived cells. 2001 , 20, 97-105	106
2203	The microenvironment of the tumour-host interface. <i>Nature</i> , 2001 , 411, 375-9	50.4 1949
2202	Cardiovascular biology. Creating unique blood vessels. <i>Nature</i> , 2001 , 412, 868-9	50.4 28
2201	Quantum engineering. Protecting the quantum world. <i>Nature</i> , 2001 , 412, 869-70	50.4 4
2200	Delivery of molecular medicine to solid tumors: lessons from in vivo imaging of gene expression and function. 2001 , 74, 7-25	234
2199	Regulation and action of angiogenic factors in the primate ovary. 2001 , 32, 567-75	131
2198	The many faces of metalloproteases: cell growth, invasion, angiogenesis and metastasis. 2001 , 11, S37-43	406
2197	Hypoxia: the tumor's gateway to progression along the angiogenic pathway. 2001 , 11, S32-6	62
2196	Hypoxia: the tumor's gateway to progression along the angiogenic pathway. 2001 , 11, S32-S36	79

2195	The many faces of metalloproteases: cell growth, invasion, angiogenesis and metastasis. 2001 , 11, S37-S43	356
2194	Clinical efforts to modulate angiogenesis in the adult: gene therapy versus conventional approaches. 2001 , 6, 689-697	14
2193	Targeting the extracellular matrix to stop tumour progression. 2001 , 6, 1077-1078	1
2192	Angiomorphology of the pigmented Bomirski melanoma growing in hamster eye. 2001 , 183, 559-65	8
2191	Common origins of blood and blood vessels in adults?. 2001 , 68, 186-92	27
2190	Gene therapy for antiangiogenesis. 2001 , 93, 965-7	17
2189	Immunogene therapy of tumors with vaccine based on Xenopus homologous vascular endothelial growth factor as a model antigen. 2001 , 98, 11545-50	110
2188	Can mosaic tumor vessels facilitate molecular diagnosis of cancer?. 2001 , 98, 398-400	86
2187	In fibroblasts Vegf-D expression is induced by cell-cell contact mediated by cadherin-11. 2001 , 276, 6576-81	64
2186	Update on tumor cell procoagulant factors. 2001 , 106, 25-32	88
2185	Vascular endothelial growth factor induction of the angiogenic phenotype requires Ras activation. 2001 , 276, 49289-98	204
2184	The sequential activation and repression of the human PDGF-B gene during chronic hypoxia reveals antagonistic roles for the depletion of oxygen and glucose. 2001 , 19, 233-45	23
2183	Fibroblast growth factor-2 antagonist activity and angiostatic capacity of sulfated Escherichia coli K5 polysaccharide derivatives. 2001 , 276, 37900-8	64
2182	Plasminogen activator inhibitor-1 regulates tumor growth and angiogenesis. 2001 , 276, 33964-8	196
2181	Potent anti-metastatic activity of combretastatin-A4. 2001 , 19, 821-5	3
2180	Selective growth inhibition by sangivamycin of human umbilical vein endothelial cells. 2001 , 18, 1009-15	1
2179	Regulation of angiogenesis and matrix remodeling by localized, matrix-mediated antisense gene delivery. 2001 , 3, 842-9	55
2178	Perinatal lethality and endothelial cell abnormalities in several vessel compartments of fibulin-1-deficient mice. 2001 , 21, 7025-34	140

2177	Kinase insert domain receptor (KDR) extracellular immunoglobulin-like domains 4-7 contain structural features that block receptor dimerization and vascular endothelial growth factor-induced signaling. 2001 , 276, 21916-23	37
2176	Can engineered bacteria help control cancer?. 2001 , 98, 14748-50	79
2175	Molecular characterization of the mouse Tem1/endosialin gene regulated by cell density in vitro and expressed in normal tissues in vivo. 2001 , 276, 38795-807	50
2174	Induction of hypervascularity without leakage or inflammation in transgenic mice overexpressing hypoxia-inducible factor-1alpha. 2001 , 15, 2520-32	245
2173	Targeting tissue factor on tumor vascular endothelial cells and tumor cells for immunotherapy in mouse models of prostatic cancer. 2001 , 98, 12180-5	96
2172	Potential of gene therapy for brain tumors. 2001 , 10, 777-87	54
2171	Decorin-mediated signal transduction in endothelial cells. Involvement of Akt/protein kinase B in up-regulation of p21(WAF1/CIP1) but not p27(KIP1). 2001 , 276, 40687-92	90
2170	Biomedicine. Clotting factors build blood vessels. 2001 , 293, 1602-4	69
2169	Lymphatic vessels as targets of tumor therapy?. 2001 , 194, F37-42	103
2168	Harmonic interplay of angiogenic growth factors in the development of coronary blood vessels. 2001 , 88, 1099-101	6
2167	Membrane type 1-matrix metalloproteinase is activated during migration of human endothelial cells and modulates endothelial motility and matrix remodeling. 2001 , 276, 37491-500	185
2166	Overexpression of p27(Kip1) by doxycycline-regulated adenoviral vectors inhibits endothelial cell proliferation and migration and impairs angiogenesis. 2001 , 15, 1877-85	81
2165	Luteal angiogenesis: prevention and intervention by treatment with vascular endothelial growth factor trap(A40). 2001 , 86, 3377-86	115
2164	Angiogenesis in acute and chronic leukemias. 2001 , 42, 847-53	18
2163	Isolation and characterization of dermal lymphatic and blood endothelial cells reveal stable and functionally specialized cell lineages. 2001 , 194, 797-808	415
2162	Statins have biphasic effects on angiogenesis. 2002 , 105, 739-45	543
2161	The molecular control of angiogenesis. 2002 , 21, 33-49	48
2160	Vascular endothelial growth factor monoclonal antibody inhibits growth of anaplastic thyroid cancer xenografts in nude mice. 2002 , 12, 953-61	62

2159	Properties of a "phase transition" induced by antiangiogenetic therapeutical protocols. 2002 , 66, 031903	7
2158	The role of angiogenesis in hematologic malignancies. 2002 , 11, 49-68	7
2157	Lung Cancer. 2002 ,	
2156	Significance of vascular endothelial cell growth factor up-regulation mediated via a chymase-angiotensin-dependent pathway during angiogenesis in hamster sponge granulomas. 2002 , 302, 949-56	31
2155	Expression of vascular endothelial growth factor receptors 1, 2, and 3 in quiescent endothelia. 2002 , 50, 767-77	122
2154	Acidic extracellular pH induces vascular endothelial growth factor (VEGF) in human glioblastoma cells via ERK1/2 MAPK signaling pathway: mechanism of low pH-induced VEGF. 2002 , 277, 11368-74	225
2153	p38 Signaling-mediated hypoxia-inducible factor 1alpha and vascular endothelial growth factor induction by Cr(VI) in DU145 human prostate carcinoma cells. 2002 , 277, 45041-8	98
2152	Roles of prolactin and related members of the prolactin/growth hormone/placental lactogen family in angiogenesis. 2002 , 173, 219-38	216
2151	Mechanisms of normal and tumor-derived angiogenesis. 2002 , 282, C947-70	551
2150	The Arf tumor suppressor gene promotes hyaloid vascular regression during mouse eye development. 2002 , 99, 3848-53	102
2149	Incipient angiogenesis in Barrett's epithelium and lymphangiogenesis in Barrett's adenocarcinoma. 2002 , 20, 2971-9	97
2148	Antiproliferative effects of 1alpha,25-dihydroxyvitamin D(3) and vitamin D analogs on tumor-derived endothelial cells. 2002 , 143, 2508-14	138
2147	The antitumoral effect of endostatin and angiostatin is associated with a down-regulation of vascular endothelial growth factor expression in tumor cells. 2002 , 16, 1802-4	131
2146	Endoglin expression is regulated by transcriptional cooperation between the hypoxia and transforming growth factor-beta pathways. 2002 , 277, 43799-808	254
2145	VEGF increases engraftment of bone marrow-derived endothelial progenitor cells (EPCs) into vasculature of newborn murine recipients. 2002 , 99, 11951-6	103
2144	Prostaglandin E2 promotes integrin alpha Vbeta 3-dependent endothelial cell adhesion, rac-activation, and spreading through cAMP/PKA-dependent signaling. 2002 , 277, 45838-46	112
2143	DNAzymes to beta 1 and beta 3 mRNA down-regulate expression of the targeted integrins and inhibit endothelial cell capillary tube formation in fibrin and matrigel. 2002 , 277, 6779-87	39
2142	Activation of vascular endothelial growth factor A transcription in tumorigenic glioblastoma cell lines by an enhancer with cell type-specific DNase I accessibility. 2002 , 277, 20087-94	23

2141	The rediscovery of the lymphatic system: old and new insights into the development and biological function of the lymphatic vasculature. 2002 , 16, 773-83	272
2140	A model for co-expression pattern analysis of genes implicated in angiogenesis and tumour cell invasion in cervical cancer. 2002 , 87, 537-44	66
2139	Fibroblast growth factors and their receptors in hematopoiesis and hematological tumors. 2002 , 11, 19-32	48
2138	Stabilization of breast cancer xenograft tumour neovasculature by angiopoietin-1. 2002 , 86, 645-51	58
2137	Arterio-venous gradients of IL-6, plasma and serum VEGF and D-dimers in human cancer. 2002 , 87, 1437-44	41
2136	Fibroblast-dependent differentiation of human microvascular endothelial cells into capillary-like 3-dimensional networks. 2002 , 16, 1316-8	115
2135	Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling. 2002 , 94, 819-25	425
2134	Molecular approaches to sarcoma therapy. 2002 , 6, 27-42	7
2133	Angiopoietin-1 negatively regulates expression and activity of tissue factor in endothelial cells. 2002 , 16, 126-8	85
2132	Dephosphorylation of endothelial nitric oxide synthase contributes to the anti-angiogenic effects of endostatin. 2002 , 16, 706-8	118
2131	A small-molecule inhibitor of the ribonucleolytic activity of human angiogenin that possesses antitumor activity. 2002 , 99, 10066-71	92
2130	Peptide blockade of HIFalpha degradation modulates cellular metabolism and angiogenesis. 2002 , 99, 10423-8	97
2129	Pulsatile flow-induced angiogenesis: role of G(i) subunits. 2002 , 22, 1610-6	47
2128	Analysis of coagulation cascade and endothelial cell activation during inhibition of vascular endothelial growth factor/vascular endothelial growth factor receptor pathway in cancer patients. 2002 , 22, 1500-5	128
2127	Etk/Bmx as a tumor necrosis factor receptor type 2-specific kinase: role in endothelial cell migration and angiogenesis. 2002 , 22, 7512-23	121
2126	Morphological characteristics of the microvasculature in healing myocardial infarcts. 2002 , 50, 71-9	137
2125	Microarray technology and gene expression analysis for the study of angiogenesis. 2002 , 2, 545-56	9
2124	Computer-assisted image analysis of neovascularization in thyroid neoplasms from dogs. 2002 , 63, 363-9	26

2123	Endogenous expression of interleukin-8 and interleukin-10 in nasopharyngeal carcinoma cells and the effect of photodynamic therapy. 2002 , 10, 73	1
2122	Suppression of the renin-angiotensin system attenuates vascular endothelial growth factor-mediated tumor development and angiogenesis in murine hepatocellular carcinoma cells. 2002 , 20, 1227	8
2121	Pyk2/CAKbeta tyrosine kinase activity-mediated angiogenesis of pulmonary vascular endothelial cells. 2002 , 277, 5441-7	35
2120	CHS 828 inhibits neuroblastoma growth in mice alone and in combination with antiangiogenic drugs. 2002 , 51, 607-11	22
2119	Tumor vascularity: evaluation in a murine model with contrast-enhanced color Doppler US effect of angiogenesis inhibitors. 2002 , 222, 460-7	54
2118	Variable sensitivity of endothelial cells to epirubicin in xenografts of human nasopharyngeal carcinoma CNE-2 cells. 2002 , 1, 263-5	6
2117	Defective pulmonary development in the absence of heparin-binding vascular endothelial growth factor isoforms. 2002 , 27, 194-203	142
2116	Differential role of bFGF and VEGF for vasculogenesis. 2002 , 12, 55-62	31
2115	[Angiogenesis, lymphangiogenesis, and tumor progression]. 2002 , 124, 497-505	4
2114	Inhibitors of angiogenesis selectively reduce the malignant cell load in rodent models of human myeloid leukemias. 2002 , 16, 376-81	42
2113	Therapies directed at vascular endothelial growth factor. 2002 , 11, 1715-36	80
2112	Development of vasculature targeting strategies for the treatment of cancer and chronic inflammatory diseases. 2002 , 8, 133-65	12
2111	Hematopoietic, vascular and cardiac fates of bone marrow-derived stem cells. 2002 , 9, 648-52	90
2110	Modellbildung und Simulation von Gefäßwachstum, Stoffverteilung und Tumorangiogenese (Modelling and Simulation of Vascular Growth, Substance Distributions and Tumorangiogenesis). 2002 , 50, 237	
2109	Expression of cell adhesion molecules, CD44s and E-cadherin, and microvessel density in carcinoid tumors. 2002 , 15, 1333-8	17
2108	Intratumoral lymphatic vessels: a case of mistaken identity or malfunction?. 2002 , 94, 417-21	104
2107	Chalkley Estimates of Angiogenesis in Early Breast Cancer - Relevance to Prognosis. 2002 , 41, 695-703	16
2106	The formation of lymphatic vessels and its importance in the setting of malignancy. 2002 , 196, 713-8	56

2105	Thrombospondin 1 protein expression relates to good prognostic indices in ductal carcinoma in situ of the breast. 2002 , 55, 921-5	24
2104	Tissue and serum angiogenic activity is associated with low prevalence of ischemic complications in patients with giant-cell arteritis. 2002 , 106, 1664-71	80
2103	Biologic Correlates of 18Fluorodeoxyglucose Uptake in Human Breast Cancer Measured by Positron Emission Tomography. 2002 , 20, 379-387	251
2102	Suppression of tumor angiogenesis through the inhibition of integrin function and signaling in endothelial cells: which side to target?. 2002 , 9, 151-60	50
2101	A novel mechanism of repression of the vascular endothelial growth factor promoter, by single strand DNA binding cold shock domain (Y-box) proteins in normoxic fibroblasts. 2002 , 30, 4845-54	24
2100	Connective tissue growth factor increased by hypoxia may initiate angiogenesis in collaboration with matrix metalloproteinases. 2002 , 23, 769-76	143
2099	Vascular growth factors and lymphangiogenesis. 2002 , 82, 673-700	322
2098	Antiangiogenesis in neurofibromatosis 1. 2002 , 17, 578-84; discussion 602-4, 646-51	12
2097	TGF- β gene shows no link with Alzheimer's. 2002 , 55, 925-925	
2096	Dose-Finding and Pharmacokinetic Study of Cisplatin, Gemcitabine, and SU5416 in Patients With Solid Tumors. 2002 , 20, 1657-1667	116
2095	Analysis of mural cell recruitment to tumor vessels. 2002 , 105, 112-7	153
2094	The presence of a single tyrosine residue at the carboxyl domain of vascular endothelial growth factor receptor-2/FLK-1 regulates its autophosphorylation and activation of signaling molecules. 2002 , 277, 27081-7	41
2093	Adaptor protein Crk is required for ephrin-B1-induced membrane ruffling and focal complex assembly of human aortic endothelial cells. 2002 , 13, 4231-42	86
2092	Transcription factor Sp1 phosphorylation induced by shear stress inhibits membrane type 1-matrix metalloproteinase expression in endothelium. 2002 , 277, 34808-14	72
2091	Three-dimensional cytoarchitecture of angiogenic blood vessels in a gelatin sheet implanted in the rat skeletal muscular layers. 2002 , 65, 347-57	10
2090	Primary brain tumours in adults. 2002 , 1431-1447	3
2089	Liver regeneration is an angiogenesis- associated phenomenon. 2002 , 236, 703-11; discussion 711-2	109
2088	Immunotherapy of tumors with vaccines based on xenogeneic homologous molecules. 2002 , 13, 229-35	16

2087	Endothelial response to hypoxia: physiologic adaptation and pathologic dysfunction. 2002 , 8, 242-50	116
2086	Immunohistochemical expression of basic fibroblast growth factor, vascular endothelial growth factor, and their receptors in stage IV non-Hodgkin lymphoma. 2002 , 10, 316-21	19
2085	A straightforward algorithm for the quantification of power Doppler signals. 2002 , 37, 343-8	7
2084	Genetic and biologic progression in astrocytomas and their relation to angiogenic dysregulation. 2002 , 9, 24-36	73
2083	Perindopril: possible use in cancer therapy. 2002 , 13, 221-8	27
2082	Endostatin inhibits adhesion of endothelial cells to collagen I via alpha(2)beta(1) integrin, a possible cause of prevention of chondrosarcoma growth. 2002 , 131, 619-26	32
2081	. 2002 , 10, 316-321	12
2080	Regulation of endothelial cell branching morphogenesis by endogenous chemokine stromal-derived factor-1. 2002 , 99, 2703-11	299
2079	Kallistatin is a new inhibitor of angiogenesis and tumor growth. 2002 , 100, 3245-52	145
2078	Tumor suppression induced by intratumor administration of adenovirus vector expressing NK4, a 4-kringle antagonist of hepatocyte growth factor, and naive dendritic cells. 2002 , 100, 3950-9	24
2077	Angiogenesis in epithelial ovarian cancer. 2002 , 55, 348-59	116
2076	Gut cancers differentiate without CDX2. 2002 , 55, 359-359	4
2075	Myoblast-mediated gene transfer for therapeutic angiogenesis. 2002 , 346, 145-57	23
2074	Oncogenes and growth factors. 2002 , 6, 51-84	
2073	15 Role of fibroblastic stroma in colon carcinoma. 2002 , 2, 255-265	
2072	Collateral arteries grow from preexisting anastomoses in the rat hindlimb. 2002 , 283, H2012-20	62
2071	Phosphatidylinositol 3-kinase but not tuberlin is required for PDGF-induced cell migration. 2002 , 282, L854-62	34
2070	Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via rapamycin (mTOR)-dependent signaling. 2002 , 16, 771-80	327

2069	Hypoxia-induced vascular endothelial growth factor expression causes vascular leakage in the brain. 2002 , 125, 2549-57	312
2068	Reduced tumor growth, experimental metastasis formation, and angiogenesis in rats with a hyperreactive dopaminergic system. 2002 , 16, 1465-7	73
2067	Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe preeclampsia and hemolysis, elevated liver enzymes, and low platelets syndrome. 2002 , 160, 1405-23	495
2066	Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis. 2002 , 161, 947-56	628
2065	Angiogenesis and vascular architecture in pheochromocytomas: distinctive traits in malignant tumors. 2002 , 161, 1235-46	112
2064	Generation of a syngeneic mouse model to study the effects of vascular endothelial growth factor in ovarian carcinoma. 2002 , 161, 2295-309	111
2063	Shedding of the matrix metalloproteinases MMP-2, MMP-9, and MT1-MMP as membrane vesicle-associated components by endothelial cells. 2002 , 160, 673-80	433
2062	Inhibition of proliferative retinopathy by the anti-vascular agent combretastatin-A4. 2002 , 160, 1097-103	48
2061	Optical imaging of cancer metastasis to bone marrow: a mouse model of minimal residual disease. 2002 , 160, 1143-53	195
2060	Identification of endothelial cell genes expressed in an in vitro model of angiogenesis: induction of ESM-1, (beta)ig-h3, and NrCAM. 2002 , 63, 159-71	123
2059	A technique for quantitative three-dimensional analysis of microvascular structure. 2002 , 63, 279-94	86
2058	Comparative analysis of in vitro angiogenic activities of endothelial cells of heterogeneous origin. 2002 , 63, 316-26	14
2057	Different effects of glucose starvation on expression and stability of VEGF mRNA isoforms in murine ovarian cancer cells. 2002 , 292, 860-8	61
2056	Atorvastatin decreases vascular endothelial growth factor in patients with coronary artery disease. 2002 , 39, 1951-5	50
2055	Motuporamines, anti-invasion and anti-angiogenic alkaloids from the marine sponge <i>Xestospongia exigua</i> (Kirkpatrick): isolation, structure elucidation, analogue synthesis, and conformational analysis. 2002 , 67, 245-58	54
2054	HSP90 as a new therapeutic target for cancer therapy: the story unfolds. 2002 , 2, 3-24	437
2053	Inhibition of vascularization in tumor growth. 2002 , 89, 218101	36
2052	Angiotensin-I-converting enzyme inhibitors may be an alternative anti-angiogenic strategy in the treatment of liver fibrosis and hepatocellular carcinoma. Possible role of vascular endothelial growth factor. 2002 , 23, 348-56	90

2051	Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers. 2002 , 4, R11	192
2050	Thalidomide in cancer treatment: a potential role in the elderly?. 2002 , 19, 85-100	15
2049	Ligand-targeted liposomes directed against pathological vasculature. 2002 , 12, 129-35	14
2048	Effects of vitamin D(3)-binding protein-derived macrophage activating factor (GcMAF) on angiogenesis. 2002 , 94, 1311-9	50
2047	Intussusceptive angiogenesis--the alternative to capillary sprouting. 2002 , 23, S1-27	178
2046	A novel gene IC53 stimulates ECV304 cell proliferation and is upregulated in failing heart. 2002 , 294, 161-6	19
2045	The X-ray crystallographic structure of the angiogenesis inhibitor angiostatin. 2002 , 318, 1009-17	32
2044	Parathyroid hormone-related peptide is a naturally occurring, protein kinase A-dependent angiogenesis inhibitor. 2002 , 8, 995-1003	87
2043	Looking to the Future: Advances in the Management of Hormone-Refractory Prostate Cancer. 2002 , 1, 44-53	7
2042	CRIM1 is involved in endothelial cell capillary formation in vitro and is expressed in blood vessels in vivo. 2002 , 119, 165-75	34
2041	Upregulation of vascular endothelial growth factor receptors is associated with advanced neuroblastoma. 2002 , 37, 582-7	40
2040	Developments in medical oncology and their implications for interventional radiology. 2002 , 5, 177-81	3
2039	Biomedical technology revolution: opportunities and challenges for oral and maxillofacial surgeons. 2002 , 31, 1-12	20
2038	Can simvastatin promote tumor growth by inducing angiogenesis similar to VEGF?. 2002 , 58, 85-6	11
2037	The expression of vascular endothelial growth factor in synovial tissues in patients with internal derangement of the temporomandibular joint. 2002 , 93, 251-6	19
2036	Co-expression of endothelin-1 and vascular endothelial growth factor mediates increased vascular permeability in lung grafts before reperfusion. 2002 , 21, 600-3	26
2035	Cardiovascular tissue engineering. 2002 , 11, 305-17	132
2034	Interplays between genetic and environmental mechanisms trigger tumorigenic VEGF signalling in human HCC cell lines: pilot study. 2002 , 56, 50-5	1

2033	Melanoma-stroma interactions: structural and functional aspects. 2002 , 3, 35-43	190
2032	The seed and soil hypothesis: vascularisation and brain metastases. 2002 , 3, 53-7	344
2031	Telomerase inhibition and the future management of head-and-neck cancer. 2002 , 3, 280-8	30
2030	Placenta growth factor-1 antagonizes VEGF-induced angiogenesis and tumor growth by the formation of functionally inactive PlGF-1/VEGF heterodimers. 2002 , 1, 99-108	162
2029	Do plant and human pathogens have a common pathogenicity strategy?. 2002 , 10, 269-75	36
2028	Update on The Big C: complexity and cross-talk between pathways. 2002 , 12, 11-13	
2027	Advancing animal models of neoplasia through in vivo bioluminescence imaging. 2002 , 38, 2128-36	193
2026	The role of new agents in the treatment of non-small cell lung cancer. 2002 , 38, 2347-61	26
2025	Expression of cysteine peptidase cathepsin L and its inhibitors stefins A and B in relation to tumorigenicity of breast cancer cell lines. 2002 , 187, 185-90	40
2024	Cancer gene therapy: scientific basis. 2002 , 53, 437-52	56
2023	Angiogenesis as a target for cancer therapy. 2002 , 16, 1125-71	20
2022	[Effects of statins on angiogenesis and vasculogenesis]. 2002 , 55, 838-44	18
2021	Angiogenesis in Health and Disease: Insights into Basic Mechanisms and Therapeutic Opportunities. 2002 , 66, 962-975	55
2020	Energy imbalance and prostate cancer. 2002 , 132, 3471S-3481S	44
2019	Thrombospondin 2 inhibits microvascular endothelial cell proliferation by a caspase-independent mechanism. 2002 , 13, 1893-905	93
2018	A Mathematical Model of an In Vitro Experiment to Investigate Endothelial Cell Migration. 2002 , 4, 251-270	5
2017	In vivo release of vascular endothelial growth factor from colorectal carcinomas. 2002 , 62, 313-7	15
2016	Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. 2002 , 20, 379-87	431

2015	Angiopoietin-2 and rat brain capillary remodeling during adaptation and deadaptation to prolonged mild hypoxia. 2002 , 93, 1131-9	107
2014	SCID mouse models to study human cancer pathogenesis and approaches to therapy: potential, limitations, and future directions. 2002 , 7, c44	10
2013	Clinical experience with angiogenesis signaling inhibitors: focus on vascular endothelial growth factor (VEGF) blockers. 2002 , 9, 36-44	206
2012	Involvement of human PECAM-1 in angiogenesis and in vitro endothelial cell migration. 2002 , 282, C1181-90	151
2011	Noninvasive Dynamic Fluorescence Imaging of Human Melanomas Reveals that Targeted Inhibition of bFGF or FGFR-1 in Melanoma Cells Blocks Tumor Growth by Apoptosis. 2002 , 8, 103-112	43
2010	Microarray Gene Expression Analysis of Murine Tumor Heterogeneity Defined by Dynamic Contrast-Enhanced MRI. 2002 , 1, 153535002002021	
2009	Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors. 2002 , 20, 1657-67	216
2008	Tumor angiogenesis and accessibility: Role of vascular endothelial growth factor. 2002 , 29, 3-9	12
2007	Role of angiogenesis in tumor growth and metastasis. 2002 , 29, 15-18	146
2006	Protein kinases as targets for anticancer agents: from inhibitors to useful drugs. 2002 , 93, 79-98	253
2005	Vascular disorder in Alzheimer's disease: role in pathogenesis of dementia and therapeutic targets. 2002 , 54, 1553-9	47
2004	[Cellular mechanism of vasculo-protection induced by polyphenols on the endothelium]. 2002 , 51, 304-15	10
2003	Dissection of angiogenic signaling in zebrafish using a chemical genetic approach. 2002 , 1, 257-67	167
2002	Three-dimensional angioarchitecture in transplantable rat fibrosarcomas. 2002 , 126, 66-70	2
2001	Structure and function of placental growth factor. 2002 , 12, 241-6	91
2000	Recent advances in cancer research: mouse models of tumorigenesis. 2002 , 1602, 97-113	22
1999	Temperature and angiogenesis: the possible role of mechanical factors in capillary growth. 2002 , 132, 773-87	23
1998	Angiogenesis in bladder cancer--prognostic marker and target for future therapy. 2002 , 11, 85-100	44

1997	Naturstoffanaloge als Tyrosinkinaseinhibitoren: Identifikation von IGF1R-, Tie-2- und VEGFR-3-Inhibitoren. 2002 , 114, 1222-1226	12
1996	Natural product derived receptor tyrosine kinase inhibitors: identification of IGF1R, Tie-2, and VEGFR-3 inhibitors. 2002 , 41, 1174-8	67
1995	Festphasensynthese von 2-Aminothiazolen unter Verwendung des spurlosen Hydrazid-Ankers: Rezeptortyrosinkinase-Inhibitoren mit dualer Selektivität für Tie-2 und VEGFR-2. 2002 , 114, 4951-4955	5
1994	Parametric imaging of tumor perfusion using flow- and permeability-limited tracers. 2002 , 16, 289-99	36
1993	Hypoxia-induced pathways in breast cancer. 2002 , 59, 41-8	53
1992	Traceless solid-phase synthesis of 2-aminothiazoles: receptor tyrosine kinase inhibitors with dual selectivity for Tie-2 and VEGFR-2. 2002 , 41, 4757-61	23
1991	Molecular basis of endothelial cell morphogenesis in three-dimensional extracellular matrices. 2002 , 268, 252-75	207
1990	Cancer spread and micrometastasis development: quantitative approaches for in vivo models. 2002 , 24, 885-93	146
1989	Tumor therapy. 2002 , 15, 87-8	5
1988	Osteopontin induces angiogenesis of murine neuroblastoma cells in mice. 2002 , 98, 707-12	74
1987	alpha v-Integrin antagonist EMD 121974 induces apoptosis in brain tumor cells growing on vitronectin and tenascin. 2002 , 98, 690-7	162
1986	Inhibition of prostate carcinoma establishment and metastatic growth in mice by an antiangiogenic monoclonal antibody. 2002 , 98, 923-9	57
1985	Flavopiridol inhibits vascular endothelial growth factor production induced by hypoxia or picolinic acid in human neuroblastoma. 2002 , 99, 658-64	39
1984	Multifunctional anti-angiogenic activity of the cyclic peroxide ANO-2 with antitumor activity. 2002 , 100, 220-7	7
1983	Human chondrosarcoma secretes vascular endothelial growth factor to induce tumor angiogenesis and stores basic fibroblast growth factor for regulation of its own growth. 2002 , 97, 313-22	47
1982	Thymidine phosphorylase and vascular endothelial growth factor in patients with Stage I lung adenocarcinoma. 2002 , 94, 1083-93	34
1981	Molecular imaging of tumor angiogenesis. 2002 , 39, 72-8	61
1980	Goniodomin A, an antifungal polyether macrolide, exhibits antiangiogenic activities via inhibition of actin reorganization in endothelial cells. 2002 , 190, 109-16	40

1979	Temporal Cre-mediated recombination exclusively in endothelial cells using Tie2 regulatory elements. 2002 , 33, 191-7	93
1978	Angiogenesis in hematologic malignancies and its clinical implications. 2002 , 75, 246-56	14
1977	Effect of sulfated beta-cyclodextrin, a water soluble cycloamylose, on the promotion and/or inhibition of angiogenesis. 2002 , 8, 47-53	4
1976	Microvascular angiogenesis and the renin-angiotensin system. 2002 , 4, 56-62	36
1975	Angiogenesis in ovarian cancer: molecular pathology and therapeutic strategies. 2002 , 4, 165-74	13
1974	[Angiogenesis--anti-angiogenesis. Significance for tumor growth and metastasis]. 2002 , 53, 373-84	4
1973	The Ets 1 transcription factor is upregulated during inflammatory angiogenesis in rheumatoid arthritis. 2002 , 80, 258-66	21
1972	Hypoxia-induced angiogenesis in human hepatocellular carcinoma. 2002 , 80, 703-14	80
1971	Elevated plasma levels of vascular endothelial growth factor and plasminogen activator inhibitor-1 decrease during improvement of psoriasis. 2002 , 51, 563-7	51
1970	VEGF concentrations in tumour arteries and veins from patients with rectal cancer. 2002 , 110, 646-50	13
1969	Synthesis and initial SAR studies of 3,6-disubstituted pyrazolo[1,5-a]pyrimidines: a new class of KDR kinase inhibitors. 2002 , 12, 2767-70	99
1968	Optimization of a pyrazolo[1,5-a]pyrimidine class of KDR kinase inhibitors: improvements in physical properties enhance cellular activity and pharmacokinetics. 2002 , 12, 3537-41	66
1967	Optical spectroscopy for detection of neoplasia. 2002 , 6, 651-8	138
1966	Dermatological aspects of angiogenesis. 2002 , 147, 841-52	38
1965	Potential role of endothelin 1 in ischaemia-induced angiogenesis in critical leg ischaemia. 2002 , 89, 741-7	12
1964	Enhanced antitumour efficacy by combining conventional chemotherapy with angiostatin or endostatin in a liver metastasis model. 2002 , 89, 1302-9	57
1963	Angiogenesis extent and expression of matrix metalloproteinase-2 and -9 agree with progression of ovarian endometriomas. 2002 , 32, 199-206	45
1962	Targeting molecular mechanisms in cancer. 2002 , 72, 760-3	1

1961	The glial precursor proteoglycan, NG2, is expressed on tumour neovasculature by vascular pericytes in human malignant brain tumours. 2002 , 28, 367-80	60
1960	Electrotransfer of gene encoding endostatin into normal and neoplastic mouse tissues: inhibition of primary tumor growth and metastatic spread. 2002 , 9, 771-7	42
1959	Single-chain antibody-based gene therapy: inhibition of tumor growth by in situ production of phage-derived human antibody fragments blocking functionally active sites of cell-associated matrices. 2002 , 9, 1049-53	48
1958	Transcriptional targeting of conditionally replicating adenovirus to dividing endothelial cells. 2002 , 9, 972-9	59
1957	Overexpression of vascular endothelial growth factor (VEGF) and its cellular receptor KDR (VEGFR-2) in the bone marrow of patients with acute myeloid leukemia. 2002 , 16, 1302-10	160
1956	The LIM-domain protein Lmo2 is a key regulator of tumour angiogenesis: a new anti-angiogenesis drug target. 2002 , 21, 1309-15	41
1955	Biological activity of substrate-bound basic fibroblast growth factor (FGF2): recruitment of FGF receptor-1 in endothelial cell adhesion contacts. 2002 , 21, 3889-97	56
1954	Microvessel morphology and vascular endothelial growth factor expression in human colonic carcinoma with or without metastasis. 2002 , 82, 555-62	31
1953	Integrin indecision. 2002 , 8, 14-6	62
1952	Enhanced pathological angiogenesis in mice lacking beta3 integrin or beta3 and beta5 integrins. 2002 , 8, 27-34	561
1951	Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. 2002 , 8, 128-35	1469
1950	HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma. 2002 , 8, 225-32	269
1949	VEGF receptor 1 stimulates stem-cell recruitment and new hope for angiogenesis therapies. 2002 , 8, 775-7	47
1948	Stabilization of atherosclerotic plaques: new mechanisms and clinical targets. 2002 , 8, 1257-62	461
1947	Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. 2002 , 8, 831-40	916
1946	Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1(+) stem cells from bone-marrow microenvironment. 2002 , 8, 841-9	553
1945	Specialization of tumour vasculature. 2002 , 2, 83-90	574
1944	Conditional mouse models of sporadic cancer. 2002 , 2, 251-65	242

1943	Dissecting tumour pathophysiology using intravital microscopy. 2002 , 2, 266-76	494
1942	Molecular imaging of cancer with positron emission tomography. 2002 , 2, 683-93	1288
1941	Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy?. 2002 , 2, 826-35	599
1940	Building drug delivery into tissue engineering. 2002 , 1, 177-86	261
1939	Angiogenesis modulation in cancer research: novel clinical approaches. 2002 , 1, 415-26	144
1938	uPAR: a versatile signalling orchestrator. 2002 , 3, 932-43	1025
1937	Anti-angiogenic effects of the thienopyridine SR 25989 in vitro and in vivo in a murine pulmonary metastasis model. 2002 , 86, 803-10	20
1936	Solid stress facilitates spheroid formation: potential involvement of hyaluronan. 2002 , 86, 947-53	61
1935	Inhibition of endothelial cell functions and of angiogenesis by the metastasis inhibitor NAMI-A. 2002 , 86, 993-8	111
1934	Dimethylarginine dimethylaminohydrolase I enhances tumour growth and angiogenesis. 2002 , 87, 673-80	80
1933	Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects. 2002 , 87, 1166-72	251
1932	Estrogens and the vascular endothelium. 2002 , 966, 143-57	106
1931	Placental growth factor (PlGF) and its receptor Flt-1 (VEGFR-1): novel therapeutic targets for angiogenic disorders. 2002 , 979, 80-93	174
1930	Lymphatic vessel activation in cancer. 2002 , 979, 120-30	41
1929	Molecular mechanisms of lymphangiogenesis in health and disease. 2002 , 1, 219-27	576
1928	[Tumor angiogenesis--value and significance in squamous epithelial carcinoma of the mouth cavity]. 2002 , 6, 217-30	
1927	A role for hypoxia and hypoxia-inducible transcription factors in tumor physiology. 2002 , 80, 562-75	73
1926	Molecular determinants of human uveal melanoma invasion and metastasis. 2002 , 19, 233-46	123

1925	Comparative study of tube assembly in three-dimensional collagen matrix and on Matrigel coats. 2002 , 5, 167-72	29
1924	A computer algorithm describing the process of vessel formation and maturation, and its use for predicting the effects of anti-angiogenic and anti-maturation therapy on vascular tumor growth. 2002 , 5, 203-14	85
1923	Anti-angiogenic therapy: rationale, challenges and clinical studies. 2002 , 5, 237-56	108
1922	Collagen type 1 retards tube formation by human microvascular endothelial cells in a fibrin matrix. 2002 , 5, 257-65	42
1921	Tie2 vascular endothelial receptor expression and function in hepatocellular carcinoma. 2002 , 35, 861-7	62
1920	Synergistic effect of basic fibroblast growth factor and vascular endothelial growth factor in murine hepatocellular carcinoma. 2002 , 35, 834-42	108
1919	Structure and function of collagen-derived endostatin inhibitors of angiogenesis. 2002 , 53, 77-84	34
1918	Chemokines: new, key players in the pathobiology of pancreatic cancer. 2002 , 31, 23-9	21
1917	Targeting tumor vasculature: reality or a dream?. 2002 , 10, 529-33	29
1916	Recent developments in antiangiogenic therapy. 2002 , 2, 953-66	11
1915	The vascular phenotype of melanoma metastasis. 2003 , 20, 229-35	18
1914	Role of homeobox genes in normal mammary gland development and breast tumorigenesis. 2003 , 8, 159-75	60
1913	17 beta -estradiol-mediated vessel assembly and stabilization in tumor angiogenesis requires TGF beta and EGFR crosstalk. 2003 , 6, 271-81	37
1912	The role of the fibrinolytic system in corneal angiogenesis. 2003 , 6, 311-6	13
1911	Abstracts of the Euroconference Angiogenesis II Institut Pasteur, Paris, France 19 20 June 2003. 2003 , 6, 331-360	
1910	A novel cell binding site in the coiled-coil domain of laminin involved in capillary morphogenesis. 2003 , 22, 1508-17	20
1909	Regulation of cell-cell interactions by phosphatidic acid phosphatase 2b/VCIP. 2003 , 22, 1539-54	55
1908	The guanylate binding protein-1 GTPase controls the invasive and angiogenic capability of endothelial cells through inhibition of MMP-1 expression. 2003 , 22, 3772-82	120

1907	Discussion: Metastasis and Angiogenesis in Epithelial Ovarian Cancer. 2003 , 88, S37-S42	6
1906	Angiogenesis and the role of epigenetics in metastasis. 2003 , 20, 215-27	18
1905	Formal synthesis of angiogenesis inhibitor NM-3. 2003 , 68, 5967-73	49
1904	Experimental microcomputed tomography study of the 3D microangioarchitecture of tumors. 2003 , 13, 1559-65	44
1903	Pleiotrophic actions of erythropoietin. 2003 , 7, 239-45	7
1902	Generation of non-permissive basement membranes by anti-laminin antibody fragments produced by matrix-embedded gene-modified cells. 2003 , 52, 643-7	13
1901	SU5416 sensitizes ovarian cancer cells to cisplatin through inhibition of nucleotide excision repair. 2003 , 60, 794-802	17
1900	Role of plasminogen activator-plasmin system in tumor angiogenesis. 2003 , 60, 463-73	95
1899	Angiogenesis factors in gliomas: a new key to tumour therapy?. 2003 , 90, 385-94	40
1898	Specific endothelial binding and tumor uptake of radiolabeled angiostatin. 2003 , 30, 1032-7	10
1897	The impact of anti-angiogenic agents on cancer therapy. 2003 , 129, 607-20	20
1896	Lymphangiogenesis and tumor metastasis. 2003 , 314, 167-77	158
1895	Role of hypoxia in tumor angiogenesis-molecular and cellular angiogenic crosstalk. 2003 , 314, 145-55	40
1894	Die Bedeutung antiangiogener Wirkstoffe ff die Krebstherapie. 2003 , 9, 1108-1120	
1893	Neuropeptide Y: a novel mechanism for ischemic angiogenesis. 2003 , 13, 86-92	72
1892	A peptide trivalent arsenical inhibits tumor angiogenesis by perturbing mitochondrial function in angiogenic endothelial cells. 2003 , 3, 497-509	135
1891	Physiological levels of tumstatin, a fragment of collagen IV alpha3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via alphaV beta3 integrin. 2003 , 3, 589-601	463
1890	Induction of tumor angiogenesis by Slit-Robo signaling and inhibition of cancer growth by blocking Robo activity. 2003 , 4, 19-29	331

1889	Effect of angiogenesis inhibition by Id loss and the contribution of bone-marrow-derived endothelial cells in spontaneous murine tumors. 2003 , 4, 277-89	224
1888	Stage-specific vascular markers revealed by phage display in a mouse model of pancreatic islet tumorigenesis. 2003 , 4, 393-403	208
1887	Progressive vascular changes in a transgenic mouse model of squamous cell carcinoma. 2003 , 4, 383-91	194
1886	Tumor vasculature address book: identification of stage-specific tumor vessel zip codes by phage display. 2003 , 4, 331-3	44
1885	Vascular endothelial growth factors and angiogenesis in eye disease. 2003 , 22, 1-29	711
1884	Adeno-associated viral vectors for retinal gene transfer. 2003 , 22, 705-19	37
1883	Simultaneous progression of oxidative stress and angiogenesis in malignant transformation of Barrett esophagus. 2003 , 126, 1952-7	34
1882	Delphinidin inhibits endothelial cell proliferation and cell cycle progression through a transient activation of ERK-1/-2. 2003 , 65, 669-75	82
1881	Effects of rhizoxin, a microbial angiogenesis inhibitor, on angiogenic endothelial cell functions. 2003 , 459, 131-8	12
1880	Different inhibitors of plasmin differentially affect angiostatin production and angiogenesis. 2003 , 460, 1-8	16
1879	Suppression of tumor growth by a new glycosaminoglycan isolated from the African giant snail <i>Achatina fulica</i> . 2003 , 465, 191-8	34
1878	The detection of stage I ovarian cancer by three-dimensional sonography and power Doppler. 2003 , 90, 258-64	48
1877	Anti-tumor efficacy of tumor vasculature-targeted liposomal doxorubicin. 2003 , 91, 115-22	274
1876	Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma. 2003 , 97, 1573-81	423
1875	Insights into the mechanisms of lymph node metastasis. 2003 , 98, 413-23	321
1874	Insulin-like growth factor binding protein-3 is overexpressed in endothelial cells of mouse breast tumor vessels. 2003 , 103, 577-86	25
1873	Dynamic T1-weighted monitoring of vascularization in human carcinoma heterotransplants by magnetic resonance imaging. 2003 , 104, 113-20	28
1872	A common 936 C/T gene polymorphism of vascular endothelial growth factor is associated with decreased breast cancer risk. 2003 , 106, 468-471	263

1871	Macrophage migration inhibitory factor: roles in regulating tumor cell migration and expression of angiogenic factors in hepatocellular carcinoma. 2003 , 107, 22-9	121
1870	Vascular endothelial growth factor expression correlates with matrix metalloproteinases MT1-MMP, MMP-2 and MMP-9 in human glioblastomas. 2003 , 106, 848-55	112
1869	Green tea catechins inhibit VEGF-induced angiogenesis in vitro through suppression of VE-cadherin phosphorylation and inactivation of Akt molecule. 2003 , 106, 871-8	106
1868	Stromal expression of invasion-promoting, matrix-degrading proteases MMP-1 and -9 and the Ets 1 transcription factor in HNPCC carcinomas and sporadic colorectal cancers. 2003 , 107, 183-8	48
1867	Functional imaging of angiogenesis in an orthotopic model of pancreatic cancer. 2003 , 90, 492-501	13
1866	Geldanamycin inhibits migration of glioma cells in vitro: a potential role for hypoxia-inducible factor (HIF-1alpha) in glioma cell invasion. 2003 , 196, 394-402	100
1865	Endothelial cell functions. 2003 , 196, 430-43	479
1864	Discovery and investigation of lead compounds as binders to the Extra-Domain B of the angiogenesis marker, fibronectin. 2003 , 58, 268-282	5
1863	Tumor vascular architecture and function evaluated by non-invasive susceptibility MRI methods and immunohistochemistry. 2003 , 17, 445-54	124
1862	High-resolution three-dimensional MR angiography of rodent tumors: morphologic characterization of intratumoral vasculature. 2003 , 18, 59-65	52
1861	Magnetic resonance image-guided proteomics of human glioblastoma multiforme. 2003 , 18, 530-6	108
1860	Endothelial cell-matrix interactions. 2003 , 60, 13-22	82
1859	Inhibition of angiogenesis at endothelial cell level. 2003 , 60, 85-97	11
1858	Physiological and pathological angiogenesis in the endocrine system. 2003 , 60, 98-106	31
1857	Lymphangiogenesis in tumors: what do we know?. 2003 , 60, 171-80	45
1856	Tumor angiogenesis of non-small cell lung cancer. 2003 , 60, 186-98	37
1855	Differences in vasculature between pilocytic and anaplastic astrocytomas of childhood. 2003 , 41, 516-26	22
1854	Multistep solid-phase synthesis of an antibiotic and receptor tyrosine kinase inhibitors using the traceless phenylhydrazide linker. 2003 , 9, 3282-91	17

1853	VEGF modulates early heart valve formation. 2003 , 271, 202-8	53
1852	Cyclo-oxygenase 2 inhibition in colorectal cancer therapy. 2003 , 90, 1055-67	40
1851	Signaling in morphogenesis: transport cues in morphogenesis. 2003 , 14, 547-50	32
1850	Natural mechanisms protecting against cancer. 2003 , 90, 103-22	142
1849	Chemotherapeutic engineering: Application and further development of chemical engineering principles for chemotherapy of cancer and other diseases. 2003 , 58, 4087-4114	278
1848	Bone marrow immunohistochemical studies of angiogenic cytokines and their receptors in myelofibrosis with myeloid metaplasia. 2003 , 27, 499-504	31
1847	High-frequency 3-D color-flow imaging of the microcirculation. 2003 , 29, 39-51	77
1846	Disparate effects of endostatin on tumor vascular perfusion and hypoxia in two murine mammary carcinomas. 2003 , 57, 1038-46	17
1845	Angiogenesis in hematologic malignancies. 2003 , 45, 227-44	95
1844	Angiogenesis inhibitors in genitourinary cancers. 2003 , 46 Suppl, S41-7	10
1843	2,4-disubstituted pyrimidines: a novel class of KDR kinase inhibitors. 2003 , 13, 1673-7	24
1842	Design and synthesis of 1,5-diarylbenzimidazoles as inhibitors of the VEGF-receptor KDR. 2003 , 13, 2485-8	14
1841	Discovery and evaluation of 3-(5-thien-3-ylpyridin-3-yl)-1H-indoles as a novel class of KDR kinase inhibitors. 2003 , 13, 2973-6	13
1840	Cochlioquinone A1, a new anti-angiogenic agent from <i>Bipolaris zeicola</i> . 2003 , 11, 4743-7	27
1839	Molecular mechanisms in lymphangiogenesis: model systems and implications in human disease. 2003 , 64, 282-92	18
1838	Common gene polymorphisms and nutrition: emerging links with pathogenesis of multifactorial chronic diseases (review). 2003 , 14, 426-51	114
1837	Paclitaxel encapsulated in cationic liposomes diminishes tumor angiogenesis and melanoma growth in a "humanized" SCID mouse model. 2003 , 120, 476-82	103
1836	From scarless fetal wounds to keloids: molecular studies in wound healing. 2003 , 11, 411-8	61

1835	Thrombin induces angiogenesis and vascular endothelial growth factor expression in human endothelial cells: possible relevance to HIF-1alpha. 2003 , 1, 1096-102	48
1834	Placental growth factor and its receptor, vascular endothelial growth factor receptor-1: novel targets for stimulation of ischemic tissue revascularization and inhibition of angiogenic and inflammatory disorders. 2003 , 1, 1356-70	279
1833	A nitric oxide synthase inhibitor, N(G)-nitro-L-arginine-methyl-ester, exerts potent antiangiogenic effects on plasmacytoma in a newly established multiple myeloma severe combined immunodeficient mouse model. 2003 , 120, 396-404	14
1832	Quantitative analysis of colorectal tissue microarrays by immunofluorescence and in situ hybridization. 2003 , 200, 577-88	40
1831	Ets 1 is expressed in capillary blood vessels but not in lymphatics. 2003 , 200, 561-7	16
1830	Role of tissue stroma in cancer cell invasion. 2003 , 200, 429-47	748
1829	Malignancy, thrombosis and Trousseau: the case for an eponym. 2003 , 1, 2463-5	96
1828	A review of Doppler sonography for the assessment of tumour vascularity. 2003 , 1, 121-30	6
1827	Chemotherapy and antiangiogenesis: drug-specific effects on microvessel sprouting. 2003 , 111, 995-1003	7
1826	Alprostadil suppresses angiogenesis in vitro and in vivo in the murine Matrigel plug assay. 2003 , 138, 377-85	15
1825	The enigmatic role of angiopoietin-1 in tumor angiogenesis. 2003 , 13, 309-17	86
1824	Expression of thymidine kinase driven by an endothelial-specific promoter inhibits tumor growth of Lewis lung carcinoma cells in transgenic mice. 2003 , 10, 1170-8	22
1823	Effects of hypoxia on the expression of proangiogenic factors in differentiated 3T3-F442A adipocytes. 2003 , 27, 1187-95	153
1822	Aplidine, a new anticancer agent of marine origin, inhibits vascular endothelial growth factor (VEGF) secretion and blocks VEGF-VEGFR-1 (flt-1) autocrine loop in human leukemia cells MOLT-4. 2003 , 17, 52-9	130
1821	Trans-activation of heparanase promoter by ETS transcription factors. 2003 , 22, 919-23	50
1820	Role and regulation of the thrombin receptor (PAR-1) in human melanoma. 2003 , 22, 3130-7	106
1819	Angiogenesis, lymphangiogenesis, and melanoma metastasis. 2003 , 22, 3172-9	183
1818	Endoglin (CD105): a powerful therapeutic target on tumor-associated angiogenetic blood vessels. 2003 , 22, 6557-63	192

1817	Monoclonal antibody therapeutics and apoptosis. 2003 , 22, 9097-106	58
1816	Absolute cerebral blood volume and blood flow measurements based on synchrotron radiation quantitative computed tomography. 2003 , 23, 499-512	41
1815	Heterologous expression of human VEGF165 in rat brain: dose-dependent, heterogeneous effects on CBF in relation to vascular density and cross-sectional area. 2003 , 23, 423-31	16
1814	Molecular regulation of vessel maturation. 2003 , 9, 685-93	2006
1813	Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration. 2003 , 9, 702-12	1404
1812	Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. 2003 , 9, 562-7	980
1811	Targeting exogenous genes to tumor angiogenesis by transplantation of genetically modified hematopoietic stem cells. 2003 , 9, 789-95	496
1810	Photodynamic therapy for cancer. 2003 , 3, 380-7	4576
1809	Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma. 2003 , 3, 411-21	681
1808	Basement membranes: structure, assembly and role in tumour angiogenesis. 2003 , 3, 422-33	1290
1807	Caveolae: mining little caves for new cancer targets. 2003 , 3, 571-81	220
1806	The human placenta remodels the uterus by using a combination of molecules that govern vasculogenesis or leukocyte extravasation. 2003 , 995, 73-83	71
1805	Angiogenic factors reconstitute hematopoiesis by recruiting stem cells from bone marrow microenvironment. 2003 , 996, 49-60	117
1804	Experimental approaches to treatment of soft tissue sarcoma. 2003 , 12, 499-521	4
1803	Improved effect of an antiangiogenic tyrosine kinase inhibitor (SU5416) by combinations with fractionated radiotherapy or low molecular weight heparin. 2003 , 5, 155-60	16
1802	A new class of potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: structure-activity relationships for a series of 9-alkoxymethyl-12-(3-hydroxypropyl)indeno[2,1-a]pyrrolo[3,4-c]carbazole-5-ones and the identification of CEP-5214 and its dimethylglycine ester prodrug clinical candidate CEP-7055. 2003 , 41, 5375-89	73
1801	Nicotine promotes arteriogenesis. 2003 , 41, 489-96	98
1800	Quantification of wound angiogenesis. 2003 , 78, 319-27	3

1799	Molecular responses to hypoxia in tumor cells. 2003 , 2, 23	129
1798	Analysis of VEGF-responsive genes involved in the activation of endothelial cells. 2003 , 2, 25	62
1797	Signaling through Raf-1 in the neovasculature and target validation by nanoparticles. 2003 , 2, 27	5
1796	Development of natural product-derived receptor tyrosine kinase inhibitors based on conservation of protein domain fold. 2003 , 46, 2917-31	68
1795	Angiogenesis in ischemic and neoplastic disorders. 2003 , 54, 17-28	317
1794	Lymphatic endothelium: morphological, molecular and functional properties. 2003 , 163, 209-13	150
1793	Lack of platelet endothelial cell adhesion molecule-1 attenuates foreign body inflammation because of decreased angiogenesis. 2003 , 162, 953-62	78
1792	Quantitative assessment of angiogenic responses by the directed in vivo angiogenesis assay. 2003 , 162, 1431-9	108
1791	Distinct role of fibroblast growth factor-2 and vascular endothelial growth factor on tumor growth and angiogenesis. 2003 , 162, 1913-26	146
1790	Tumor lymphangiogenesis: a novel prognostic indicator for cutaneous melanoma metastasis and survival. 2003 , 162, 1951-60	420
1789	Caveolin-1 knockout mice show an impaired angiogenic response to exogenous stimuli. 2003 , 162, 2059-68	106
1788	RhoA induces MMP-9 expression at CD44 lamellipodial focal complexes and promotes HMEC-1 cell invasion. 2003 , 291, 363-76	84
1787	Non steroidal anti-inflammatory drugs and COX-2 inhibitors as anti-cancer therapeutics: hopes, hopes and reality. 2003 , 35, 476-87	56
1786	HIV protease inhibitors as new treatment options for Kaposi's sarcoma. 2003 , 6, 173-81	10
1785	Bystander cell killing spreading from endothelial to tumor cells in a three-dimensional multicellular nodule model after Escherichia coli nitroreductase gene delivery. 2003 , 311, 822-8	10
1784	Sphingosine-1-phosphate markedly induces matrix metalloproteinase and integrin-dependent human endothelial cell invasion and lumen formation in three-dimensional collagen and fibrin matrices. 2003 , 312, 903-13	123
1783	Abnormalities of the umbilico-portal venous system in Down syndrome: a report of two new patients. 2003 , 120A, 528-32	26
1782	NO and angiogenesis. 2003 , 4, 53-60	199

1781	Hepatocyte growth factor activates endothelial proangiogenic mechanisms relevant in chronic hepatitis C-associated neoangiogenesis. 2003 , 38, 660-7	47
1780	Novel approaches in oncology at AstraZeneca. 2003 , 1, 3-8	7
1779	Fluid shear stress-induced transcriptional activation of the vascular endothelial growth factor receptor-2 gene requires Sp1-dependent DNA binding. 2003 , 535, 87-93	52
1778	Angiogenesis is involved in the pathogenesis of nonrheumatic aortic valve stenosis. 2003 , 34, 756-63	103
1777	TIMP-2 mediated inhibition of angiogenesis: an MMP-independent mechanism. 2003 , 114, 171-80	427
1776	Overexpression of hepatocyte growth factor receptor in renal carcinoma cells indirectly stimulates tumor growth in vivo. 2003 , 302, 892-7	12
1775	Vector-based RNAi, a novel tool for isoform-specific knock-down of VEGF and anti-angiogenesis gene therapy of cancer. 2003 , 303, 1169-78	95
1774	The role of c-Fes in vascular endothelial growth factor-A-mediated signaling by endothelial cells. 2003 , 306, 1056-63	12
1773	Bone-marrow-derived myofibroblasts contribute to the cancer-induced stromal reaction. 2003 , 309, 232-40	240
1772	Automated tracing and change analysis of angiogenic vasculature from in vivo multiphoton confocal image time series. 2003 , 66, 113-25	44
1771	Recruitment of human umbilical vein endothelial cells and human primary fibroblasts into experimental tumors growing in SCID mice. 2003 , 287, 28-38	24
1770	Regulation of endothelial cell differentiation and transformation by H-Ras. 2003 , 291, 189-200	6
1769	Inactivation of Src family kinases inhibits angiogenesis in vivo: implications for a mechanism involving organization of the actin cytoskeleton. 2003 , 291, 70-82	64
1768	Expression of angiopoietic factors in normal and type-I diabetes human placenta: a pilot study. 2003 , 111, 153-6	15
1767	Expression levels of vascular endothelial growth factor, matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 and 2 in the plasma of patients with ovarian carcinoma. 2003 , 39, 1948-56	79
1766	Anti-angiogenesis in cancer therapy. 2003 , 19, 180-92	15
1765	Use of HIV protease inhibitors to block Kaposi's sarcoma and tumour growth. 2003 , 4, 537-47	111
1764	Cyclooxygenase inhibitors: drugs for cancer prevention. 2003 , 3, 352-61	30

1763	Cancer prevention -- the potential for diet to modulate molecular signalling. 2003 , 9, 11-8	167
1762	Cyclooxygenase-2: a therapeutic target in angiogenesis. 2003 , 9, 73-8	165
1761	The extracellular matrix: a new turn-of-the-screw for anti-angiogenic strategies. 2003 , 9, 256-62	21
1760	An antibody to VEGF upregulates factor VIII via interleukin-1 in activated adrenal cortex-derived capillary endothelial cells. 2003 , 3, 493-512	3
1759	The effects of 2-methoxy oestrogens and their sulphamoylated derivatives in conjunction with TNF-alpha on endothelial and fibroblast cell growth, morphology and apoptosis. 2003 , 86, 189-96	13
1758	Emerging role of endothelin-1 in tumor angiogenesis. 2003 , 14, 44-50	108
1757	Microenvironmental and cellular consequences of altered blood flow in tumours. 2003 , 76 Spec No 1, S11-22	184
1756	The fibroblast growth factors. 2003 , 747-781	1
1755	A novel anti-CD146 monoclonal antibody, AA98, inhibits angiogenesis and tumor growth. 2003 , 102, 184-91	161
1754	Statin effects beyond lipid lowering--are they clinically relevant?. 2003 , 24, 225-48	360
1753	Rapid and efficient synthesis of 1H-indol-2-yl-1H-quinolin-2-ones. 2003 , 5, 3975-8	51
1752	Mechanisms in Carcinogenesis and Cancer Prevention. 2003 ,	
1751	IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis. 2003 , 170, 3369-76	958
1750	Role of the estrogen antagonist ICI 182,780 in vessel assembly and apoptosis of endothelial cells. 2003 , 27, 33-9	23
1749	Early vascular benefits of statin therapy. 2003 , 19, 540-56	132
1748	Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. 2003 , 111, 43-50	270
1747	Correlations of the expression of fibroblast growth factor-2, vascular endothelial growth factor, and their receptors with angiogenesis in synovial tissues from patients with internal derangement of the temporomandibular joint. 2003 , 82, 272-7	22
1746	VE-cadherin simultaneously stimulates and inhibits cell proliferation by altering cytoskeletal structure and tension. 2003 , 116, 3571-81	104

1745	Amifostine inhibits angiogenesis in vivo. 2003 , 304, 729-37	23
1744	The transcription factor Net regulates the angiogenic switch. 2003 , 17, 2283-97	53
1743	Vascular endothelial growth factor and receptor interaction is a prerequisite for murine hepatic fibrogenesis. 2003 , 52, 1347-54	228
1742	Identification of a novel domain of fibroblast growth factor 2 controlling its angiogenic properties. 2003 , 278, 8751-60	31
1741	Rho kinase and matrix metalloproteinase inhibitors cooperate to inhibit angiogenesis and growth of human prostate cancer xenotransplants. 2003 , 17, 223-34	89
1740	Etk/Bmx transactivates vascular endothelial growth factor 2 and recruits phosphatidylinositol 3-kinase to mediate the tumor necrosis factor-induced angiogenic pathway. 2003 , 278, 51267-76	118
1739	Enhancing radiotherapy with cyclooxygenase-2 enzyme inhibitors: a rational advance?. 2003 , 95, 1440-52	130
1738	Angiogenesis: Basic Mechanisms and Clinical Applications. 2003 , 7, 253-280	3
1737	Leads for development of new naphthalenesulfonate derivatives with enhanced antiangiogenic activity: crystal structure of acidic fibroblast growth factor in complex with 5-amino-2-naphthalene sulfonate. 2003 , 278, 21774-81	36
1736	Modelling solid tumour growth using the theory of mixtures. 2003 , 20, 341-66	290
1735	Lowering of tumor interstitial fluid pressure specifically augments efficacy of chemotherapy. 2003 , 17, 1756-8	93
1734	VEGF-A and alphaVbeta3 integrin synergistically rescue angiogenesis via N-Ras and PI3-K signaling in human microvascular endothelial cells. 2003 , 17, 1931-3	34
1733	Potential role for ADAM15 in pathological neovascularization in mice. 2003 , 23, 5614-24	160
1732	Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by alpha v beta 3 and alpha 5 beta 1 integrins. 2003 , 100, 4766-71	433
1731	Paracrine regulation of angiogenesis and adipocyte differentiation during in vivo adipogenesis. 2003 , 93, e88-97	263
1730	Vascular endothelial cell growth factor (VEGF), an emerging target for cancer chemotherapy. 2003 , 3, 95-117	148
1729	Interferon-alpha is implicated in the transcriptional regulation of vascular endothelial growth factor. 2003 , 95, 420-1	6
1728	Rapid analysis of angiogenesis drugs in a live fluorescent zebrafish assay. 2003 , 23, 911-2	171

1727	Deletion of neuropeptide Y (NPY) 2 receptor in mice results in blockage of NPY-induced angiogenesis and delayed wound healing. 2003 , 100, 6033-8	148
1726	Optical systems for in vivo molecular imaging of cancer. 2003 , 2, 491-504	167
1725	Circulating vascular progenitor cells do not contribute to compensatory lung growth. 2003 , 93, 372-9	74
1724	Potential role of platelets in endothelial damage observed during treatment with cisplatin, gemcitabine, and the angiogenesis inhibitor SU5416. 2003 , 21, 2192-8	100
1723	Chemotherapy and antiangiogenesis: drug-specific effects on microvessel sprouting. 2003 , 111, 995-1003	32
1722	Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis. 2003 , 95, 437-48	265
1721	Hypoxia induces an autocrine-paracrine survival pathway via platelet-derived growth factor (PDGF)-B/PDGF-beta receptor/phosphatidylinositol 3-kinase/Akt signaling in RN46A neuronal cells. 2003 , 17, 1709-11	87
1720	Contact inhibition of VEGF-induced proliferation requires vascular endothelial cadherin, beta-catenin, and the phosphatase DEP-1/CD148. 2003 , 161, 793-804	340
1719	Heparin inhibition of endothelial cell proliferation and organization is dependent on molecular weight. 2003 , 23, 2110-5	114
1718	Tumour-Induced Angiogenesis: A Review. 2003 , 5, 137-153	26
1717	Oncogenic transformation induces tumor angiogenesis: a role for PAR1 activation. 2003 , 17, 163-74	99
1716	Up-regulation of vascular endothelial growth factor C in breast cancer cells by heregulin-beta 1. A critical role of p38/nuclear factor-kappa B signaling pathway. 2003 , 278, 5750-9	117
1715	Calreticulin. 2003 ,	4
1714	Arsenic stimulates angiogenesis and tumorigenesis in vivo. 2003 , 76, 271-9	89
1713	IL-1 is required for tumor invasiveness and angiogenesis. 2003 , 100, 2645-50	755
1712	The hepatitis C virus internal ribosome entry site facilitates efficient protein synthesis in blood vessel endothelium during tumour angiogenesis. 2003 , 31, e46	3
1711	Confirmation of the microsomal triglyceride transfer protein genetic effect on lipids in young African American men from the CARDIA study. 2003 , 23, 912-3	7
1710	Increased Sp1 phosphorylation as a mechanism of hepatocyte growth factor (HGF/SF)-induced vascular endothelial growth factor (VEGF/VPF) transcription. 2003 , 116, 225-38	92

1709	Small GTP-binding protein Rac is an essential mediator of vascular endothelial growth factor-induced endothelial fenestrations and vascular permeability. 2003 , 107, 1532-8	103
1708	MMP-2 and MMP-9 synergize in promoting choroidal neovascularization. 2003 , 17, 2290-2	145
1707	A reinforced random walk model of tumour angiogenesis and anti-angiogenic strategies. 2003 , 20, 135-81	83
1706	von Hippel-Lindau disease: recent advances and therapeutic perspectives. 2003 , 3, 215-33	14
1705	Genetics of vascular anomalies: an update. 2003 , 1, 283-9	4
1704	Potential inhibitors of angiogenesis. Part I: 3-(imidazol-4(5)-ylmethylene)indolin-2-ones. 2003 , 18, 243-52	9
1703	In vivo targeting of tumor endothelial cells by systemic delivery of lentiviral vectors. 2003 , 14, 1193-206	105
1702	Suppression of angiogenesis and tumor growth by adenoviral-mediated gene transfer of pigment epithelium-derived factor. 2003 , 8, 72-9	76
1701	Spatial Evolutionary Games of Interaction among Generic Cancer Cells. 2003 , 5, 47-58	28
1700	Tumor Suppressor Genes. 2003 ,	
1699	Inhibition of epidermoid carcinoma A431 cell growth and angiogenesis in nude mice by early and late treatment with a novel dextran derivative. 2003 , 88, 1987-94	18
1698	Coelectrotransfer to skeletal muscle of three plasmids coding for antiangiogenic factors and regulatory factors of the tetracycline-inducible system: tightly regulated expression, inhibition of transplanted tumor growth, and antimetastatic effect. 2003 , 8, 425-33	29
1697	Inhibition of tumor growth with a vaccine based on xenogeneic homologous fibroblast growth factor receptor-1 in mice. 2003 , 278, 21831-6	60
1696	Thymidine phosphorylase and 2-deoxyribose stimulate human endothelial cell migration by specific activation of the integrins alpha 5 beta 1 and alpha V beta 3. 2003 , 278, 19272-9	57
1695	Oxidative stress regulates vascular endothelial growth factor-A gene transcription through Sp1- and Sp3-dependent activation of two proximal GC-rich promoter elements. 2003 , 278, 8190-8	149
1694	Suicide Gene Therapy. 2003 ,	
1693	The collagen type XVIII endostatin domain is co-localized with perlecan in basement membranes in vivo. 2003 , 51, 285-96	57
1692	Trefoil peptides as proangiogenic factors in vivo and in vitro: implication of cyclooxygenase-2 and EGF receptor signaling. 2003 , 17, 7-16	106

1691	Inhibition of tumor angiogenesis by cannabinoids. 2003 , 17, 529-31	198
1690	Osteopontin (Eta-1) and fibroblast growth factor-2 cross-talk in angiogenesis. 2003 , 171, 1085-93	115
1689	VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. 2003 , 161, 1163-77	2122
1688	The antiangiogenic factor 16K human prolactin induces caspase-dependent apoptosis by a mechanism that requires activation of nuclear factor-kappaB. 2003 , 17, 1815-23	68
1687	Inhibition of rat corneal angiogenesis by a nuclease-resistant RNA aptamer specific for angiopoietin-2. 2003 , 100, 5028-33	137
1686	Vitamin A deficiency inhibits intestinal adaptation by modulating apoptosis, proliferation, and enterocyte migration. 2003 , 285, G424-32	43
1685	NAB2, a corepressor of EGR-1, inhibits vascular endothelial growth factor-mediated gene induction and angiogenic responses of endothelial cells. 2003 , 278, 11433-40	81
1684	Inhibition of angiogenesis and angiogenesis-dependent tumor growth by the cryptic kringle fragments of human apolipoprotein(a). 2003 , 278, 29000-8	62
1683	Biologically active fragment of a human tRNA synthetase inhibits fluid shear stress-activated responses of endothelial cells. 2003 , 100, 14903-7	50
1682	Mechanisms of hypoxic gene regulation of angiogenesis factor Cyr61 in melanoma cells. 2003 , 278, 45651-60	81
1681	Evidence for hypoxia-induced neuronal-to-chromaffin metaplasia in neuroblastoma. 2003 , 17, 598-609	15
1680	Possible impact of tetrahydrobiopterin and sepiapterin on endothelial dysfunction. 2003 , 23, 913-4; author reply 914-5	4
1679	Zoledronate sensitizes endothelial cells to tumor necrosis factor-induced programmed cell death: evidence for the suppression of sustained activation of focal adhesion kinase and protein kinase B/Akt. 2003 , 278, 43603-14	107
1678	Poly(vinyl alcohol) gels for use as tissue phantoms in photoacoustic mammography. 2003 , 48, 357-70	115
1677	Interstitial flow as a guide for lymphangiogenesis. 2003 , 92, 801-8	233
1676	The Complexity of Tumor Vascularity. 2003 , 2, 257-258	17
1675	Expression of angiogenic factors including VEGFs and the effects of hypoxia and thalidomide on human myeloma cells. 2003 , 22, 165	1
1674	In vivo chamber angiogenesis assay: An optimized Matrigel plug assay for fast assessment of anti-angiogenic activity. 2003 , 22, 305	1

1673	Potential antitumor effects of statins (Review). 2003 , 23, 1055	19
1672	Molecular regulators of angiogenesis in the developing nervous system and adult brain tumors (Review). 2003 , 23, 557	2
1671	Steady-state blood volume measurements in experimental tumors with different angiogenic burdens a study in mice. 2003 , 226, 214-20	75
1670	Mapping of ATP, glucose, glycogen, and lactate concentrations within the arterial wall. 2003 , 23, 1801-7	31
1669	Chemotherapy and antiangiogenesis--drug-specific, dose-related effects. 2003 , 42, 294-303	54
1668	Bioreductive prodrugs for cancer therapy. 2004 , 90, 515-42	4
1667	Chemokines and breast cancer: a gateway to revolutionary targeted cancer treatments?. 2003 , 10, 579-92	25
1666	Emerging role of endoglin (CD105) as a marker of angiogenesis with clinical potential in human malignancies. 2003 , 3, 427-32	68
1665	Tumor-specific gene delivery using genetically engineered bacteria. 2003 , 3, 207-21	40
1664	Endothelial expression of the alpha6beta4 integrin is negatively regulated during angiogenesis. 2003 , 116, 3771-81	37
1663	Molecular imaging using magnetic resonance: new tools for the development of tumour therapy. 2003 , 76 Spec No 2, S111-7	22
1662	Plasminogen activator inhibitor-1 in tumor growth, angiogenesis and vascular remodeling. 2003 , 9, 1545-64	142
1661	Therapeutic strategies using inhibitors of angiogenesis. 2003 , 223, 599-634	2
1660	Endoglin (CD105): a target for anti-angiogenetic cancer therapy. 2003 , 4, 291-6	46
1659	. 2003 , 38, 516-524	7
1658	Angiomyofibroblastoma of the vulva: report of a case with immunohistochemical and molecular analysis. 2003 , 22, 277-84	25
1657	Photoacoustic imaging of inhomogeneities embedded in breast tissue phantoms. 2003 ,	6
1656	Proangiogenic function of CD40 ligand-CD40 interactions. 2003 , 171, 1534-41	61

1655	Physiopathology of liver metastasis. 2003 , 103, 444-7	1
1654	Angiogenesis: vascular remodeling of the extracellular matrix involves metalloproteinases. 2003 , 10, 136-41	133
1653	Rat aorta-derived mural precursor cells express the Tie2 receptor and respond directly to stimulation by angiopoietins. 2003 , 116, 3635-43	63
1652	Automated in vivo change analysis of tumor vasculature from two-photon confocal image time series. 2003 ,	
1651	Angiogenesis in nervous system disorders. 2003 , 53, 1362-74; discussion 1374-6	54
1650	Modelling Tumour-Induced Angiogenesis. 2003 ,	2
1649	Assessment of tumor angiogenesis using fluorescence contrast agents. 2003 ,	2
1648	Comparing dynamic parameters of tumor vascularization in nude mice revealed by magnetic resonance imaging and contrast-enhanced intermittent power Doppler sonography. 2003 , 38, 516-24	33
1647	Abstracts of NAVBO Workshop on Vascular Development (Asilomar). 2003 , 10, 337-374	1
1646	Converging roads: evidence for an adult hemangioblast. 2003 , 31, 987-993	61
1645	Transendothelial transport and migration in vessels of the apparatus lymphaticus periphericus absorbens (ALPA). 2003 , 230, 41-87	11
1644	A critical role of placental growth factor in the induction of inflammation and edema formation. 2003 , 101, 560-7	135
1643	HGF receptor up-regulation contributes to the angiogenic phenotype of human endothelial cells and promotes angiogenesis in vitro. 2003 , 101, 4816-22	139
1642	Paracrine interactions of basic fibroblast growth factor and interleukin-6 in multiple myeloma. 2003 , 101, 2775-83	107
1641	Proangiogenic properties of human myeloma cells: production of angiopoietin-1 and its potential relationship to myeloma-induced angiogenesis. 2003 , 102, 638-45	96
1640	Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. 2003 , 102, 1340-6	720
1639	A mathematical model of the contribution of endothelial progenitor cells to angiogenesis in tumors: implications for antiangiogenic therapy. 2003 , 102, 2555-61	104
1638	Thrombospondin 1 as a scavenger for matrix-associated fibroblast growth factor 2. 2003 , 102, 4399-406	70

1637 Angiogenesis. **2003**, 121-126

1636 Role of CD4+ T lymphocytes in antitumor immunity. **2003**, 87, 195-249

7

1635 HIF-1-dependent VEGF reporter gene assay by a stable transformant of CHO cells. **2003**, 26, 417-20

17

1634 Magnetic resonance imaging of tumor vasculature. **2003**, 89, 25-33

31

1633 Structural elements of kallistatin required for inhibition of angiogenesis. **2003**, 284, C1604-13

46

1632 Neurotrophins: novel mediators of angiogenesis. **2003**, 8, s1181-6

24

1631 Zebrafish: a genetic model for vertebrate organogenesis and human disorders. **2003**, 8, d1227-53

64

1630 Corneal transduction to inhibit angiogenesis and graft failure. **2003**, 44, 1837-42

53

1629 Use of adenovirus vectors for functional gene analysis in the chicken chorioallantoic membrane. **2003**, 34, 178-83

5

1628 Viral and cellular cytokines as therapeutic targets in AIDS-related lymphoproliferative disorders. **2003**, 3, 81-96

1

1627 Regulation of endothelial cell integrin function and angiogenesis by COX-2, cAMP and Protein Kinase A. **2003**, 90, 577-85

39

1626 Cyclooxygenase-2 expression and angiogenesis in colorectal cancer. **2003**, 9, 1237-40

18

1625 Implication des matricryptines issues des collagènes non fibrillaires, de MMP-2 et de SPARC dans le contrôle de l'angiogénèse. **2003**, 197, 41-44

3

1624 [Hyperglycemia and angiogenesis]. **2003**, 19, 840-6

3

1623 The role of VEGF in oncology: effects on hemostasis and thrombosis. **2003**, 33 Suppl 1, 11-2

10

1622 Genetic modulation of hypoxia induced gene expression and angiogenesis: relevance to brain tumors. **2003**, 8, d100-16

54

1621 Aminopeptidase inhibitor bestatin stimulates microvascular endothelial cell invasion in a fibrin matrix. **2003**, 90, 921-9

7

1620 Vascular endothelial growth factor as a therapeutic target in cancer. **2004**, 61, S4-11

28

1619	The Pleiotropic Effects of Statins: Relevance to Their Salutary Effects. 2004 , 163-187	3
1618	Absence of OX-43 antigen expression in invasive capillary sprouts: identification of a capillary sprout-specific endothelial phenotype. 2004 , 286, H346-53	13
1617	Infliximab for the Treatment of Posterior Uveitis with Retinal Neovascularization in Behçet Disease. 2004 , 14, 445-448	51
1616	Bacterial models for tumor development. Mini-review. 2004 , 51, 321-32	4
1615	Comparison of expression of cathepsins B and L and MMP2 in endothelial cells and in capillary sprouting in collagen gel. 2004 , 19, 120-9	5
1614	Prognostic significance of microvessel density and vascular endothelial growth factor expression in advanced ovarian serous carcinoma. 2004 , 14, 815-823	13
1613	. 2004 ,	7
1612	Blood vessels and parkinsonism. 2004 , 9, 277-82	32
1611	Localization of collagen XVIII and the endostatin portion of collagen XVIII in aged human control eyes and eyes with age-related macular degeneration. 2004 , 45, 1544-52	81
1610	HIF-1alpha: a valid therapeutic target for tumor therapy. 2004 , 36, 343-53	55
1609	Angiogenesis and its role in the behavior of astrocytic brain tumors. 2004 , 9, 3105-23	23
1608	Increased angiogenesis and lymphangiogenesis in inflammatory versus noninflammatory breast cancer by real-time reverse transcriptase-PCR gene expression quantification. 2004 , 10, 7965-71	196
1607	A spatio-temporal simulation model of the response of solid tumours to radiotherapy in vivo: parametric validation concerning oxygen enhancement ratio and cell cycle duration. 2004 , 49, 1485-504	32
1606	Crucial role of activin a in tubulogenesis of endothelial cells induced by vascular endothelial growth factor. 2004 , 145, 3739-45	35
1605	Oncogenes as regulators of tissue factor expression in cancer: implications for tumor angiogenesis and anti-cancer therapy. 2004 , 30, 21-30	46
1604	Inhibition of lung carcinogenesis and effects on angiogenesis and apoptosis in A/J mice by oral administration of green tea. 2004 , 48, 44-53	82
1603	The fibrinolytic system and matrix metalloproteinases in angiogenesis and tumor progression. 2004 , 30, 71-82	17
1602	Contribution of the hemostatic system to angiogenesis in cancer. 2004 , 30, 5-20	50

1601	Recent studies on natural products as anticancer agents. 2004 , 4, 241-65	115
1600	Pulmonary antioxidant defenses in the preterm newborn with respiratory distress and bronchopulmonary dysplasia in evolution: implications for antioxidant therapy. 2004 , 6, 155-67	78
1599	Principles of Molecular Oncology. 2004 ,	6
1598	Locally enhanced angiogenesis promotes transplanted cell survival. 2004 , 10, 63-71	106
1597	Combinatorial administration of molecules that simultaneously inhibit angiogenesis and invasion leads to increased therapeutic efficacy in mouse models of malignant glioma. 2004 , 10, 4527-37	44
1596	Pretreatment with dexamethasone increases antitumor activity of carboplatin and gemcitabine in mice bearing human cancer xenografts: in vivo activity, pharmacokinetics, and clinical implications for cancer chemotherapy. 2004 , 10, 1633-44	92
1595	Vascular endothelial growth factor expression is up-regulated by EWS-ETS oncoproteins and Sp1 and may represent an independent predictor of survival in Ewing's sarcoma. 2004 , 10, 1344-53	106
1594	The minimal active domain of endostatin is a heparin-binding motif that mediates inhibition of tumor vascularization. 2004 , 64, 9012-7	47
1593	Physiological levels of amyloid peptides stimulate the angiogenic response through FGF-2. 2004 , 18, 1943-5	44
1592	Up-regulation of vascular endothelial growth factor-A by active membrane-type 1 matrix metalloproteinase through activation of Src-tyrosine kinases. 2004 , 279, 13564-74	110
1591	Dendritic cell subsets differentially regulate angiogenesis in human ovarian cancer. 2004 , 64, 5535-8	230
1590	Suppression of colorectal cancer liver metastasis and extension of survival by expression of apolipoprotein(a) kringle. 2004 , 64, 7092-8	32
1589	High-resolution magnetic resonance imaging of disparities in the transcapillary transfer rates in orthotopically inoculated invasive breast tumors. 2004 , 64, 3155-61	30
1588	Use of blood outgrowth endothelial cells as virus-producing vectors for gene delivery to tumors. 2004 , 287, H494-500	45
1587	Quantitative assessment of tumor vasculature and response to therapy in kaposi's sarcoma using functional noninvasive imaging. 2004 , 3, 451-7	30
1586	Fibroblast growth factor-2-mediated capillary morphogenesis of endothelial cells requires signals via Flt-1/vascular endothelial growth factor receptor-1: possible involvement of c-Akt. 2004 , 279, 4007-16	50
1585	9-beta-D-arabinofuranosyl-2-fluoroadenine inhibits expression of vascular endothelial growth factor through hypoxia-inducible factor-1 in human ovarian cancer cells. 2004 , 66, 178-86	23
1584	VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression. 2004 , 64, 7822-35	370

1583	Roles of thrombospondin-1 and -2 in regulating corneal and iris angiogenesis. 2004 , 45, 1117-24	149
1582	Inhibition of hemangiogenesis and lymphangiogenesis after normal-risk corneal transplantation by neutralizing VEGF promotes graft survival. 2004 , 45, 2666-73	261
1581	A fragment of histidine-rich glycoprotein is a potent inhibitor of tumor vascularization. 2004 , 64, 599-605	73
1580	Soluble decoy receptor 3 induces angiogenesis by neutralization of TL1A, a cytokine belonging to tumor necrosis factor superfamily and exhibiting angiostatic action. 2004 , 64, 1122-9	96
1579	Cross-talk of integrin alpha3beta1 and tissue factor in cell migration. 2004 , 15, 4416-25	130
1578	Effects of angiogenesis inhibitors on vascular network formation by human endothelial and melanoma cells. 2004 , 96, 1473-7	192
1577	Oral silibinin inhibits lung tumor growth in athymic nude mice and forms a novel chemocombination with doxorubicin targeting nuclear factor kappaB-mediated inducible chemoresistance. 2004 , 10, 8641-7	104
1576	The antitumor properties of the alpha3(IV)-(185-203) peptide from the NC1 domain of type IV collagen (tumstatin) are conformation-dependent. 2004 , 279, 2091-100	57
1575	Evidence for the involvement of SDF-1 and CXCR4 in the disruption of endothelial cell-branching morphogenesis and angiogenesis by TNF-alpha and IFN-gamma. 2004 , 76, 217-26	41
1574	Endothelin-1 is a critical mediator of myogenic tone in tumor arterioles: implications for cancer treatment. 2004 , 64, 3209-14	50
1573	Cancer gene therapy Current status in the clinics. 2004 , 2, 219-274	3
1572	Utilization of bone marrow-derived endothelial cell precursors in spontaneous prostate tumors varies with tumor grade. 2004 , 64, 6137-43	78
1571	Blockade of vascular endothelial growth factor suppresses experimental restenosis after intraluminal injury by inhibiting recruitment of monocyte lineage cells. 2004 , 110, 2444-52	117
1570	Identification of synthetic endothelial cell-specific promoters by use of a high-throughput screen. 2004 , 78, 6209-21	16
1569	MT1-MMP-dependent neovessel formation within the confines of the three-dimensional extracellular matrix. 2004 , 167, 757-67	281
1568	The Shc adaptor protein is critical for VEGF induction by Met/HGF and ErbB2 receptors and for early onset of tumor angiogenesis. 2004 , 101, 2345-50	64
1567	Adeno-associated virus 2-mediated antiangiogenic cancer gene therapy: long-term efficacy of a vector encoding angiostatin and endostatin over vectors encoding a single factor. 2004 , 64, 1781-7	70
1566	Undersulfated, low-molecular-weight glycol-split heparin as an antiangiogenic VEGF antagonist. 2005 , 15, 1C-6C	45

1565	Membrane associated proteases and their inhibitors in tumour angiogenesis. 2004 , 57, 577-84	86
1564	Critical role of N-cadherin in myofibroblast invasion and migration in vitro stimulated by colon-cancer-cell-derived TGF-beta or wounding. 2004 , 117, 4691-703	130
1563	Inhibition of matrix metalloproteinase-9 reduces in vitro invasion and angiogenesis in human microvascular endothelial cells. 2004 , 25, 1407	7
1562	Antiangiogenic therapy of head and neck squamous cell carcinoma by vascular endothelial growth factor antisense therapy. 2005 , 62, 103-20	9
1561	Anti-angiogenic gene therapy for cancer (Review). 2004 , 25, 335	2
1560	Anti-angiogenic and anti-tumor apoptotic activities of SJ-8002, a new piperazine derivative. 2004 , 25, 365	
1559	Role of Ang1 and its interaction with VEGF-A in astrocytomas. 2004 , 63, 978-89	26
1558	Liposomal mediated transfer of ErbB2 antisense DNA: coming of age in the war against cancer. 2004 , 3, 205-6	3
1557	Expression pattern of the novel gene EG-1 in cancer. 2004 , 10, 3504-8	23
1556	Nitric oxide induces hypoxia-inducible factor 1 activation that is dependent on MAPK and phosphatidylinositol 3-kinase signaling. 2004 , 279, 2550-8	160
1555	The urokinase plasminogen activator system: role in malignancy. 2004 , 10, 39-49	314
1554	Exercise-induced overexpression of angiogenic factors and reduction of ischemia/reperfusion injury in stroke. 2004 , 1, 411-20	114
1553	Alphaviruses and their derived vectors as anti-tumor agents. 2004 , 4, 597-607	13
1552	HIFs, hypoxia, and vascular development. 2004 , 62, 37-54	83
1551	CXCL1/macrophage inflammatory protein-2-induced angiogenesis in vivo is mediated by neutrophil-derived vascular endothelial growth factor-A. 2004 , 172, 5034-40	195
1550	Cross-talk between vascular endothelial growth factor and semaphorin-3A pathway in the regulation of normal and malignant mesothelial cell proliferation. 2004 , 18, 358-60	62
1549	The Edpm5 locus prevents the 'angiogenic switch' in an estrogen-induced rat pituitary tumor. 2004 , 25, 1829-38	12
1548	Antiangiogenic and antitumor efficacy of EphA2 receptor antagonist. 2004 , 64, 910-9	140

1547	Induction of ID2 expression by hypoxia-inducible factor-1: a role in dedifferentiation of hypoxic neuroblastoma cells. 2004 , 279, 39223-31	110
1546	Laminin-1 promotes angiogenesis in synergy with fibroblast growth factor by distinct regulation of the gene and protein expression profile in endothelial cells. 2004 , 279, 23766-72	48
1545	Differential transplantability of tumor-associated stromal cells. 2004 , 64, 5920-4	48
1544	Intercellular adhesion molecule-1 (ICAM-1) regulates endothelial cell motility through a nitric oxide-dependent pathway. 2004 , 279, 19230-8	65
1543	Inhibition of activator protein 1 activation, vascular endothelial growth factor, and cyclooxygenase-2 expression by 15-deoxy-Delta12,14-prostaglandin J2 in colon carcinoma cells: evidence for a redox-sensitive peroxisome proliferator-activated receptor-gamma-independent mechanism. 2004 , 64, 5162-71	48
1542	Microtubule depolymerization rapidly collapses capillary tube networks in vitro and angiogenic vessels in vivo through the small GTPase Rho. 2004 , 279, 11686-95	98
1541	Stem cell factor/c-kit signaling promotes the survival, migration, and capillary tube formation of human umbilical vein endothelial cells. 2004 , 279, 18600-7	152
1540	In vivo suppression of hormone-refractory prostate cancer growth by inositol hexaphosphate: induction of insulin-like growth factor binding protein-3 and inhibition of vascular endothelial growth factor. 2004 , 10, 244-50	63
1539	Characterization of vascular endothelial growth factor (VEGF) in the uterine cervix over pregnancy: effects of denervation and implications for cervical ripening. 2004 , 52, 1665-74	29
1538	The carboxyl terminus controls ligand-dependent activation of VEGFR-2 and its signaling. 2004 , 279, 735-42	20
1537	Short-term human prostate primary xenografts: an in vivo model of human prostate cancer vasculature and angiogenesis. 2004 , 64, 1712-21	46
1536	Comparative evaluation of FGF-2-, VEGF-A-, and VEGF-C-induced angiogenesis, lymphangiogenesis, vascular fenestrations, and permeability. 2004 , 94, 664-70	229
1535	Platelet-activating factor (PAF) induces activation of matrix metalloproteinase 2 activity and vascular endothelial cell invasion and migration. 2004 , 18, 568-70	45
1534	The homeobox transcription factor Hox D3 promotes integrin alpha5beta1 expression and function during angiogenesis. 2004 , 279, 4862-8	103
1533	Anti-tumor efficacy of human angiostatin using liver-mediated adeno-associated virus gene therapy. 2004 , 9, 56-66	31
1532	Antiangiogenic activity of aplidine, a new agent of marine origin. 2004 , 90, 2418-24	76
1531	Nonlinear analysis of a model of vascular tumour growth and treatment. 2004 , 17, 867-895	23
1530	A digital ultrasonic system for small animal imaging. 2004 , 26, 85-99	7

1529 Molecular Targeting and Signal Transduction. **2004,**

1528	Molecular regulation of vascular smooth muscle cell differentiation in development and disease. 2004, 84, 767-801	2444
1527	Role of immunoreceptor tyrosine-based inhibitory motifs of PECAM-1 in PECAM-1-dependent cell migration. 2004, 287, C1103-13	50
1526	Tumor cell-derived nitric oxide is involved in the immune-rejection of an immunogenic murine lymphoma. 2004, 64, 152-61	23
1525	HIFs and tumors--causes and consequences. 2004, 286, R608-23	353
1524	Matricellular proteins in the heart: possible role during stress and remodeling. 2004, 64, 24-31	142
1523	The expression of thrombospondin-1 in benign prostatic hyperplasia and prostatic intraepithelial neoplasia is decreased in prostate cancer. 2004, 93, 1339-43	19
1522	Vaccination with autologous endothelium inhibits angiogenesis and metastasis of colon cancer through autoimmunity. 2004, 95, 85-90	54
1521	The new DR-70 immunoassay detects cancer of the gastrointestinal tract: a validation study. 2004, 20, 983-7	20
1520	Manipulating angiogenesis in medicine. 2004, 255, 538-61	160
1519	Antiangiogenic effect of metronomic paclitaxel treatment in prostate cancer and non-tumor tissue in the same animals: a quantitative study. 2004, 112, 201-9	29
1518	Molecular regulation of the VEGF family -- inducers of angiogenesis and lymphangiogenesis. 2004, 112, 463-80	111
1517	Photochemotherapy inhibits angiogenesis and induces apoptosis of endothelial cells in vitro. 2004, 20, 191-9	11
1516	Local rh-VEGF administration enhances skin flap survival more than other types of rh-VEGF administration: a clinical, morphological and immunohistochemical study. 2004, 13, 682-90	32
1515	Prognostic significance of microvessel density and vascular endothelial growth factor expression in advanced ovarian serous carcinoma. 2004, 14, 815-23	70
1514	Chronic systemic hypoxia causes intra-retinal angiogenesis. 2004, 205, 349-56	25
1513	Volumetric computed tomography (VCT): a new technology for noninvasive, high-resolution monitoring of tumor angiogenesis. 2004, 10, 1133-8	177
1512	Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. 2004, 10, 145-7	1648

1511	Tumour-educated macrophages promote tumour progression and metastasis. 2004 , 4, 71-8	2580
1510	Friends or foes - bipolar effects of the tumour stroma in cancer. 2004 , 4, 839-49	1446
1509	Endothelial cell-cell junctions: happy together. 2004 , 5, 261-70	876
1508	VEGF-null cells require PDGFR alpha signaling-mediated stromal fibroblast recruitment for tumorigenesis. 2004 , 23, 2800-10	268
1507	Discordant effects of a soluble VEGF receptor on wound healing and angiogenesis. 2004 , 11, 302-9	46
1506	Intra-arterial delivery of endostatin gene to brain tumors prolongs survival and alters tumor vessel ultrastructure. 2004 , 11, 1283-9	44
1505	Activation of the HIF pathway in childhood ALL, prognostic implications of VEGF. 2004 , 18, 926-33	84
1504	Crosstalk between angiogenesis and lymphangiogenesis in tumor progression. 2004 , 18, 1054-8	61
1503	Activated Ras induces a proangiogenic phenotype in primary endothelial cells. 2004 , 23, 192-200	79
1502	Vascular endothelial growth factor-mediated activation of p38 is dependent upon Src and RAFTK/Pyk2. 2004 , 23, 1275-82	61
1501	Upregulation of macrophage migration inhibitory factor contributes to induced N-Myc expression by the activation of ERK signaling pathway and increased expression of interleukin-8 and VEGF in neuroblastoma. 2004 , 23, 4146-54	74
1500	Degradation of PKB/Akt protein by inhibition of the VEGF receptor/mTOR pathway in endothelial cells. 2004 , 23, 4624-35	65
1499	Activation of diacylglycerol kinase alpha is required for VEGF-induced angiogenic signaling in vitro. 2004 , 23, 4828-38	62
1498	Downregulation of ICAM-1 and VCAM-1 expression in endothelial cells treated by photodynamic therapy. 2004 , 23, 8649-58	42
1497	A conserved siRNA-degrading RNase negatively regulates RNA interference in <i>C. elegans</i> . <i>Nature</i> , 2004 , 427, 645-9	50.4 488
1496	Identification of an angiogenic factor that when mutated causes susceptibility to Klippel-Trenaunay syndrome. <i>Nature</i> , 2004 , 427, 640-5	50.4 235
1495	The candidate tumour suppressor protein ING4 regulates brain tumour growth and angiogenesis. <i>Nature</i> , 2004 , 428, 328-32	50.4 315
1494	Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. <i>Nature</i> , 2004 , 428, 332-7	50.4 830

1493	The endothelial-cell-derived secreted factor Egfl7 regulates vascular tube formation. <i>Nature</i> , 2004 , 428, 754-8	50.4	310
1492	Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis. <i>Nature</i> , 2004 , 428, 758-63	50.4	691
1491	Stromal fibroblasts in cancer initiation and progression. <i>Nature</i> , 2004 , 432, 332-7	50.4	1811
1490	Retroviral delivery of homeobox D3 gene induces cerebral angiogenesis in mice. 2004 , 24, 1280-7		32
1489	Self-assembled nanoparticles based on glycol chitosan bearing 5beta-cholanic acid for RGD peptide delivery. 2004 , 95, 579-88		174
1488	A novel method for isolation of endothelial cells and macrophages from murine tumors based on Ac-LDL uptake and CD16 expression. 2004 , 295, 183-93		9
1487	Lactate: mirror and motor of tumor malignancy. 2004 , 14, 267-74		320
1486	Reduced splenic natural killer cell activity in rats with a hyperreactive dopaminergic system. 2004 , 29, 1058-64		19
1485	Intravascular embolization therapy in a patient with an enlarged polycystic liver. 2004 , 43, 733-8		31
1484	Robust model-based vasculature detection in noisy biomedical images. 2004 , 8, 360-76		57
1483	Expression of p53, Ki-67, and CD31 in the vaginal margins of radical hysterectomy in patients with stage IB carcinoma of the cervix. 2004 , 95, 646-54		12
1482	Hedgehog-interacting protein is highly expressed in endothelial cells but down-regulated during angiogenesis and in several human tumors. 2004 , 4, 43		111
1481	Tumour metabolites regulate tissue kallikrein in human umbilical vein endothelial cells. 2004 , 1691, 117-27		2
1480	Molecular targeting of angiogenesis. 2004 , 1654, 39-49		28
1479	Genetic dissection of tumor angiogenesis: are PlGF and VEGFR-1 novel anti-cancer targets?. 2004 , 1654, 79-94		32
1478	Endothelial cell integrins and COX-2: mediators and therapeutic targets of tumor angiogenesis. 2004 , 1654, 51-67		48
1477	Surgery and angiogenesis. 2004 , 1654, 95-104		20
1476	PDGF-BB induces intratumoral lymphangiogenesis and promotes lymphatic metastasis. 2004 , 6, 333-45		427

1475	Vascular frontiers without borders: multifaceted roles of platelet-derived growth factor (PDGF) in supporting postnatal angiogenesis and lymphangiogenesis. 2004 , 6, 307-9	23
1474	Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. 2004 , 6, 553-63	592
1473	Role of focal adhesion formation in migration and morphogenesis of endothelial cells. 2004 , 16, 1273-81	33
1472	Functional role of matrix metalloproteinases in ovarian tumor cell plasticity. 2004 , 190, 899-909	84
1471	Incorporation of naive bone marrow derived cells into the vascular architecture of brain tumor. 2004 , 11, 699-708	17
1470	Circulating basic fibroblast growth factor is partly derived from the tumour in patients with colon, cervical and ovarian cancer. 2004 , 7, 29-32	9
1469	Brain endothelial cells as pharmacological targets in brain tumors. 2004 , 30, 157-83	20
1468	Angiopoietin-related/angiopoietin-like proteins regulate angiogenesis. 2004 , 80, 21-8	101
1467	Immunotherapy of tumor by targeting angiogenesis. 2004 , 47, 545-52	
1466	Angiogenic and antiangiogenic balance regulates concomitant antitumoral resistance. 2004 , 21, 177-83	13
1465	Functional significance of vascular endothelial growth factor receptor expression on human glioma cells. 2004 , 67, 9-18	39
1464	Plasma protein extravasation and vascular endothelial growth factor expression with endothelial nitric oxide synthase induction in gentamicin-induced acute renal failure in rats. 2004 , 444, 362-74	13
1463	Inhibition of FGF receptor activity in glioma implanted into the mouse brain using the tetracyclin-regulated expression system. 2004 , 7, 105-13	17
1462	In vivo videomicroscopy reveals differential effects of the vascular-targeting agent ZD6126 and the anti-angiogenic agent ZD6474 on vascular function in a liver metastasis model. 2004 , 7, 157-64	20
1461	The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vessels. 2004 , 7, 225-33	138
1460	Placenta growth factor is not required for exercise-induced angiogenesis. 2004 , 7, 277-84	32
1459	A highly efficient electroporation method for the transfection of endothelial cells. 2004 , 7, 235-41	15
1458	The importance of angiogenesis in ovarian cancer. 2004 , 6, 462-467	0

1457	Selection of optimum expression system for production of kringle fragment of human apolipoprotein(a) in <i>Saccharomyces cerevisiae</i> . 2004 , 9, 523-527	7
1456	Interleukin-6 increases vascular endothelial growth factor and angiogenesis in gastric carcinoma. 2004 , 11, 517-27	133
1455	Introduction: stroma reaction and cancer progression. 2004 , 49, 177-8	3
1454	Optimization of the indolyl quinolinone class of KDR (VEGFR-2) kinase inhibitors: effects of 5-amido- and 5-sulphonamido-indolyl groups on pharmacokinetics and hERG binding. 2004 , 14, 351-5	49
1453	Viscoelastic imaging of breast tumor microenvironment with ultrasound. 2004 , 9, 393-404	79
1452	The 936C>T polymorphism of the gene for vascular endothelial growth factor is associated with 18F-fluorodeoxyglucose uptake. 2004 , 88, 205-8	29
1451	Response of rat prostate and lung tumors to ionizing radiation combined with the angiogenesis inhibitor AMCA. 2004 , 180, 798-804	9
1450	Vascular endothelial growth factor expression and neovascularization in Barrett's carcinoma. 2004 , 28, 675-9	18
1449	Mathematical modeling of tumor-induced angiogenesis. 2004 , 49, 111-87	231
1448	Apoptose und Antiangiogenese. 2004 , 37, 222-229	1
1447	Vascular targeting agents. 2004 , 6, 103-10	7
1446	Canstatin, a endogenous inhibitor of angiogenesis and tumor growth. 2004 , 16, 229-234	2
1445	Are tumours angiogenesis-dependent?. 2004 , 202, 5-13	103
1444	Serum concentrations of insulin-like growth factor-1, soluble tumor necrosis factor receptor-1 and angiogenin in endometriosis patients. 2004 , 51, 166-73	32
1443	Microvessel density, cyclo-oxygenase 2 expression, K-ras mutation and p53 overexpression in colonic cancer. 2004 , 91, 355-61	42
1442	Angiogenesis and neoplastic transformation of Barrett's epithelium. 2004 , 91, 941-2	4
1441	Hypoxia-inducible factor-1 and oncogenic signalling. 2004 , 26, 262-9	163
1440	Silica Particles: A Novel Drug-Delivery System. 2004 , 16, 1959-1966	694

1439	Vascular endothelial growth factor prolongs survival in a transgenic mouse model of ALS. 2004 , 56, 564-7	128
1438	Angiogenesis in chronic inflammatory liver disease. 2004 , 39, 1185-95	167
1437	Halting the interaction between vascular endothelial growth factor and its receptors attenuates liver carcinogenesis in mice. 2004 , 39, 1517-24	94
1436	Tumor lymphangiogenesis in head and neck squamous cell carcinoma: a morphometric study with clinical correlations. 2004 , 101, 973-8	136
1435	Influence of endostatin on embryonic vasculo- and angiogenesis. 2004 , 230, 468-80	41
1434	Effects of adrenomedullin on endothelial cells in the multistep process of angiogenesis: involvement of CRLR/RAMP2 and CRLR/RAMP3 receptors. 2004 , 108, 797-804	105
1433	Loss of p16INK4a expression is associated with vascular endothelial growth factor expression in squamous cell carcinoma of the esophagus. 2004 , 109, 483-90	20
1432	Inhibition of in vitro angiogenesis by 2-methoxy- and 2-ethyl-estrogen sulfamates. 2004 , 109, 533-40	55
1431	Identification of an HLA-A*0201 cytotoxic T lymphocyte epitope specific to the endothelial antigen Tie-2. 2004 , 110, 245-50	12
1430	Irradiated C6 glioma cells induce angiogenesis in vivo and activate endothelial cells in vitro. 2004 , 110, 807-14	22
1429	Spontaneous regression of lung metastasis in the absence of tumor necrosis factor receptor p55. 2004 , 112, 927-33	33
1428	An anticopper antiangiogenic approach for advanced cancer in spontaneously occurring tumors using tetrathiomolybdate: A pilot study in a canine animal model. 2004 , 17, 9-20	18
1427	Imaging of small vessels using photoacoustics: an in vivo study. 2004 , 35, 354-62	11
1426	Assessment of tumor blood perfusion by high-resolution dynamic contrast-enhanced MRI: a preclinical study of human melanoma xenografts. 2004 , 52, 269-76	82
1425	A facile synthesis of cytogenin (8-hydroxy-3-hydroxymethyl-6-methoxyisocoumarin). 2004 , 41, 975-978	11
1424	Novel radiosensitizers for locally advanced epithelial tumors: inhibition of the PI3K/Akt survival pathway in tumor cells and in tumor-associated endothelial cells as a novel treatment strategy?. 2004 , 58, 361-8	10
1423	A robust method for measuring trabecular bone orientation anisotropy at in vivo resolution using tensor scale. 2004 , 37, 1935-1944	47
1422	Angiogenesis inhibitor TX-1898: syntheses of the enantiomers of sterically diverse haloacetylcarbomoyl-2-nitroimidazole hypoxic cell radiosensitizers. 2004 , 12, 4917-27	16

1421	In vitro anti-proliferative activities of ellagic acid. 2004 , 15, 672-8	211
1420	Simulating the time series of a selected gene expression profile in an agent-based tumor model. 2004 , 196, 193-204	21
1419	Role of copper in tumour angiogenesis--clinical implications. 2004 , 18, 1-8	117
1418	Radiobiology of BNCT mediated by GB-10 and GB-10+BPA in experimental oral cancer. 2004 , 61, 939-45	28
1417	Design and synthesis of 3,7-diarylimidazopyridines as inhibitors of the VEGF-receptor KDR. 2004 , 14, 909-12	38
1416	The discovery of N-(1,3-thiazol-2-yl)pyridin-2-amines as potent inhibitors of KDR kinase. 2004 , 14, 2941-5	30
1415	Competition and natural selection in a mathematical model of cancer. 2004 , 66, 663-87	64
1414	Lattice and non-lattice models of tumour angiogenesis. 2004 , 66, 1785-819	102
1413	Nicotine and angiogenesis: a new paradigm for tobacco-related diseases. 2004 , 36, 33-40	96
1412	Monitoring angiogenesis in human melanoma xenografts using contrast-enhanced ultrasound.	
1411	Segmentation of in-vitro endothelial cell networks.	2
1410	Recent advances in the discovery and development of stilbenes and lactones in anticancer therapy. 2004 , 14, 819-835	22
1409	Antioxidants inhibit angiogenesis in vivo through down-regulation of nitric oxide synthase expression and activity. 2004 , 38, 501-8	38
1408	Alkylated derivatives of poly(ethylacrylic acid) can be inserted into preformed liposomes and trigger pH-dependent intracellular delivery of liposomal contents. 2004 , 21, 385-93	23
1407	Integrins: roles in cancer development and as treatment targets. 2004 , 90, 561-5	439
1406	Effect of shear stress on microvessel network formation of endothelial cells with in vitro three-dimensional model. 2004 , 287, H994-1002	53
1405	A novel strategy to modify adenovirus tropism and enhance transgene delivery to activated vascular endothelial cells in vitro and in vivo. 2004 , 15, 433-43	119
1404	Fibulin-5 antagonizes vascular endothelial growth factor (VEGF) signaling and angiogenic sprouting by endothelial cells. 2004 , 23, 367-79	111

1403	Pediatric CNS Tumors. 2004,	13
1402	Dopamine in vivo inhibits VEGF-induced phosphorylation of VEGFR-2, MAPK, and focal adhesion kinase in endothelial cells. 2004, 287, H1554-60	66
1401	Depleted dopamine in gastric cancer tissues: dopamine treatment retards growth of gastric cancer by inhibiting angiogenesis. 2004, 10, 4349-56	118
1400	Studies toward the synthesis of luminacin D: assembly of simplified analogues devoid of the epoxide displaying antiangiogenic activity. 2004, 6, 3909-12	7
1399	Human integrin alphavbeta5: homology modeling and ligand binding. 2004, 47, 4166-77	51
1398	Vascular endothelial growth factor and angiogenesis. 2004, 56, 549-80	1342
1397	The role of imaging in the clinical development of antiangiogenic agents. 2004, 18, 1183-206, x	14
1396	The use of chemotherapy in exotic animals. 2004, 7, 807-20, viii	17
1395	Photodynamic therapy for pancreatic carcinoma: experimental and clinical studies. 2004, 1, 145-55	10
1394	Anti-VEGF receptor-2 monoclonal antibody prevents portal-systemic collateral vessel formation in portal hypertensive mice. 2004, 126, 886-94	198
1393	Activin A stimulates vascular endothelial growth factor gene transcription in human hepatocellular carcinoma cells. 2004, 126, 1828-43	39
1392	New insights into the biology and pathology of the cutaneous lymphatic system. 2004, 35, 1-8	36
1391	Gene therapy of liver diseases. 2004, 4, 1073-91	28
1390	Hypoxia and hypoxia inducible factors (HIF) as important regulators of tumor physiology. 2004, 117, 219-48	39
1389	Angiogenesis in multiple sclerosis: is it good, bad or an epiphenomenon?. 2004, 217, 125-30	58
1388	Transplantation of monocytes: a novel strategy for in vivo augmentation of collateral vessel growth. 2004, 15, 1-12	50
1387	Highlights on endoglin (CD105): from basic findings towards clinical applications in human cancer. 2004, 2, 18	114
1386	Signaling pathways for arsenic-stimulated vascular endothelial growth factor-a expression in primary vascular smooth muscle cells. 2004, 17, 555-63	31

1385	Cell Adhesion. 2004,	1
1384	Helicobacter pylori stimulates host vascular endothelial growth factor-A (vegf-A) gene expression via MEK/ERK-dependent activation of Sp1 and Sp3. 2004, 18, 218-20	55
1383	Overexpression of dimethylarginine dimethylaminohydrolase enhances tumor hypoxia: an insight into the relationship of hypoxia and angiogenesis in vivo. 2004, 6, 401-11	21
1382	Dynamic Contrast-Enhanced Magnetic Resonance Imaging Rapidly Indicates Vessel Regression in Human Squamous Cell Carcinomas Grown in Nude Mice Caused by VEGF Receptor 2 Blockade with DC101. 2004, 6, 213-223	55
1381	Endothelial cell effects of cytotoxics: balance between desired and unwanted effects. 2004, 30, 495-513	41
1380	Constitutive and inducible expression and regulation of vascular endothelial growth factor. 2004, 15, 297-324	136
1379	1,2,3,4,6-Penta-O-galloyl-beta-D-glucose blocks endothelial cell growth and tube formation through inhibition of VEGF binding to VEGF receptor. 2004, 208, 89-94	38
1378	Common gene polymorphisms, cancer progression and prognosis. 2004, 208, 1-33	91
1377	Improved targeting of platinum chemotherapeutics. the antitumour activity of the HPMA copolymer platinum agent AP5280 in murine tumour models. 2004, 40, 291-7	54
1376	Modelling approaches for angiogenesis. 2004, 40, 881-9	77
1375	Monoclonal antibodies in the treatment of colorectal cancer. 2004, 40, 1292-301	65
1374	Angiogenesis of gastrointestinal tumours and their metastases--a target for intervention?. 2004, 40, 1302-13	19
1373	Tumor angiogenesis and metastasis formation are associated with individual differences in behavior of inbred Lewis rats. 2004, 18, 497-504	8
1372	A novel small peptide as a targeting ligand for receptor tyrosine kinase Tie2. 2004, 315, 1004-10	11
1371	Regulatory role of vHL/HIF-1alpha in hypoxia-induced VEGF production in hepatic stellate cells. 2004, 317, 358-62	66
1370	Suppression of angiogenesis by the plant alkaloid, sanguinarine. 2004, 317, 618-24	92
1369	VEGF selectively induces Down syndrome critical region 1 gene expression in endothelial cells: a mechanism for feedback regulation of angiogenesis?. 2004, 321, 648-56	62
1368	Beta4 integrin is involved in statin-induced endothelial cell death. 2004, 323, 858-64	17

1367	Interaction of cortactin and Arp2/3 complex is required for sphingosine-1-phosphate-induced endothelial cell remodeling. 2004 , 298, 107-21	29
1366	Targeting the tumor vascular compartment to improve conventional cancer therapy. 2004 , 25, 536-42	48
1365	Targeting the Tie2/Tek receptor in astrocytomas. 2004 , 164, 467-76	47
1364	Overexpression of pigment epithelium-derived factor decreases angiogenesis and inhibits the growth of human malignant melanoma cells in vivo. 2004 , 164, 1225-32	104
1363	Minodronate, a newly developed nitrogen-containing bisphosphonate, suppresses melanoma growth and improves survival in nude mice by blocking vascular endothelial growth factor signaling. 2004 , 165, 1865-74	78
1362	Angiopoietin-1 promotes tumor angiogenesis in a rat glioma model. 2004 , 165, 1557-70	102
1361	Differential expression of splicing variants of the human caldesmon gene (CALD1) in glioma neovascularization versus normal brain microvasculature. 2004 , 164, 2217-28	42
1360	Angiogenesis as an immunopharmacologic target in inflammation and cancer. 2004 , 4, 1537-47	42
1359	Role of eNOS in neovascularization: NO for endothelial progenitor cells. 2004 , 10, 143-5	187
1358	Infantile hemangioma is a proliferation of beta 4-negative endothelial cells adjacent to HLA-DR-positive cells with dendritic cell morphology. 2004 , 35, 739-44	47
1357	Tumour eradication by antiangiogenic therapy: analysis and extensions of the model by Hahnfeldt et al. (1999). 2004 , 191, 159-84	133
1356	Involvement of the vascular endothelial growth factor receptor-1 in murine hepatocellular carcinoma development. 2004 , 41, 97-103	27
1355	A soluble VE-cadherin fragment forms 2D arrays of dimers upon binding to a lipid monolayer. 2004 , 337, 881-92	10
1354	The three Es of cancer immunoediting. 2004 , 22, 329-60	1946
1353	Endothelial cell surface ATP synthase-triggered caspase-apoptotic pathway is essential for k1-5-induced antiangiogenesis. 2004 , 64, 3679-86	73
1352	Tumour-selective drug delivery via folate receptor-targeted liposomes. 2004 , 1, 7-17	54
1351	Prompt tumor formation and maintenance of constitutive NF-kappaB activity of multiple myeloma cells in NOD/SCID/gammacnull mice. 2004 , 95, 564-8	26
1350	Blocking angiogenesis and tumorigenesis with GFA-116, a synthetic molecule that inhibits binding of vascular endothelial growth factor to its receptor. 2004 , 64, 3586-92	61

1349	Antiangiogenic therapy for the treatment of pediatric solid malignancies. 2004 , 13, 53-60	8
1348	Neuroblastoma and dendritic cell function. 2004 , 13, 61-71	13
1347	Expression of angiopoietin 1 and 2 in ectopic endometrium on the chicken chorioallantoic membrane. 2004 , 81 Suppl 1, 869-75	15
1346	Bibliography Current World Literature. 2004 , 11, 285-319	
1345	Effects of nicotine on the number and activity of circulating endothelial progenitor cells. 2004 , 44, 881-9	58
1344	In vivo assessment of trabecular bone architecture via three-dimensional tensor scale. 2004 ,	3
1343	Angiogenic switch in multiple myeloma. 2004 , 9, 377-81	20
1342	Report from the society for biological therapy and vascular biology faculty of the NCI workshop on angiogenesis monitoring. 2004 , 27, 161-75	25
1341	Angiopoietin-related growth factor (AGF) promotes angiogenesis. 2004 , 103, 3760-5	84
1340	Syndecan-2 is essential for angiogenic sprouting during zebrafish development. 2004 , 103, 1710-9	128
1339	Bifunctional role for VEGF-induced heme oxygenase-1 in vivo: induction of angiogenesis and inhibition of leukocytic infiltration. 2004 , 103, 761-6	166
1338	Activated Fps/Fes partially rescues the in vivo developmental potential of Flk1-deficient vascular progenitor cells. 2004 , 103, 912-20	12
1337	Angiogenic switch during 5T2MM murine myeloma tumorigenesis: role of CD45 heterogeneity. 2004 , 103, 3131-7	45
1336	Do antiangiogenic protein fragments have amyloid properties?. 2004 , 104, 1601-5	23
1335	Regulators of vascular endothelial growth factor expression in cancer. 2004 , 119, 33-58	3
1334	Visualization of tumor-induced VEGF expression using in vivo bioluminescence. 2004 , 5329, 178	
1333	Anaplastic giant cell thyroid carcinoma. 2004 , 93, 272-7	18
1332	An Introduction to Dynamic Contrast-Enhanced MRI in Oncology. 2005 , 1-22	6

1331	The contribution of bone marrow-derived cells to the tumor vasculature in neuroblastoma is matrix metalloproteinase-9 dependent. 2005 , 65, 3200-8	137
1330	Chapter 15 Advances in protection of endothelial barrier function. 2005 , 35, 423-470	1
1329	Targets and Approaches for Cancer Drug Discovery. 2005 , 1343-1373	
1328	Expression profiling reveals functionally important genes and coordinately regulated signaling pathway genes during in vitro angiogenesis. 2005 , 22, 57-69	16
1327	Luminescence investigation of endothelial cells using metallic and semiconductor nanocrystals. 2005 , 5969, 596906	
1326	Predicting mechanical competence of trabecular bone using 3D tensor-scale-based parameters. 2005 ,	2
1325	Role of monocytes and macrophages in angiogenesis. 2005 , 127-46	23
1324	Angiogenesis, choroidal neovascularization, and the coagulation system. 2005 , 25, 19-25	2
1323	Dosage Determination of Ultrasmall Particles of Iron Oxide for the Delineation of Microvasculature in the Wistar Rat Brain. 2005 , 40, 655-660	13
1322	High-resolution photoacoustic vascular imaging in vivo using a large-aperture acoustic lens. 2005 , 5697, 7	3
1321	Vascular development: from precursor cells to branched arterial and venous networks. 2005 , 49, 259-67	111
1320	Effects of retinoic acid steroidal analogs on human leukemic HL60 cell proliferation in vitro and on angiogenesis in vivo. 2005 , 16, 151-8	9
1319	Novel tempeh (fermented soyabean) isoflavones inhibit in vivo angiogenesis in the chicken chorioallantoic membrane assay. 2005 , 93, 317-23	52
1318	Induction of angiogenesis in the beta-amyloid peptide-injected rat hippocampus. 2005 , 16, 129-32	29
1317	ERRATUM. 2005 , 40, 660	
1316	Circulating endothelial progenitor cells in multiple myeloma: implications and significance. 2005 , 105, 3286-94	171
1315	Unresolved questions, changing definitions, and novel paradigms for defining endothelial progenitor cells. 2005 , 106, 1525-31	382
1314	Endostatin dramatically inhibits endothelial cell migration, vascular morphogenesis, and perivascular cell recruitment in vivo. 2005 , 105, 1044-51	65

1313	Vascular endothelial growth factor regulation of Weibel-Palade-body exocytosis. 2005 , 105, 207-14	68
1312	The role of CXCL12 in the organ-specific process of artery formation. 2005 , 105, 3155-61	83
1311	CD97, an adhesion receptor on inflammatory cells, stimulates angiogenesis through binding integrin counterreceptors on endothelial cells. 2005 , 105, 2836-44	144
1310	The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications. 2005 , 105, 1383-95	277
1309	Erratum for vol. 104, p. 2368. 2005 , 105, 1395-1395	
1308	Anti-angiogenic and immunomodulatory effect of the herbal medicine "Juzen-taiho-to" on malignant glioma. 2005 , 28, 2111-6	41
1307	Study of vascular endothelial cell morphology during hyperthermia. 2005 , 30, 111-117	26
1306	Solid-phase refolding of inclusion body protein in a packed and expanded bed adsorption chromatography. 2005 , 40, 1967-1972	11
1305	Differential Prox-1 and CD 31 expression in mucosae, cutaneous and soft tissue vascular lesions and tumors. 2005 , 201, 771-6	30
1304	Intravascular contrast agent-enhanced MRI measuring contrast clearance and tumor blood volume and the effects of vascular modifiers in an experimental tumor. 2005 , 61, 1208-15	23
1303	Enhancement of radiation effects by pXLG-mEndo in a lung carcinoma model. 2005 , 63, 553-64	19
1302	Dynamic contrast-enhanced magnetic resonance imaging of radiation therapy-induced microcirculation changes in rectal cancer. 2005 , 63, 1309-15	116
1301	Femur window--a new approach to microcirculation of living bone in situ. 2005 , 23, 1073-82	30
1300	Novel diterpenoids with potent inhibitory activity against endothelium cell HMEC and cytotoxic activities from a well-known TCM plant Daphne genkwa. 2005 , 13, 645-55	97
1299	Vascular disrupting agents: a new class of drug in cancer therapy. 2005 , 17, 277-90	112
1298	Efficient total synthesis of bastadin 6, an anti-angiogenic brominated tyrosine-derived metabolite from marine sponge. 2005 , 61, 7211-7218	40
1297	Discovery of a novel and potent series of dianilinopyrimidineurea and urea isostere inhibitors of VEGFR2 tyrosine kinase. 2005 , 15, 3519-23	21
1296	Effects of vascular endothelial growth factor (VEGF) and chondroitin sulfate A on human monocytic THP-1 cell migration. 2005 , 43, 216-20	22

1295	Evolving molecular-based targeted therapy for cancer: an exciting field. 2005 , 31, 299-305	
1294	Neovascularization and angiogenic gene expression following chronic arsenic exposure in mice. 2005 , 5, 29-41	58
1293	Angiogenesis in craniopharyngiomas: Microvascular density and tissue expression of the vascular endothelial growth factor (VEGF) and endostatin. 2005 , 16, 355-62	8
1292	Photodynamic therapy for pancreatic and biliary tract carcinoma. 2005 , 35, 1-13	24
1291	Endothelial progenitor cells. 2005 , 56, 79-101	315
1290	Human guanylate binding protein-1 (hGBP-1) characterizes and establishes a non-angiogenic endothelial cell activation phenotype in inflammatory diseases. 2005 , 45, 215-27	34
1289	beta-Catenin expression during vascular development and degeneration of avian mesonephros. 2005 , 206, 165-74	8
1288	Combination of interferon-beta and angiotensin-converting enzyme inhibitor, perindopril, attenuates the murine liver fibrosis development. 2005 , 25, 153-61	18
1287	Immunohistochemical study of angiogenesis and proliferative activity in epiretinal membranes. 2005 , 59, 1157-61	20
1286	Expression of cell adhesion molecules, CD44s and E-cadherin, and microvessel density in invasive micropapillary carcinoma of the breast. 2005 , 46, 24-30	50
1285	Hypoxia-inducible factor-1alpha is associated with angiogenesis, and expression of bFGF, PDGF-BB, and EGFR in invasive breast cancer. 2005 , 46, 31-6	153
1284	The MAPK-AP-1/Runx2 signalling axes are implicated in chondrosarcoma pathobiology either independently or via up-regulation of VEGF. 2005 , 47, 565-74	32
1283	Review article: angiogenesis soluble factors as liver disease markers. 2005 , 22, 23-30	23
1282	Inhibiting the growth of malignant melanoma by blocking the expression of vascular endothelial growth factor using an RNA interference approach. 2005 , 153, 715-24	31
1281	The realisation of targeted antitumour therapy. 2005 , 92 Suppl 1, S2-5	16
1280	The endothelin B (ETB) receptor agonist IRL 1620 is highly vasoconstrictive in two syngeneic rat tumour lines: potential for selective tumour blood flow modification. 2005 , 93, 98-106	9
1279	A comparison of the effects of unfractionated heparin, dalteparin and danaparoid on vascular endothelial growth factor-induced tumour angiogenesis and heparanase activity. 2005 , 146, 333-43	35
1278	Cathepsin L is required for endothelial progenitor cell-induced neovascularization. 2005 , 11, 206-13	261

1277	Quantum dots spectrally distinguish multiple species within the tumor milieu in vivo. 2005 , 11, 678-82	381
1276	Immunosuppressive networks in the tumour environment and their therapeutic relevance. 2005 , 5, 263-74	1627
1275	Opinion: emerging mechanisms of tumour lymphangiogenesis and lymphatic metastasis. 2005 , 5, 735-43	249
1274	Chronic gene delivery of interferon-inducible protein 10 through replication-competent retrovirus vectors suppresses tumor growth. 2005 , 12, 900-12	25
1273	Endostatin promotes the anabolic program of rabbit chondrocyte. 2005 , 15, 201-6	16
1272	High-resolution blood-brain barrier permeability and blood volume imaging using quantitative synchrotron radiation computed tomography: study on an F98 rat brain glioma. 2005 , 25, 145-53	29
1271	SP100 inhibits ETS1 activity in primary endothelial cells. 2005 , 24, 916-31	33
1270	Silibinin strongly inhibits growth and survival of human endothelial cells via cell cycle arrest and downregulation of survivin, Akt and NF-kappaB: implications for angioprevention and antiangiogenic therapy. 2005 , 24, 1188-202	129
1269	Vasculostatin, a proteolytic fragment of brain angiogenesis inhibitor 1, is an antiangiogenic and antitumorigenic factor. 2005 , 24, 3632-42	140
1268	Inhibiting angiogenesis and tumorigenesis by a synthetic molecule that blocks binding of both VEGF and PDGF to their receptors. 2005 , 24, 4701-9	91
1267	The human VE-cadherin promoter is subjected to organ-specific regulation and is activated in tumour angiogenesis. 2005 , 24, 2992-3001	54
1266	Identification of pigment epithelium-derived factor as a direct target of the p53 family member genes. 2005 , 24, 5131-6	41
1265	STUDY OF THE TUMOR VESSELS IN DEPRESSED-TYPE EARLY GASTRIC CANCERS USING NARROW BAND IMAGING MAGNIFYING ENDOSCOPY AND CDNA ARRAY ANALYSIS. 2005 , 17, 210-217	6
1264	New aspects of vascular remodelling: the involvement of all vascular cell types. 2005 , 90, 469-75	65
1263	Tumor lymphangiogenesis predicts melanoma metastasis to sentinel lymph nodes. 2005 , 18, 1232-42	285
1262	Vascular endothelial growth factor concentrations in synovial fluids of patients with symptomatic internal derangement of the temporomandibular joint. 2005 , 34, 170-7	17
1261	Thalidomide enhances the anti-tumor activity of standard chemotherapy in a human melanoma xenotransplantation model. 2005 , 125, 201-6	13
1260	Therapeutic targeting of the tumor microenvironment. 2005 , 7, 513-20	440

1259	Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. 2005 , 8, 211-26	1076
1258	Antioxidants inhibit human endothelial cell functions through down-regulation of endothelial nitric oxide synthase activity. 2005 , 510, 31-8	46
1257	Antiangiogenic activity of beta-eudesmol in vitro and in vivo. 2005 , 512, 105-15	92
1256	Negative and positive regulation of HIF-1: a complex network. 2005 , 1755, 107-20	137
1255	Stimulation of HIF-1alpha, HIF-2alpha, and VEGF by prolyl 4-hydroxylase inhibition in human lung endothelial and epithelial cells. 2005 , 38, 1002-13	78
1254	Matrix metalloproteinases and angiogenesis. 2005 , 9, 267-85	672
1253	Novel highly efficient intrabody mediates complete inhibition of cell surface expression of the human vascular endothelial growth factor receptor-2 (VEGFR-2/KDR). 2005 , 300, 146-59	28
1252	Diagnostic and prognostic value of angiogenesis-modulating genes in malignant thyroid neoplasms. 2005 , 138, 1102-9; discussion 1109-10	30
1251	Normal human fibroblasts enable melanoma cells to induce angiogenesis in type I collagen. 2005 , 138, 439-49	18
1250	An in vivo role for Trypanosoma cruzi calreticulin in antiangiogenesis. 2005 , 140, 133-40	29
1249	FGF-1 and S100A13 possibly contribute to angiogenesis in endometriosis. 2005 , 67, 87-101	32
1248	Does Trypanosoma cruzi calreticulin modulate the complement system and angiogenesis?. 2005 , 21, 169-74	26
1247	[Antiangiogenic treatment of cancer]. 2005 , 78, 3-11	2
1246	Safrole oxide inhibits angiogenesis by inducing apoptosis. 2005 , 43, 69-74	16
1245	T-cell factor-4-dependent up-regulation of fibronectin is involved in fibroblast growth factor-2-induced tube formation by endothelial cells. 2005 , 94, 835-47	5
1244	Hypoxia-inducible factor 1alpha modulates adhesion, migration, and FAK phosphorylation in vascular smooth muscle cells. 2005 , 96, 971-85	37
1243	The potential of angiogenesis soluble markers in chronic hepatitis C. 2005 , 42, 696-701	59
1242	Downregulation of metastasis suppressor genes in malignant pheochromocytoma. 2005 , 114, 139-43	87

1241	Altered extent, pattern and characteristics of microvascular density are indicators of neoplastic progression in the endometrium. 2005 , 115, 975-80	5
1240	Metalloproteinases and their inhibitors in tumor angiogenesis. 2005 , 115, 849-60	217
1239	Effect of differences in cancer cells and tumor growth sites on recruiting bone marrow-derived endothelial cells and myofibroblasts in cancer-induced stroma. 2005 , 115, 885-92	65
1238	In vivo and in vitro characterization of human fibroblasts recruited selectively into human cancer stroma. 2005 , 117, 212-20	42
1237	Hyperforin, a bio-active compound of St. John's Wort, is a new inhibitor of angiogenesis targeting several key steps of the process. 2005 , 117, 775-80	77
1236	Overexpression of macrophage migration inhibitory factor induces angiogenesis and deteriorates prognosis after radical resection for hepatocellular carcinoma. 2005 , 103, 588-98	85
1235	Magnetic resonance imaging reveals functional diversity of the vasculature in benign and malignant breast lesions. 2005 , 104, 708-18	82
1234	Detection of circulating endothelial cells and endothelial progenitor cells by flow cytometry. 2005 , 64, 1-8	237
1233	Low-pH-sensitive poly(ethylene glycol) (PEG)-stabilized plasmid nanolipoparticles: effects of PEG chain length, lipid composition and assembly conditions on gene delivery. 2005 , 7, 67-79	119
1232	Expression of human apolipoprotein(a) kringle in colon cancer cells suppresses angiogenesis-dependent tumor growth and peritoneal dissemination. 2005 , 7, 39-49	19
1231	Lymph node metastasis in an animal model: effect of piecemeal laser surgical resection. 2005 , 36, 371-6	18
1230	Nitric oxide modulation of low-density mononuclear cell transendothelial migration. 2005 , 25, 452-6	6
1229	Inhibition of angiogenesis-relevant receptor tyrosine kinases by sulindac analogues. 2005 , 6, 527-31	6
1228	Hepatic tumor growth: target for angiogenesis inhibition?. 2005 , 29, 287-92	3
1227	Antiangiogenic and antitumoral properties of a polysaccharide isolated from the seaweed <i>Sargassum stenophyllum</i> . 2005 , 56, 436-46	70
1226	[Vascular imaging with contrast-enhanced sonography for experimental use]. 2005 , 45, 552-9	1
1225	Self-assembled nanoparticles of bile acid-modified glycol chitosans and their applications for cancer therapy. 2005 , 13, 167-175	31
1224	Synthesis and SAR of 4-(3-hydroxyphenylamino)pyrrolo[2,1-f][1,2,4]triazine based VEGFR-2 kinase inhibitors. 2005 , 15, 1429-33	34

1223	Novel 4-amino-furo[2,3-d]pyrimidines as Tie-2 and VEGFR2 dual inhibitors. 2005 , 15, 2203-7	125
1222	The antivasular action of physiotherapy ultrasound on murine tumors. 2005 , 31, 1403-10	57
1221	The anti-angiogenic effect of sinomenine. 2005 , 8, 3-12	76
1220	Autocrine role of interleukin-8 in induction of endothelial cell proliferation, survival, migration and MMP-2 production and angiogenesis. 2005 , 8, 63-71	218
1219	Interferon alpha 2a down-regulates VEGF expression through PI3 kinase and MAP kinase signaling pathways. 2005 , 131, 169-78	52
1218	Anti-angiogenic effects of SN38 (active metabolite of irinotecan): inhibition of hypoxia-inducible factor 1 alpha (HIF-1alpha)/vascular endothelial growth factor (VEGF) expression of glioma and growth of endothelial cells. 2005 , 131, 205-13	52
1217	Changes in vascularization in substantia nigra pars compacta of monkeys rendered parkinsonian. 2005 , 112, 1237-48	75
1216	Prokaryotic expression and biological activity analysis of human arresten gene. 2005 , 25, 8-12	1
1215	Cyclooxygenase-2 increases hypoxia-inducible factor-1 and vascular endothelial growth factor to promote angiogenesis in gastric carcinoma. 2005 , 12, 229-41	82
1214	The merits of vascular targeting for gynecologic malignancies. 2005 , 7, 444-50	2
1213	Multifaceted role of Rho proteins in angiogenesis. 2005 , 10, 291-8	55
1212	Protein delivery of caspase-3 induces cell death in malignant C6 glioma, primary astrocytes and immortalized and primary brain capillary endothelial cells. 2005 , 71, 127-34	17
1211	Endothelin B receptor agonist, IRL 1620, enhances the anti-tumor efficacy of paclitaxel in breast tumor rats. 2005 , 94, 237-47	34
1210	Roles for neuregulins in human cancer. 2004 , 21, 665-84	40
1209	A natural compound (ginsenoside Re) isolated from Panax ginseng as a novel angiogenic agent for tissue regeneration. 2005 , 22, 636-46	71
1208	Novel hepatocyte growth factor (HGF) binding domains on fibronectin and vitronectin coordinate a distinct and amplified Met-integrin induced signalling pathway in endothelial cells. 2005 , 6, 8	113
1207	Anti-lipid phosphate phosphohydrolase-3 (LPP3) antibody inhibits bFGF- and VEGF-induced capillary morphogenesis of endothelial cells. 2005 , 3, 9	22
1206	Effect of preterm birth on hypoxia-inducible factors and vascular endothelial growth factor in primate lungs. 2005 , 40, 538-46	46

1205	Dual inhibition of the epidermal growth factor and vascular endothelial growth factor phosphorylation for antivasular therapy of human prostate cancer in the prostate of nude mice. 2005 , 65, 203-15	33
1204	Differential expression of Hela-type caldesmon in tumour neovascularization: a new marker of angiogenic endothelial cells. 2005 , 205, 408-14	26
1203	Tumor Angiogenesis Regulated by Gaseous Molecules in Tumor Microenvironment: Oxygen, pH, and Nitric Oxide. 2005 , 283-290	1
1202	Practical Vessel Imaging by Computed Tomography in Live Transgenic Mouse Models for Human Tumors. 2005 , 4, 7290.2005.05166	28
1201	Antibody engineering, virus retargeting and cellular immunotherapy: one ring to rule them all?. 2005 , 5, 63-70	10
1200	Gene Therapy Models. 2005 ,	
1199	RNAi in drug development: Practical considerations. 2005 , 384-395	
1198	Integrins, cancer and snake toxins (mini-review). 2005 , 11, 217	8
1197	Dietary Prevention of Cancer: Anticancer and Antiangiogenic Properties of Green Tea Polyphenols. 2005 , 2, 49-58	2
1196	Vascular endothelial growth factor and soluble FLT-1 receptor interactions and biological implications. 2005 , 14, 1565	1
1195	The urokinase receptor and the regulation of cell proliferation. 2005 , 93, 641-6	32
1194	Imaging Dose-dependent Pharmacokinetics of an RGD-Fluorescent Dye Conjugate Targeted to $\alpha_5\beta_1$ Receptor Expressed in Kaposi's Sarcoma. 2005 , 4, 153535002005051	25
1193	Combination of interferon and angiotensin-converting enzyme inhibitor, perindopril, suppresses liver carcinogenesis and angiogenesis in mice. 2005 , 13, 491	4
1192	Molecular pathways of endothelial cell activation for (targeted) pharmacological intervention of chronic inflammatory diseases. 2005 , 3, 11-39	62
1191	Mapping of the functional microcirculation in vital organs using contrast-enhanced in vivo video microscopy. 2005 , 288, H185-93	27
1190	Tie2 activation contributes to hemangiogenic regeneration after myelosuppression. 2005 , 106, 505-13	95
1189	The postnatal rat aorta contains pericyte progenitor cells that form spheroidal colonies in suspension culture. 2005 , 289, C1396-407	105
1188	Expression and function of laminins in the embryonic and mature vasculature. 2005 , 85, 979-1000	410

1187	New indications for established drugs: combined tumor-stroma-targeted cancer therapy with PPARgamma agonists, COX-2 inhibitors, mTOR antagonists and metronomic chemotherapy. 2005 , 5, 393-419	50
1186	Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors. 2005 , 16, 1391-7	251
1185	Angiogenesis inhibition by vascular endothelial growth factor receptor-2 blockade reduces stromal matrix metalloproteinase expression, normalizes stromal tissue, and reverts epithelial tumor phenotype in surface heterotransplants. 2005 , 65, 1294-305	108
1184	Vascular endothelial growth factor levels in vitreous and serum of patients with either proliferative diabetic retinopathy or proliferative vitreoretinopathy. 2005 , 37, 188-90	38
1183	Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials. 2005 , 16, 558-65	103
1182	Conserved molecular players for axon guidance and angiogenesis. 2005 , 6, 473-8	13
1181	Mechanisms of colon cancer prevention with and beyond COX-2 inhibition. 2005 , 5, 505-16	7
1180	Biotechnological engineering of heparin/heparan sulphate: a novel area of multi-target drug discovery. 2005 , 11, 2489-99	47
1179	MMP-1 activation by serine proteases and MMP-10 induces human capillary tubular network collapse and regression in 3D collagen matrices. 2005 , 118, 2325-40	153
1178	Anti-angiogenic therapy as a cancer treatment paradigm. 2005 , 5, 115-30	32
1177	Vitamin k epoxide reductase: a protein involved in angiogenesis. 2005 , 3, 317-23	20
1176	Functional genomic analysis of cancer metastasis: biologic insights and clinical implications. 2005 , 5, 385-95	25
1175	Penta-O-galloyl-beta-D-glucose suppresses tumor growth via inhibition of angiogenesis and stimulation of apoptosis: roles of cyclooxygenase-2 and mitogen-activated protein kinase pathways. 2005 , 26, 1436-45	92
1174	Chapter 10 Heterogeneity of lung endothelial cells. 2005 , 35, 277-310	0
1173	Emerging role of the endothelin axis in ovarian tumor progression. 2005 , 12, 761-72	71
1172	Specific occlusion of murine and human tumor vasculature by VCAM-1-targeted recombinant fusion proteins. 2005 , 97, 733-47	62
1171	Identification and characterization of regulator of G protein signaling 4 (RGS4) as a novel inhibitor of tubulogenesis: RGS4 inhibits mitogen-activated protein kinases and vascular endothelial growth factor signaling. 2005 , 16, 609-25	57
1170	Formylpeptide receptor FPR and the rapid growth of malignant human gliomas. 2005 , 97, 823-35	98

1169	Placenta growth factor expression is correlated with survival of patients with colorectal cancer. 2005 , 54, 666-72	91
1168	Tumor necrosis factor and vascular endothelial growth factor induce endothelial integrin repertoires, regulating endovascular differentiation and apoptosis in a human extravillous trophoblast cell line. 2005 , 73, 172-9	41
1167	Liver failure after delivery. 2005 , 54, 672, 709	2
1166	Vascular endothelial growth factor: a therapeutic target for tumors of the Ewing's sarcoma family. 2005 , 11, 2364-78	109
1165	MR angiography of tumor-related vasculature: from the clinic to the micro-environment. 2005 , 25 Suppl 1, S85-97; discussion S97-8	25
1164	Human neutrophils promote angiogenesis by a paracrine feedforward mechanism involving endothelial interleukin-8. 2005 , 288, H1186-92	68
1163	Synergistic effects of light-emitting probes and peptides for targeting and monitoring integrin expression. 2005 , 102, 7976-81	119
1162	Mesenchymal stem cell targeting of microscopic tumors and tumor stroma development monitored by noninvasive in vivo positron emission tomography imaging. 2005 , 11, 7749-56	251
1161	Vascular endothelial growth factor-a promotes peritumoral lymphangiogenesis and lymphatic metastasis. 2005 , 65, 9261-8	154
1160	Tomographic fluorescence mapping of tumor targets. 2005 , 65, 6330-6	158
1159	Insulin-like growth factors 1 and 2 induce lymphangiogenesis in vivo. 2005 , 102, 15593-8	204
1158	Expression of vascular endothelial growth factor (VEGF) and VEGF receptors in tumor angiogenesis and malignancies. 2005 , 4, 315-21	64
1157	Cathepsin B regulates the intrinsic angiogenic threshold of endothelial cells. 2005 , 16, 3488-500	99
1156	Pigment epithelium-derived factor inhibits fibroblast-growth-factor-2-induced capillary morphogenesis of endothelial cells through Fyn. 2005 , 118, 961-70	19
1155	Vascular endothelial-cadherin tyrosine phosphorylation in angiogenic and quiescent adult tissues. 2005 , 96, 384-91	101
1154	Angiogenic and antiangiogenic gene therapy. 2005 , 12 Suppl 1, S159-69	24
1153	A hypoxia-independent hypoxia-inducible factor-1 activation pathway induced by phosphatidylinositol-3 kinase/Akt in HER2 overexpressing cells. 2005 , 65, 3257-63	84
1152	Tumor Vasculature as a Target for Cancer Therapy. 2005 , 415-428	

1151	Delivery of systemic chemotherapeutic agent to tumors by using focused ultrasound: study in a murine model. 2005 , 234, 431-7	106
1150	Gene transfer of vasostatin, a calreticulin fragment, into neuroendocrine tumor cells results in enhanced malignant behavior. 2005 , 82, 1-10	13
1149	Fibulin-5 function during tumorigenesis. 2005 , 1, 23-35	42
1148	Phase 2 trial of copper depletion and penicillamine as antiangiogenesis therapy of glioblastoma. 2005 , 7, 246-53	87
1147	Activation of p38 has opposing effects on the proliferation and migration of endothelial cells. 2005 , 280, 20995-1003	114
1146	Inhibition of angiogenesis in cancer patients. 2005 , 10, 403-12	16
1145	Hyperforin acts as an angiogenesis inhibitor. 2005 , 71, 999-1004	44
1144	A molecular cascade showing nitric oxide-heme oxygenase-1-vascular endothelial growth factor-interleukin-8 sequence in human endothelial cells. 2005 , 146, 2229-38	49
1143	Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients. 2005 , 25, 144-51	106
1142	Correlation between melanoma angiogenesis and the mesenchymal stem cells and endothelial progenitor cells derived from bone marrow. 2005 , 14, 292-8	65
1141	Paracrine regulation of vascular endothelial growth factor--a expression during macrophage-melanoma cell interaction: role of monocyte chemotactic protein-1 and macrophage colony-stimulating factor. 2005 , 25, 674-83	47
1140	Antiangiogenic properties of gold nanoparticles. 2005 , 11, 3530-4	369
1139	Antiangiogenic strategies in hepatocellular carcinoma: current status. 2005 , 5, 645-56	12
1138	Interfacial biology of in-stent restenosis. 2005 , 2, 429-43	15
1137	Oncolytic HSV exerts direct antiangiogenic activity in ovarian carcinoma. 2005 , 16, 765-78	70
1136	Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. 2005 , 65, 2412-21	283
1135	A MATHEMATICAL MODEL FOR TUMOR CORDS INCORPORATING THE FLOW OF INTERSTITIAL FLUID. 2005 , 15, 1735-1777	44
1134	In vivo target modulation and biological activity of CHIR-258, a multitargeted growth factor receptor kinase inhibitor, in colon cancer models. 2005 , 11, 3633-41	156

1133	Effective gene-virotherapy for complete eradication of tumor mediated by the combination of hTRAIL (TNFSF10) and plasminogen k5. 2005 , 11, 531-41	53
1132	MATHEMATICAL MODELLING OF CANCER CELL INVASION OF TISSUE: THE ROLE OF THE UROKINASE PLASMINOGEN ACTIVATION SYSTEM. 2005 , 15, 1685-1734	196
1131	The clinical potential of antiangiogenic fragments of extracellular matrix proteins. 2005 , 93, 967-72	40
1130	Endostatin cDNA/cationic liposome complexes as a promising therapy to prevent lung metastases in osteosarcoma: study in a human-like rat orthotopic tumor. 2005 , 11, 311-9	46
1129	Transcriptional regulation of the Vascular Endothelial Growth Factor gene--a concert of activating factors. 2005 , 65, 564-73	331
1128	New insights into intussusceptive angiogenesis. 2005 , 17-33	17
1127	Integrin-mediated adhesion and soluble ligand binding stabilize COX-2 protein levels in endothelial cells by inducing expression and preventing degradation. 2005 , 280, 1077-85	45
1126	Epstein-Barr virus lytic infection is required for efficient production of the angiogenesis factor vascular endothelial growth factor in lymphoblastoid cell lines. 2005 , 79, 13984-92	81
1125	Platelet-derived growth factor-AA is an essential and autocrine regulator of vascular endothelial growth factor expression in non-small cell lung carcinomas. 2005 , 65, 7241-8	81
1124	Invasion and Metastasis. 2005 ,	
1123	Oxygen distribution in murine tumors: characterization using oxygen-dependent quenching of phosphorescence. 2005 , 98, 1503-10	75
1122	Tumor dose response to the vascular disrupting agent, 5,6-dimethylxanthenone-4-acetic acid, using in vivo magnetic resonance spectroscopy. 2005 , 11, 3705-13	32
1121	Delivery of antiangiogenic agents for cancer gene therapy. 2005 , 4, 331-41	3
1120	Function of endogenous inhibitors of angiogenesis as endothelium-specific tumor suppressors. 2005 , 102, 2934-9	156
1119	A novel model for the investigation of orthotopically growing primary and secondary bone tumours using intravital microscopy. 2005 , 39, 377-83	12
1118	17 beta-estradiol transiently disrupts adherens junctions in endothelial cells. 2005 , 19, 1368-70	42
1117	Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors. 2005 , 169, 681-91	600
1116	Calcitonin stimulates multiple stages of angiogenesis by directly acting on endothelial cells. 2005 , 65, 8519-29	34

1115	Update on therapeutic neovascularization. 2005 , 65, 639-48	79
1114	Ozone. 2005 ,	2
1113	Integration/Interaction of Oncologic Growth. 2005 ,	3
1112	Elastin-derived peptides enhance angiogenesis by promoting endothelial cell migration and tubulogenesis through upregulation of MT1-MMP. 2005 , 118, 343-56	185
1111	Enhanced susceptibility of irradiated tumor vessels to vascular endothelial growth factor receptor tyrosine kinase inhibition. 2005 , 65, 5374-9	47
1110	Anti-angiogenic and anti-inflammatory effects of statins: relevance to anti-cancer therapy. 2005 , 5, 579-94	144
1109	Targeting invasion induction as a therapeutic strategy for the treatment of cancer. 2005 , 5, 489-503	16
1108	Endothelin-1 and angiogenesis in cancer. 2005 , 3, 309-14	68
1107	Molecularly targeted therapy for gastrointestinal cancer. 2005 , 5, 171-93	73
1106	Systems biology and the mathematical modelling of antibody-directed enzyme prodrug therapy (ADEPT). 2005 , 152, 291-302	5
1105	In vitro evaluation of the angiostatic potential of drugs using an endothelialized tissue-engineered connective tissue. 2005 , 315, 510-6	36
1104	Apigenin inhibits VEGF and HIF-1 expression via PI3K/AKT/p70S6K1 and HDM2/p53 pathways. 2005 , 19, 342-53	246
1103	Association of genetic polymorphisms in the VEGF gene with breast cancer survival. 2005 , 65, 5015-9	133
1102	Apoptotic cells initiate endothelial cell sprouting via electrostatic signaling. 2005 , 65, 11529-35	46
1101	Matrix Metalloproteinases: Mediators of Tumour-Host Cell Interactions. 2005 , 81-126	
1100	Angiogenic capacity of human omental stem cells. 2005 , 27, 807-11	62
1099	Differential expression of angiopoietin-1 and angiopoietin-2 may enhance recruitment of bone-marrow-derived endothelial precursor cells into brain tumors. 2005 , 27, 801-6	25
1098	Identification of circulating prostate cancer cells: A challenge to the clinical implementation of molecular biology (Review). 2005 , 26, 565	1

1097	Anti-angiogenic and anti-tumor apoptotic activities of a topoisomerase II inhibiting agent SJ-8026. 2005 , 26, 1613	
1096	Anti-angiogenic effects of Hypericin-photodynamic therapy in combination with Celebrex [®] in the treatment of human nasopharyngeal carcinoma. 2005 , 16, 993	5
1095	[Value of angiogenesis inhibitors in tumor diseases--preclinical data]]. 2005 , 28 Suppl 4, 25-8	1
1094	Anti-angiogenic strategies for cancer therapy (Review). 2005 , 27, 563	2
1093	Ionizing radiation inhibits tumor neovascularization by inducing ineffective angiogenesis. 2005 , 4, 1395-1400	48
1092	Angiogenesis and hematological malignancies. 2005 , 10, 11-24	7
1091	Comparing contrast-enhanced us to markers of angiogenesis in a murine glioma model.	
1090	MR molecular imaging and fluorescence microscopy for identification of activated tumor endothelium using a bimodal lipidic nanoparticle. 2005 , 19, 2008-10	234
1089	Hypoxia inducible factor pathways as targets for functional foods. 2005 , 53, 3751-68	23
1088	Design, synthesis, and evaluation of orally active 4-(2,4-difluoro-5-(methoxycarbonyl)phenylamino)pyrrolo[2,1-f][1,2,4]triazines as dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 inhibitors. 2005 , 48, 3991-4008	59
1087	Microvascular density, vascular endothelial growth factor A, and its receptors in endometrial blood vessels in patients with menorrhagia. 2005 , 84, 692-700	16
1086	VEGF profiling and angiogenesis in human microtissues. 2005 , 118, 213-29	75
1085	TEM8 expression stimulates endothelial cell adhesion and migration by regulating cell-matrix interactions on collagen. 2005 , 305, 133-44	88
1084	Inhibition of Src kinase activity by Ad-mda7 suppresses vascular endothelial growth factor expression in prostate carcinoma cells. 2005 , 12, 707-15	45
1083	Medicinal benefits of green tea: part II. review of anticancer properties. 2005 , 11, 639-52	127
1082	A concise synthesis of a novel antiangiogenic tyrosine kinase inhibitor. 2005 , 70, 175-8	56
1081	Retinal vascular development and pathologic retinal angiogenesis are not impaired in matrix metalloproteinase-2 deficient mice. 2005 , 30, 259-67	10
1080	Assessment of microvascular perfusion changes in a rat breast tumor model using SonoVue to monitor the effects of different anti-angiogenic therapies. 2005 , 12 Suppl 1, S28-33	25

1079	Tumor vessel compression hinders perfusion of ultrasonographic contrast agents. 2005 , 7, 528-36	25
1078	Prognostic impact of race and ethnicity in the treatment of colorectal cancer. 2005 , 89, 1045-57, 1054	5
1077	Acute tumor response to ZD6126 assessed by intrinsic susceptibility magnetic resonance imaging. 2005 , 7, 466-74	31
1076	The IGF-1 receptor and its contributions to metastatic tumor growth-novel approaches to the inhibition of IGF-1R function. 2005 , 23, 1-14	52
1075	Differentially expressed genes in endothelial differentiation. 2005 , 24, 432-7	5
1074	Mechanisms of Angiogenesis. 2005 ,	5
1073	Anti-angiogenic activity of resveratrol, a natural compound from medicinal plants. 2005 , 7, 205-13	73
1072	Molecular targets of growth, differentiation, tissue integrity, and ectopic cell death in cancer cells. 2005 , 20, 579-88	9
1071	Therapeutic neovascularization: contributions from bioengineering. 2005 , 11, 567-84	76
1070	Endothelial precursors and mature endothelial cells are increased in the peripheral blood of myelodysplastic syndromes. 2005 , 46, 1345-51	36
1069	Angiogenesis and lung cancer: prognostic and therapeutic implications. 2005 , 23, 3243-56	207
1068	Angiopoietin-1 and myeloma-induced angiogenesis. 2005 , 46, 29-33	6
1067	Antibody-based antiangiogenic cancer therapy. 2005 , 9, 1235-45	5
1066	The vascular endothelial growth factor (VEGF) +405G>C 5'-untranslated region polymorphism and increased risk of endometriosis in South Indian women: a case control study. 2005 , 20, 1844-9	76
1065	Vascular endothelial growth factor expression and microvessel parameters of colonic mucosa correlate with sensitivity to steroid in patients with ulcerative colitis. 2005 , 40, 188-93	6
1064	Heparan sulfate: a complex polymer charged with biological activity. 2005 , 105, 2745-64	323
1063	Dynamic contrast-enhanced MR imaging kinetic parameters and molecular weight of dendritic contrast agents in tumor angiogenesis in mice. 2005 , 235, 65-72	98
1062	Angiogenesis: a curse or cure?. 2005 , 81, 236-42	58

1061	Imaging of tumor angiogenesis in rat brains in vivo by photoacoustic tomography. 2005 , 44, 770-5	152
1060	Serial noninvasive photoacoustic imaging of neovascularization in tumor angiogenesis. 2005 , 13, 89-95	166
1059	In vivo dark-field reflection-mode photoacoustic microscopy. 2005 , 30, 625-7	295
1058	Combination of vitamin K2 and the angiotensin-converting enzyme inhibitor, perindopril, attenuates the liver enzyme-altered preneoplastic lesions in rats via angiogenesis suppression. 2005 , 42, 687-93	62
1057	A heretical view on the role of NO and cGMP in vascular proliferative diseases. 2005 , 11, 71-5	41
1056	Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. 2005 , 69, 56-63	232
1055	A 2-D/3-D model-based method to quantify the complexity of microvasculature imaged by in vivo multiphoton microscopy. 2005 , 70, 165-78	24
1054	Medial thickening of hepatic artery branches in biliary atresia. A morphometric study. 2005 , 40, 637-42	45
1053	Angiogenesis and lymphangiogenesis and expression of lymphangiogenic factors in the atherosclerotic intima of human coronary arteries. 2005 , 36, 330-40	102
1052	Role of heme oxygenase-1 in hydrogen peroxide-induced VEGF synthesis: effect of HO-1 knockout. 2005 , 326, 670-6	67
1051	Engineering and characterization of a divalent single-chain Fv angiotensin II fusion construct of the monoclonal antibody CC49. 2005 , 329, 168-76	11
1050	Pleiotrophin induces formation of functional neovasculature in vivo. 2005 , 332, 1146-52	47
1049	Tumstatin, the NC1 domain of alpha3 chain of type IV collagen, is an endogenous inhibitor of pathological angiogenesis and suppresses tumor growth. 2005 , 333, 292-8	92
1048	Simulated hypogravity impairs the angiogenic response of endothelium by up-regulating apoptotic signals. 2005 , 334, 491-9	61
1047	Annexin A3 is a potential angiogenic mediator. 2005 , 337, 1283-7	94
1046	Cellular abnormalities of blood vessels as targets in cancer. 2005 , 15, 102-11	592
1045	EWS-ETS oncoproteins: the linchpins of Ewing tumors. 2005 , 363, 1-14	138
1044	Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. 2005 , 16, 159-78	1005

1043	Vessel maturation effects on tumour growth: validation of a computer model in implanted human ovarian carcinoma spheroids. 2005 , 41, 159-67	40
1042	Phase I investigation of recombinant anti-human vascular endothelial growth factor antibody in patients with advanced cancer. 2005 , 41, 555-63	49
1041	Long-term observation reveals time-course-dependent characteristics of tumour vascularisation. 2005 , 41, 1073-85	17
1040	Tumour parameters affected by combretastatin A-4 phosphate therapy in a human colorectal xenograft model in nude mice. 2005 , 41, 799-806	46
1039	Molecularly targeted agents: their promise as cancer chemopreventive interventions. 2005 , 41, 2003-15	22
1038	Growth factors and their relationship to neoplastic and paraneoplastic disease. 2005 , 16, 83-94	3
1037	Recent developments in the regulation of the angiogenic switch by cellular stress factors in tumors. 2005 , 218, 1-14	108
1036	VEGF, FGF2, TGFB1 and TGFBR1 mRNA expression levels correlate with the malignant transformation of the uterine cervix. 2005 , 221, 105-18	59
1035	Prospects for therapeutic inhibition of neuroblastoma angiogenesis. 2005 , 228, 171-9	34
1034	Toxicological overview of cigarette smoking on angiogenesis. 2005 , 20, 335-44	17
1033	Delayed inflammation-associated corneal neovascularization in MMP-2-deficient mice. 2005 , 80, 159-66	52
1032	Upregulation of placental growth factor by vascular endothelial growth factor via a post-transcriptional mechanism. 2005 , 579, 1227-34	30
1031	Immune cell-induced synthesis of NO and reactive oxygen species in lymphoma cells causes their death by apoptosis. 2005 , 579, 2833-41	13
1030	Rapid vessel regression, protease inhibition, and stromal normalization upon short-term vascular endothelial growth factor receptor 2 inhibition in skin carcinoma heterotransplants. 2005 , 167, 1389-403	30
1029	EGFL7 is a chemoattractant for endothelial cells and is up-regulated in angiogenesis and arterial injury. 2005 , 167, 275-84	111
1028	Tumor-induced mechanical hyperalgesia involves CGRP receptors and altered innervation and vascularization of DsRed2 fluorescent hindpaw tumors. 2005 , 115, 95-106	41
1027	Soluble factors released by endothelial progenitor cells promote migration of endothelial cells and cardiac resident progenitor cells. 2005 , 39, 733-42	634
1026	Thienopyrimidine ureas as novel and potent multitargeted receptor tyrosine kinase inhibitors. 2005 , 48, 6066-83	142

1025	A comparison of cyclohexanone and tetrahydro-4H-thiopyran-4-one 1,1-dioxide as pharmacophores for the design of peptide-based inhibitors of the serine protease plasmin. 2005 , 70, 8309-21	9
1024	Synthesis of 5-substituted-1H-indol-2-yl-1H-quinolin-2-ones: a novel class of KDR kinase inhibitors. 2005 , 70, 2555-67	81
1023	Interleukin-8 in non-small cell lung carcinoma: relation with angiogenic pattern and p53 alterations. 2005 , 50, 309-17	29
1022	Angiopoietin-like proteins: potential new targets for metabolic syndrome therapy. 2005 , 11, 473-9	101
1021	Regulation of the pathological vasculature of malignant astrocytomas by angiopoietin-1. 2005 , 7, 1081-90	18
1020	Gene therapy for malignant glioma: current clinical status. 2005 , 12, 585-98	163
1019	Angiogenesis in the female reproductive system. 2005 , 35-52	5
1018	2-(Quinazolin-4-ylamino)-[1,4]benzoquinones as covalent-binding, irreversible inhibitors of the kinase domain of vascular endothelial growth factor receptor-2. 2005 , 48, 7560-81	52
1017	Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. 2005 , 307, 58-62	4088
1016	Muscarinic receptors participation in angiogenic response induced by macrophages from mammary adenocarcinoma-bearing mice. 2005 , 7, R345-52	20
1015	Relative microvessel area of the primary tumour, and not lymph node status, predicts the presence of bone marrow micrometastases detected by reverse transcriptase polymerase chain reaction in patients with clinically non-metastatic breast cancer. 2005 , 7, R210-9	26
1014	The vascular endothelial growth factor (VEGF) family: angiogenic factors in health and disease. 2005 , 6, 209	362
1013	Functional inhibition of NF-kappaB signal transduction in alphavbeta3 integrin expressing endothelial cells by using RGD-PEG-modified adenovirus with a mutant IkappaB gene. 2006 , 8, R32	24
1012	Therapeutic options to target angiogenesis in human malignancies. 2006 , 11, 635-50	63
1011	Vascular Targeting and Therapeutics for Squamous Cell Carcinoma of the Head and Neck. 2006 , 5, 7-18	
1010	The Vascular Endothelium II. 2006 ,	4
1009	Target Discovery and Validation Reviews and Protocols. 2006 ,	
1008	Lowering of tumor interstitial fluid pressure reduces tumor cell proliferation in a xenograft tumor model. 2006 , 8, 89-95	76

1007	Cutting edge: extracellular high mobility group box-1 protein is a proangiogenic cytokine. 2006 , 176, 12-5	193
1006	Molecular imaging: a primer for interventionalists and imagers. 2006 , 17, 1405-23	14
1005	Comparison of the performance of tracer kinetic model-driven registration for dynamic contrast enhanced MRI using different models of contrast enhancement. 2006 , 13, 1112-23	39
1004	Angiogenesis-like activity of endothelial cells co-cultured with VEGF-producing smooth muscle cells. 2006 , 12, 381-90	44
1003	Lessons from phase III clinical trials on anti-VEGF therapy for cancer. 2006 , 3, 24-40	865
1002	Cancer Drug Resistance. 2006 ,	17
1001	Hyperthermia in Cancer Treatment: A Primer. 2006 ,	40
1000	Fluorescent core-shell silica nanoparticles: an alternative radiative materials platform. 2006 , 6096, 609605	7
999	Cell surface F1Fo ATP synthase: a new paradigm?. 2006 , 38, 429-38	93
998	The HUVEC/Matrigel assay: an in vivo assay of human angiogenesis suitable for drug validation. 2007 , 360, 253-68	15
997	Localized angiogenesis induced by human vascular endothelial growth factor-activated PLGA sponge. 2006 , 12, 959-68	59
996	Innate immune recognition and suppression of tumors. 2006 , 95, 293-322	50
995	A multitargeted receptor tyrosine kinase inhibitor, SU6668, does not affect the healing of cutaneous full-thickness incisional wounds in SKH-1 mice. 2006 , 19, 245-54	7
994	Mechanisms of disease: angiogenesis in urologic malignancies. 2006 , 3, 157-69	44
993	VEGF gene and phenotype relation with Alzheimer's disease and mild cognitive impairment. 2006 , 9, 485-93	74
992	Endothelial cells and cancer. 2006 , 307-34	10
991	Complex Systems Science in Biomedicine. 2006 ,	18
990	Effects of boron neutron capture therapy on human oral squamous cell carcinoma in a nude mouse model. 2006 , 82, 21-9	15

989	Recent clinical progress in virus-based therapies for cancer. 2006 , 6, 1123-34	12
988	Bone marrow-derived stem cell therapy in ischemic heart disease. 2006 , 1, 337-45	7
987	Glioma-specific antigens for immune tumor therapy. 2006 , 5, 793-802	11
986	Apigenin inhibits tumor angiogenesis through decreasing HIF-1alpha and VEGF expression. 2007 , 28, 858-64	160
985	Evidence for an association of high levels of endogenous Acetyl-Ser-Asp-Lys-Pro, a potent mediator of angiogenesis, with acute myeloid leukemia development. 2006 , 47, 1915-20	12
984	A review of the latest clinical compounds to inhibit VEGF in pathological angiogenesis. 2006 , 10, 867-76	71
983	Pericytes and vascular stability. 2006 , 312, 623-9	386
982	Towards a Two-Scale Cellular Automata Model of Tumour-Induced Angiogenesis. 2006 , 337-346	2
981	Vascular endothelial growth factor localization in the adult. 2006 , 168, 639-48	226
980	Differential angiogenic regulation of experimental colitis. 2006 , 169, 2014-30	114
979	Preferential attachment of peritoneal tumor metastases to omental immune aggregates and possible role of a unique vascular microenvironment in metastatic survival and growth. 2006 , 169, 1739-52	131
978	Bovine lactoferricin inhibits basic fibroblast growth factor- and vascular endothelial growth factor-induced angiogenesis by competing for heparin-like binding sites on endothelial cells. 2006 , 169, 1753-66	69
977	Recruitment of a prostaglandin E receptor subtype, EP3-expressing bone marrow cells is crucial in wound-induced angiogenesis. 2006 , 169, 1458-72	45
976	Vascularized organoid engineered by modular assembly enables blood perfusion. 2006 , 103, 11461-6	313
975	Combined biodifferentiating and antiangiogenic oral metronomic therapy is feasible and effective in relapsed solid tumors in children: single-center pilot study. 2006 , 29, 308-13	39
974	Hierarchical microimaging for multiscale analysis of large vascular networks. 2006 , 32, 626-36	138
973	Angiogenesis in the mouse retina: a model system for experimental manipulation. 2006 , 312, 676-83	68
972	Neural-cell adhesion molecule (NCAM) expression by immature and tumor-derived endothelial cells favors cell organization into capillary-like structures. 2006 , 312, 913-24	44

971	Relationship of smoking and fibrosis in patients with chronic hepatitis C. 2006 , 4, 797-801	42
970	Bioavailability of VEGF in tumor-shed vesicles depends on vesicle burst induced by acidic pH. 2006 , 8, 96-103	143
969	[The effect of human IL-17F on growth of human hepatocarcinoma xenograft tumor in nude mice]. 2006 , 22, 772-8	
968	Heparin binding nanostructures to promote growth of blood vessels. 2006 , 6, 2086-90	374
967	Angiogenese tumorale. 2006 , 26, 67-69	0
966	Tumor stroma and regulation of cancer development. 2006 , 1, 119-50	750
965	Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan- 2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor. 2006 , 49, 2143-6	119
964	Discovery and evaluation of N-cyclopropyl- 2,4-difluoro-5-((2-(pyridin-2-ylamino)thiazol-5-ylmethyl)amino)benzamide (BMS-605541), a selective and orally efficacious inhibitor of vascular endothelial growth factor receptor-2. 2006 , 49, 3766-9	39
963	Flow correlated percolation during vascular remodeling in growing tumors. 2006 , 96, 058104	65
962	Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. 2006 , 49, 1271-81	78
961	Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. 2006 , 90, 1-50	568
960	Sequential changes in vessel formation and micro-vascular function during bone repair. 2006 , 77, 429-39	25
959	Role of transforming growth factor-beta in cancer progression. 2006 , 2, 743-63	67
958	Anti-angiogenic therapy: Prospects for treatment of ocular tumors. 2006 , 21, 151-60	22
957	p53-mediated inhibition of angiogenesis through up-regulation of a collagen prolyl hydroxylase. 2006 , 313, 968-71	155
956	Incidence and management of bevacizumab-related toxicities in colorectal cancer. 2006 , 5, 553-66	86
955	Expression of integrins in cerebral arteriovenous and cavernous malformations. 2006 , 58, 159-68; discussion 159-68	35
954	Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. 2006 , 66, 4426-33	456

953	Rationale for combination therapies for choroidal neovascularization. 2006 , 141, 149-56	100
952	The host's genetic background determines the extent of angiogenesis induced by schistosome egg antigens. 2006 , 99, 243-51	10
951	Biology of vascular endothelial growth factors. 2006 , 580, 2879-87	355
950	Expression of VEGFR-2 on HaCaT cells is regulated by VEGF and plays an active role in mediating VEGF induced effects. 2006 , 349, 31-8	42
949	Characterization of the human EDF-1 minimal promoter: involvement of NFY and Sp1 in the regulation of basal transcription. 2006 , 374, 87-95	11
948	Transcriptional deregulation of VEGF, FGF2, TGF-beta1, 2, 3 and cognate receptors in breast tumorigenesis. 2006 , 235, 100-13	17
947	Potential of cyclophosphamide chemotherapy using the anti-angiogenic drug thalidomide: importance of optimal scheduling to exploit the 'normalization' window of the tumor vasculature. 2006 , 244, 129-35	58
946	Current status of angiogenesis inhibitors combined with radiation therapy. 2006 , 32, 348-64	97
945	Angiopoietin 1 (Ang-1), angiopoietin 2 (Ang-2) and Tie-2 (a receptor tyrosine kinase) concentrations in peripheral blood of patients with thyroid cancers. 2006 , 36, 291-5	27
944	Microtubule-targeting agents in angiogenesis: where do we stand?. 2006 , 9, 74-86	70
943	Mechanisms of pericyte recruitment in tumour angiogenesis: a new role for metalloproteinases. 2006 , 42, 310-8	112
942	Angiogenesis in multiple myeloma. 2006 , 42, 1581-90	118
941	Vaccines targeting tumour angiogenesis--a novel strategy for cancer immunotherapy. 2006 , 32, 363-70	36
940	In vivo volumetric imaging of subcutaneous microvasculature by photoacoustic microscopy. 2006 , 14, 9317-23	96
939	Ischemic vascular disease and solid cancers: opposing ends of the angiogenic spectrum?. 2006 , 67, 1317-9	1
938	Does cancer growth depend on surface extension?. 2006 , 67, 1338-41	14
937	On the transendothelial passage of tumor cell from extravasal matrix into the lumen of absorbing lymphatic vessel. 2006 , 72, 74-85	19
936	Increased angiogenic capabilities of endothelial cells from microvessels of malignant human gliomas. 2006 , 6, 90-9	28

935	The biology of vascular endothelial growth factor-B (VEGF-B). 2006 , 19, 61-9	70
934	Cloning, purification, and characterization of a non-collagenous anti-angiogenic protein domain from human alpha1 type IV collagen expressed in Sf9 cells. 2006 , 49, 211-8	22
933	Expression of the non-glycosylated kringle domain of tissue type plasminogen activator in Pichia and its anti-endothelial cell activity. 2006 , 50, 1-8	3
932	Polymer-peptide conjugates for angiogenesis targeted tumor radiotherapy. 2006 , 33, 43-52	61
931	Synthesis and evaluation of 4-[(18)F]fluorothalidomide for the in vivo studies of angiogenesis. 2006 , 33, 255-62	9
930	An improved method of 18F peptide labeling: hydrazone formation with HYNIC-conjugated c(RGDyK). 2006 , 33, 677-83	34
929	A Case of Pulmonary Thromboembolism Developed during Chemotherapy with Gemcitabine and Cisplatin for Nonsmall Cell Lung Cancer -A case report-. 2006 , 5, 47	
928	[Treatment of neovascular age-related macular degeneration with antiangiogenic drugs]. 2006 , 69, 756-65	1
927	Abnormal Microvasculature and Defective Microcirculatory Function in Solid Tumors. 2006 , 9-29	10
926	The Role of Microvasculature in Metastasis Formation. 2006 , 31-62	5
925	Meaning of the DR-70 Immunoassay for Patients with the Malignant Tumor. 2006 , 6, 43	5
924	The Effect of Venous Thromboembolism on Survival of Cancer Patients and its Relationship with Serum Levels of Factor VIII and Vascular Endothelial Growth Factor: A Prospective Matched-Paired Study. 2006 , 21, 206-210	1
923	Quercetin inhibits eNOS, microtubule polymerization, and mitotic progression in bovine aortic endothelial cells. 2006 , 136, 1178-84	51
922	Promotion of angiogenesis in tissue engineering: developing multicellular matrices with multiple capacities. 2006 , 29, 1148-57	23
921	Chemokines in gastrointestinal disorders. 2006 , 7, 47-64	22
920	. 2006 ,	1
919	LFA-1 and VLA-4 involved in human high proliferative potential endothelial progenitor cells homing to ischemic tissue. 2006 , 96, 807-815	47
918	Cadherin Antagonists as Vasculature-targeting Agents. 2006 , 195-204	1

917	. 2006,	22
916	Use of Vasculature-disrupting Agents in Non-Oncology Indications. 2006, 323-340	1
915	Anthracyclines, small-molecule inhibitors of hypoxia-inducible factor-1 alpha activation. 2006, 29, 1999-2003	11
914	Optical biopsy of non-melanin pigmented cutaneous benign and malignant lesions. 2006,	1
913	Amelioration of liver fibrogenesis by dual inhibition of PDGF and TGF- β with a combination of imatinib mesylate and ACE inhibitor in rats. 2006, 17, 899	4
912	Estradiol and nicotine exposure enhances A549 bronchioloalveolar carcinoma xenograft growth in mice through the stimulation of angiogenesis. 2006, 28, 337	1
911	Polymeric Conjugates for Angiogenesis-Targeted Tumor Imaging and Therapy. 2006, 159-184	
910	Polymeric Nanoparticles for Tumor-Targeted Drug Delivery. 2006, 215-229	
909	The role of heparan sulphate proteoglycans in angiogenesis. 2006, 34, 451-3	85
908	Differential gene and protein expression in abluminal sprouting and intraluminal splitting forms of angiogenesis. 2006, 110, 587-95	53
907	Evidence for incorporation of bone marrow-derived endothelial cells into perfused blood vessels in tumors. 2006, 107, 2774-6	131
906	Hypoxic induction of an HIF-1alpha-dependent bFGF autocrine loop drives angiogenesis in human endothelial cells. 2006, 107, 2705-12	202
905	Endoglin expression in the endothelium is regulated by Fli-1, Erg, and Elf-1 acting on the promoter and a -8-kb enhancer. 2006, 107, 4737-45	57
904	Peroxisome-proliferator-activated receptor alpha agonists inhibit cyclo-oxygenase 2 and vascular endothelial growth factor transcriptional activation in human colorectal carcinoma cells via inhibition of activator protein-1. 2006, 395, 81-8	67
903	Flavonoids and vitamin E reduce the release of the angiogenic peptide vascular endothelial growth factor from human tumor cells. 2006, 136, 1477-82	121
902	Anti-angiogenic action of plasma hyaluronan binding protein in human umbilical vein endothelial cells. 2006, 29, 209	1
901	Vitreous fluid biomarkers. 2006, 42, 111-66	9
900	A Phase I Dose-Escalation Study of ZD6474 in Japanese Patients with Solid, Malignant Tumors. 2006, 1, 1002-1009	48

899	Hypoxia-targeted bioreductive tyrosine kinase inhibitors with glutathione-depleting function. 2006 , 17, 21-4	2
898	Vascular endothelial growth factor (VEGF) is suppressed in WT1-transfected LNCaP cells. 2006 , 13, 1-14	13
897	Tumour-associated host cells participating at invasion and metastasis : targets for therapy?. 2006 , 106, 635-40	23
896	Protein and Peptide-Based Cancer Gene Therapy. 2006 , 335-370	
895	Amelioration of carcinogenesis and tumor growth in the rat liver by combination of vitamin K2 and angiotensin-converting enzyme inhibitor via anti-angiogenic activities. 2006 , 15, 155	2
894	Role of Vascular Endothelial Growth Factor in the Prognosis of Papillary Thyroid Cancer. 2006 , 16, 168-171	1
893	Early destruction of tumor vasculature in tumor necrosis factor-alpha-based isolated limb perfusion is responsible for tumor response. 2006 , 17, 949-59	27
892	Contribution of endothelial progenitors and proangiogenic hematopoietic cells to vascularization of tumor and ischemic tissue. 2006 , 13, 175-81	173
891	Protein and Peptide Drugs to Suppress Tumor Angiogenesis. 2006 , 255-284	
890	Role of lymphangiogenesis and lymphangiogenic factors during pancreatic cancer progression and lymphatic spread. 2006 , 28, 883	6
889	Core/Shell fluorescent silica nanoparticles for chemical sensing: towards single-particle laboratories. 2006 , 2, 723-6	252
888	Antiproliferative effects of 5-fluorouracil and interferon-alpha in combination on a hepatocellular carcinoma cell line in vitro and in vivo. 2006 , 21, 129-37	11
887	Different isoform patterns for vascular endothelial growth factor between clear cell and papillary renal cell carcinoma. 2006 , 97, 1102-8	29
886	The role of the lymphatic system and its specific growth factor, vascular endothelial growth factor C, for lymphogenic metastasis in prostate cancer. 2006 , 98, 903-6	20
885	Angiogenesis in gliomas: biology and molecular pathophysiology. 2005 , 15, 297-310	254
884	Expression pattern of angiogenic factors and prognosis after hepatic resection in hepatocellular carcinoma: importance of angiopoietin-2 and hypoxia-induced factor-1 alpha. 2006 , 26, 414-23	97
883	Increased angiogenesis and permeability in the mesenteric microvasculature of rats with cirrhosis and portal hypertension: an in vivo study. 2006 , 26, 889-98	53
882	Induction of transcription factor CEBP homology protein mediates hypoglycaemia-induced necrotic cell death in human neuroblastoma cells. 2006 , 99, 952-64	12

881	Association between CD31 expression and histopathologic features in stage IB squamous cell carcinoma of the cervix. 2006 , 16, 757-62	9
880	Hypoxia and expression of the proapoptotic regulator BNIP3 in cervical cancer. 2006 , 16, 1314-20	20
879	Ocular angiogenesis: the role of growth factors. 2006 , 84, 282-8	77
878	Perinatal expression of HSP70 and VEGF in neonatal rat lung vessels exposed to nicotine during gestation. 2006 , 114, 10-4	7
877	Low-molecular-weight heparins and angiogenesis. 2006 , 114, 79-102	111
876	p130-angiomotin associates to actin and controls endothelial cell shape. 2006 , 273, 2000-11	81
875	Discovery of diphenylmethanepropionic and dihydrostilbeneacetic acids as antagonists of the integrin $\alpha v \beta 3$. 2006 , 67, 177-81	5
874	Peptide-based molecules in angiogenesis. 2006 , 67, 115-26	81
873	Role of fibrin matrix in angiogenesis. 2001 , 936, 426-37	212
872	New therapeutic option for autosomal dominant polycystic kidney disease patients with enlarged kidney and liver. 2006 , 10, 333-41	27
871	Immunohistochemical detection of platelet-derived endothelial cell growth factor/thymidine phosphorylase and angiopoietins in ameloblastic tumors. 2006 , 35, 606-12	13
870	Regeneration of vascularized bone. 2006 , 41, 109-22	62
869	Effect and mechanism of melatonin's action on the proliferation of human umbilical vein endothelial cells. 2006 , 41, 358-62	47
868	Intrinsic tyrosine kinase activity is required for vascular endothelial growth factor receptor 2 ubiquitination, sorting and degradation in endothelial cells. 2006 , 7, 1270-82	144
867	[Stroma-targeted palliative tumor therapy with biomodulators]. 2006 , 4, 242-53; quiz 254-5	5
866	Stroma-orientierte palliative Tumorthherapie mit Biomodulatoren. 2006 , 4, ---	
865	[A trip through the signaling pathways of melanoma]. 2006 , 4, 205-17	9
864	Ein Streifzug durch die (Signal-)Wege des malignen Melanoms. 2006 , 4, ---	

863	The use of clostridial spores for cancer treatment. 2006 , 101, 571-8	50
862	Cationized gelatin delivery of a plasmid DNA expressing small interference RNA for VEGF inhibits murine squamous cell carcinoma. 2006 , 97, 313-21	56
861	Vascular endothelial growth factor C--a potent risk factor in childhood acute lymphoblastic leukaemia: an immunocytochemical approach. 2006 , 49, 170-7	6
860	Functional photoacoustic microscopy for high-resolution and noninvasive in vivo imaging. 2006 , 24, 848-51	1304
859	Fabrication of cell-containing gel modules to assemble modular tissue-engineered constructs [corrected]. 2006 , 1, 2963-9	54
858	The role of nitric oxide in tumour progression. 2006 , 6, 521-34	944
857	Predicting benefit from anti-angiogenic agents in malignancy. 2006 , 6, 626-35	202
856	Crystal structures of the Tie2 receptor ectodomain and the angiopoietin-2-Tie2 complex. 2006 , 13, 524-32	98
855	Phase 1 trial of the antiangiogenic peptide ATN-161 (Ac-PHSCN-NH(2)), a beta integrin antagonist, in patients with solid tumours. 2006 , 94, 1621-6	131
854	Infantile hemangioma is a proliferation of LYVE-1-negative blood endothelial cells without lymphatic competence. 2006 , 19, 291-8	16
853	Phosphorylated KDR can be located in the nucleus of neoplastic cells. 2006 , 16, 93-8	32
852	Knockdown of CD146 reduces the migration and proliferation of human endothelial cells. 2006 , 16, 313-8	58
851	A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium. 2006 , 13, 1222-34	313
850	Promoter region methylation and reduced expression of thrombospondin-1 after oxygen-glucose deprivation in murine cerebral endothelial cells. 2006 , 26, 1519-26	52
849	Dexamethasone induction of keloid regression through effective suppression of VEGF expression and keloid fibroblast proliferation. 2006 , 126, 1264-71	103
848	Functional MR imaging of tumor angiogenesis predicts outcome of patients with acute myeloid leukemia. 2006 , 20, 357-62	16
847	Hypoxic regulation of stability of connective tissue growth factor/CCN2 mRNA by 3'-untranslated region interacting with a cellular protein in human chondrosarcoma cells. 2006 , 25, 1099-110	52
846	Antiangiogenic activity of deoxoartemisinin derivatives on chorioallantoic membrane. 2006 , 16, 1227-30	34

845	Hit-to-lead optimization of 1,4-dihydroindeno[1,2-c]pyrazoles as a novel class of KDR kinase inhibitors. 2006 , 16, 4371-5	23
844	Synthesis and biological study of 4-aminopyrimidine-5-carboxaldehyde oximes as antiproliferative VEGFR-2 inhibitors. 2006 , 16, 6063-6	21
843	N-Glycosyl-thiophene-2-carboxamides: synthesis, structure and effects on the growth of diverse cell types. 2006 , 341, 1370-90	9
842	Study of the labeling of two novel RGD-peptidic derivatives with the precursor [^{99m} Tc(H ₂ O) ₃ (CO) ₃] ⁺ and evaluation for early angiogenesis detection in cancer. 2006 , 64, 151-9	11
841	Simulating chemotherapeutic schemes in the individualized treatment context: the paradigm of glioblastoma multiforme treated by temozolomide in vivo. 2006 , 36, 1216-34	19
840	Advances in understanding angiogenesis through molecular studies. 2006 , 64, 26-32	2
839	Combining radiotherapy and angiogenesis inhibitors: clinical trial design. 2006 , 64, 15-25	36
838	Noninvasive monitoring of radiotherapy-induced microvascular changes using dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) in a colorectal tumor model. 2006 , 64, 1188-96	52
837	Angiotensin-II and vascular endothelial growth factor interaction plays an important role in rat liver fibrosis development. 2006 , 36, 124-9	28
836	The dynamic evolution of the power exponent in a universal growth model of tumors. 2006 , 240, 459-63	55
835	Histopathological observations of the antivasular effects of physiotherapy ultrasound on a murine neoplasm. 2006 , 32, 453-61	24
834	Ultrasound assessment of angiogenesis in a matrigel model in rats. 2006 , 32, 673-81	33
833	Mechanisms of Angiogenesis in Brain Tumors and their Translation into Therapeutic Anti-tumor Strategies. 2006 , 219-235	
832	Fluorescent core-shell silica nanoparticles: towards "Lab on a Particle" architectures for nanobiotechnology. 2006 , 35, 1028-42	752
831	Characterization of mesenchymal stem cells isolated from mouse fetal bone marrow. 2006 , 24, 482-93	47
830	VEGF and angiopoietin-1 stimulate different angiogenic phenotypes that combine to enhance functional neovascularization in adult tissue. 2006 , 13, 423-37	56
829	TNF-alpha in cancer treatment: molecular insights, antitumor effects, and clinical utility. 2006 , 11, 397-408	510
828	MT1-MMP: universal or particular player in angiogenesis?. 2006 , 25, 77-86	112

827	Novel functions of TIMPs in cell signaling. 2006 , 25, 99-113	320
826	Bacterial expression strategies for human angiogenesis proteins. 2006 , 7, 23-30	3
825	HER-2/neu Cancer Vaccines: Present Status and Future Prospects. 2006 , 12, 65-77	4
824	Isolation and culture of microvascular endothelial cells from gliomas of different WHO grades. 2006 , 76, 39-48	58
823	Fibroblast growth factor-2 augments recombinant human bone morphogenetic protein-2-induced osteoinductive activity. 2006 , 34, 717-25	29
822	Three-dimensional reconstruction of tumor microvasculature: simultaneous visualization of multiple components in paraffin-embedded tissue. 2005 , 8, 297-305	32
821	Inhibition of angiogenesis by vitamin D-binding protein: characterization of anti-endothelial activity of DBP-maf. 2005 , 8, 349-60	28
820	Reduced vascular endothelial growth inhibitor (VEGI) expression is associated with poor prognosis in breast cancer patients. 2006 , 9, 73-81	44
819	TNP-470 fails to block the onset of angiogenesis and early tumor establishment in an intravital minimal disease model. 2006 , 21, 143-54	8
818	Neural driven angiogenesis by overexpression of nerve growth factor. 2006 , 125, 637-49	42
817	An adiponectin receptor, T-cadherin, was selectively expressed in intratumoral capillary endothelial cells in hepatocellular carcinoma: possible cross talk between T-cadherin and FGF-2 pathways. 2006 , 448, 311-8	32
816	Current status and perspective of antiangiogenic therapy for cancer: urinary cancer. 2006 , 11, 90-107	11
815	Current status and perspective of antiangiogenic therapy for cancer: hepatocellular carcinoma. 2006 , 11, 82-9	28
814	Angiogenesis and capillary maturation phenotypes associated with the Edpm3 locus on rat chromosome 3. 2006 , 17, 49-57	7
813	[(Side) effects of VEGF inhibition]. 2006 , 103, 484-92	14
812	Asymmetric dimethylarginine (ADMA): an endogenous inhibitor of angiogenesis. 2006 , 62, 115-121	7
811	Alphavbeta3-integrin imaging: a new approach to characterise angiogenesis?. 2006 , 33 Suppl 1, 54-63	128
810	Aplidin reduces growth of anaplastic thyroid cancer xenografts and the expression of several angiogenic genes. 2006 , 57, 7-14	47

809	Preferential extravasation and accumulation of liposomal vincristine in tumor comparing to normal tissue enhances antitumor activity. 2006 , 58, 245-55	16
808	Metastasis: cell-autonomous mechanisms versus contributions by the tumor microenvironment. 2006 , 63, 449-68	190
807	The proangiogenic phenotype of human tumor-derived endothelial cells depends on thrombospondin-1 downregulation via phosphatidylinositol 3-kinase/Akt pathway. 2006 , 84, 852-63	37
806	The application of NMR in tumor angiogenesis research. 2006 , 49, 27-44	12
805	N-Glycosyl-thiophene-2-carboxamides: effects on endothelial cell growth in the presence and absence of bFGF--a significant increase in potency using per-O-acetylated sugar analogues. 2006 , 16, 1316-9	7
804	Novel C-3 N-urea, amide, and carbamate dihydroindazolo[5,4-a]pyrrolo[3,4-c]carbazole analogs as potent TIE-2 and VEGF-R2 dual inhibitors. 2006 , 16, 5368-72	15
803	NC-100717: a versatile RGD peptide scaffold for angiogenesis imaging. 2006 , 16, 6190-3	53
802	Contribution of VEGF and PEDF to choroidal angiogenesis: a need for balanced expressions. 2006 , 39, 267-76	72
801	The evolution of n-player cooperation-threshold games and ESS bifurcations. 2006 , 238, 426-34	64
800	Vascular network remodeling via vessel cooption, regression and growth in tumors. 2006 , 241, 903-18	93
799	Change of individual vascular endothelial calcium during hyperthermia. 2006 , 31, 302-306	6
798	New antiangiogenetic agents and non-small cell lung cancer. 2006 , 60, 76-86	19
797	Bastadins, cyclic tetramers of brominated-tyrosine derivatives, selectively inhibit the proliferation of endothelial cells. 2006 , 60, 231-235	15
796	Signal transduction in endothelial cells by the angiogenesis inhibitor histidine-rich glycoprotein targets focal adhesions. 2006 , 312, 2547-56	30
795	Insulin-induced vascular endothelial growth factor expression is mediated by the NADPH oxidase NOX3. 2006 , 312, 3413-24	39
794	Hypoxia-induced mitogenic factor enhances angiogenesis by promoting proliferation and migration of endothelial cells. 2006 , 312, 3559-69	24
793	Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain. 2006 , 9, 287-300	624
792	Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin. 2006 , 10, 159-70	351

791	CD34+/CD133- circulating endothelial precursor cells (CEP): characterization, senescence and in vivo application. 2006 , 41, 600-8	29
790	Antiangiogenic peptides and proteins: from experimental tools to clinical drugs. 2006 , 1765, 155-77	18
789	Assessing responses to cancer therapy using molecular imaging. 2006 , 1766, 242-61	45
788	Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway. 2006 , 33, 392-406	269
787	Mechanisms of action of bevacizumab as a component of therapy for metastatic colorectal cancer. 2006 , 33, S1-7	104
786	The angiogenic switch molecule, secreted FGF-binding protein, an indicator of early stages of pancreatic and colorectal adenocarcinoma. 2006 , 33, S50-6	161
785	A spatiotemporal, patient individualized simulation model of solid tumor response to chemotherapy in vivo: the paradigm of glioblastoma multiforme treated by temozolomide. 2006 , 53, 1467-77	44
784	Imidazole ring-opened DNA purines and their biological significance. 2003 , 36, 12-9	48
783	Hypoxia-induced angiogenesis during carcinogenesis. 2003 , 36, 120-7	100
782	Roles of matrix metalloproteinases in tumor metastasis and angiogenesis. 2003 , 36, 128-37	171
781	Identification of specifically activated angiogenic molecules in HMGB-1-induced angiogenesis. 2017 , 50, 590-595	3
780	Expression and purification of functional human vascular endothelial growth factor- α 121; the most important angiogenesis factor. 2014 , 4, 323-8	21
779	Lymphatic vessel density is not associated with lymph node metastasis in non-small cell lung carcinoma. 2008 , 132, 1882-8	16
778	In silico Meta-Analysis of Circulatory microRNAs in Prostate Cancer. 2017 , 6, 107-116	1
777	Computed tomographic laser mammography, a practical review. 2003 , 59, 687-93	4
776	SRPK1 Dissimilarly Impacts on the Growth, Metastasis, Chemosensitivity and Angiogenesis of Glioma in Normoxic and Hypoxic Conditions. 2013 , 4, 727-35	25
775	Expression of endogenous hypoxia markers in vulvar squamous cell carcinoma. 2012 , 13, 3675-80	7
774	Barbigerone inhibits tumor angiogenesis, growth and metastasis in melanoma. 2014 , 15, 167-74	16

773	Efficacy and safety of sorafenib for advanced non-small cell lung cancer: a meta-analysis of randomized controlled trials. 2014 , 15, 5691-6	7
772	Effect of grape procyanidins on tumor angiogenesis in liver cancer xenograft models. 2014 , 15, 737-41	28
771	Prognostic value of PLCE1 expression in upper gastrointestinal cancer: a systematic review and meta-analysis. 2014 , 15, 9661-6	15
770	Targeting EGFL7 expression through RNA interference suppresses renal cell carcinoma growth by inhibiting angiogenesis. 2014 , 15, 3045-50	12
769	Microvessel density as a prognostic factor in ovarian cancer: a systematic review and meta-analysis. 2015 , 16, 869-74	12
768	Assessment of the effects of ischaemia/ hypoxia on angiogenesis in rat myofascial trigger points using colour Doppler flow imaging. 2020 , 8, e10481	2
767	(210)Po microsphere radiological design for tumor vascular disruption. 2015 , 3, e1143	0
766	Tumor vascular disruption using various radiation types. 2014 , 2, e320	3
765	Chitosan-Based Hydrogels for Tissue Engineering. 2021 , 519-571	0
764	Aptamer-modified DNA tetrahedra-gated metal-organic framework nanoparticle carriers for enhanced chemotherapy or photodynamic therapy. 2021 , 12, 14473-14483	10
763	Targeting microRNAs with thymoquinone: a new approach for cancer therapy. 2021 , 26, 43	5
762	Fibrinolytic nanocages dissolve clots in the tumor microenvironment, improving the distribution and therapeutic efficacy of anticancer drugs. 2021 , 53, 1592-1601	1
761	MicroRNAs: Important Players in Breast Cancer Angiogenesis and Therapeutic Targets. 2021 , 8, 764025	2
760	Effects and Mechanism of Plasma-Activated Medium on Angiogenesis of Vascular Endothelial Cells. 2021 , 11, 9603	
759	Role of Nectin-4 protein in cancer (Review). 2021 , 59,	1
758	CD93 a potential player in cytotrophoblast and endothelial cell migration. 2021 , 1	1
757	Natriuretic peptide receptor a promotes gastric malignancy through angiogenesis process. 2021 , 12, 968	1
756	Anti-cancer efficacy including Rb-deficient tumors and VHL-independent HIF1 α proteasomal destabilization by dual targeting of CDK1 or CDK4/6 and HSP90. 2021 , 11, 20871	2

755	Reinforcing vascular normalization therapy with a bi-directional nano-system to achieve therapeutic-friendly tumor microenvironment. 2021 , 340, 87-101	0
754	Endothelial Cell Morphogenesis and Capillary-like Network Induced by Soluble and Bound VEGF in a Definite Biogel Composed of Collagen and Fibronectin. 2021 , 11, 9501	
753	Vascular Endothelial Cells: Heterogeneity and Targeting Approaches. 2021 , 10,	9
752	3D tumor angiogenesis models: recent advances and challenges. 2021 , 147, 3477-3494	5
751	IQ Motif-Containing GTPase-Activating Protein 2 Inhibits Breast Cancer Angiogenesis By Suppressing VEGFR2-AKT Signaling. 2021 ,	1
750	Selective and competitive functions of the AAR and UPR pathways in stress-induced angiogenesis. 2021 , 7, 98	0
749	Stereotactic Radiosurgery for Recurrent Glioblastoma Multiforme: A Retrospective Multi-Institutional Experience. 2021 , 13, e18480	1
748	Aspiration-mediated hydrogel micropatterning using rail-based open microfluidic devices for high-throughput 3D cell culture. 2021 , 11, 19986	0
747	Epstein-Barr Virus Promotes Tumor Angiogenesis by Activating STIM1-Dependent Ca Signaling in Nasopharyngeal Carcinoma. 2021 , 10,	0
746	Effect of energy requirements in the growth of brain tumor: a theoretical approach. 2021 , 8,	
745	Peritumoral B cells drive proangiogenic responses in HMGB1-enriched esophageal squamous cell carcinoma. 2021 , 1	0
744	Multimodal obstruction of tumorigenic energy supply via bionic nanocarriers for effective tumor therapy. 2021 , 278, 121181	2
743	Nutraceuticals and their role in tumor angiogenesis. 2021 , 408, 112859	0
742	Understanding and improving cellular immunotherapies against cancer: From cell-manufacturing to tumor-immune models. 2021 , 179, 114003	2
741	Growth and Development. 2001 , 1879-1916	
740	Molecular and Cellular Angiogenesis. 2002 , 273-287	
739	Molekulare Therapie. 2002 , 389-441	
738	Engineering Design Aspects of Tissue Engineering. 2003 , 71-82	

- 737 Angiogenese [Molekulare Hintergründe und therapeutische Relevanz. **2003**, 206-208
- 736 Angiogenesis: Cellular and Molecular Aspects of Postnatal Vessel Formation. **2003**, 455-462
- 735 Angiogenesis: A Promising Target for Cancer Prevention. **2003**, 169-185
- 734 Calreticulin and Tumor Suppression. **2003**, 162-179
- 733 A New Paradigm for Vascular Endothelial Cell Growth Factor Receptor Signaling in Adult Endothelium. **2003**, 153-166
- 732 Tumorangiogenese. **2003**, 28-31
- 731 Anti-angiogenic Therapy in Acute Myeloid Leukemia. **2003**, 186-192
- 730 Advanced Glycated End Products as Markers of Complications. **2003**, 1-18
- 729 Molecular and Cell Biology of Lung Carcinoma. **2004**, 3-27
- 728 Mouse Models to Study Pro-and Antiangiogenic Potential: Novel Roles for PLGF and FLT1. **2004**, 329-347
- 727 Molecular and Cellular Pathways Involved in the Recruitment of Proangiogenic Stem Cells from Bone Marrow Microenvironments. **2004**, 377-385
- 726 Advances in Radiation Therapy. **2004**, 261-277
- 725 Molekulare Mechanismen von Verfallsstörungen und Erkrankungen der Prostata. **2004**, 296-343
- 724 Recent advances in cancer chemotherapy. **2004**, 583-608
- 723 Exploiting biology for therapeutic gain. **2004**, 417-429
- 722 Angiogenesis.
- 721 Molecular Mechanisms of Hepatocellular Carcinoma. **2005**, 23-57
- 720 The hemostatic system in angiogenesis. **2005**, 247-66

719 Tumor Angiogenesis: General Principles and Therapeutic Approaches. **2005**, 41-55

718 Lymphatic Endothelium. **2005**, 65-75

717 Antiangiogenic Proteins, Peptides, and Amino Acids. **2005**, 191-215

1

716 Pituitary Tumor-Transforming Gene (PTTG) Induces both Vascular Endothelial Growth Factor (VEGF) and Basic Fibroblast Growth Factor (bFGF). **2005**, 26, 1823-1825

1

715 Engineering Cell Adhesion. **2006**, 325-343

714 Opioid-Induced Proliferation of Vascular Endothelial Cells. **2006**, 2, 33-40

713 Pro-Invasive Molecular Cross-Signaling between Cancer Cells and Myofibroblasts. **2006**, 74-87

712 Vasculogenic Mimicry: Angiogenesis in Disguise?. **2006**, 97-109

711 Neue antineoplastische Substanzen und ihre klinische Entwicklung. **2006**, 1455-1537

1

710 Angiogenesis-like Activity of Endothelial Cells Co-cultured with VEGF-producing Smooth Muscle Cells. **2006**, 060328075711002

709 Angiogenesis-like Activity of Endothelial Cells Co-cultured with VEGF-producing Smooth Muscle Cells. **2006**, 060421084845001

708 Fibroblast Growth Factor Receptor 3 Up-regulates Vascular Endothelial Growth Factor Expression in L6 Cells. **2006**, 2, 324-330

2

707 Small Molecule Inducers of Angiogenesis for Tissue Engineering. **2006**, 060706073730072

706 Adenovirus-Mediated HSV-tk Gene Therapy for Malignant Glioma. **2006**, 327-342

705 Small Molecule Inducers of Angiogenesis for Tissue Engineering. **2006**, 060802052515050

704 Myelodysplasia-Related AML. **2007**, 43-70

703 Cancer chemotherapy. **2007**, 718-735

1

702 The vascular system. **2007**, 298-320

1

701 Nano DDS. **2007**, 7, 99-103

700 The Type I Interferon System With Emphasis on Its Role in Malignancies. **2007**, 339-372

699 Antiangiogenic Agents in Breast Cancer. **2007**, 269-284

698 Cell proliferation and apoptosis. **2007**, 72-86

697 Screening Functional Foods as Inhibitors of Angiogenesis Biomarkers. **2007**, 507-526

696 Angiogenesis in Inflammatory Arthritis. **2007**, 403-440

695 Reactive Oxygen Species and Angiogenesis. **2007**, 389-402

694 N-Myc Downstream-Regulated Gene 2 Induces Angiogenesis. **2007**, 28, 1206-1208

693 Angiogenesis in Solid Tumors. **2007**, 61-108

692 Targeting Fibroblast Growth Factor= Fibroblast Growth Factor Receptor System in Angiogenesis. **2007**, 207-242

691 Nanogold in Cancer Therapy and Diagnosis.

690 Endothelial CellMatrix Interactions in Neovascularization. 110306233438005

689 Effects of Therapy on Cytologic Specimens. **2008**, 951-974

688 Emerging Molecular Therapies: Drugs Interfering With Signal Transduction Pathways. **2008**, 317-365

687 TGF- β Signaling and Vascular Morphogenesis. **2008**, 507-521

686 Das durch Knochenmarkssuppression verstärkte Wachstum von kolorektalen Metastasen wird über Stromal cell-derived factor (SDF)-1 durch Beeinflussung der Angiogenese und Induktion der Tumorzellproliferation vermittelt. **2008**, 53-54

685 Noninvasive Determination of Angiogenesis. **2008**, 211-223

684 A Proliferation-inducing Ligand (APRIL) Acts as an Angiogenic Factor by Inducing Vascular Endothelial Growth Factor (VEGF). **2008**, 29, 1860-1862

683 [Antiangiogenic therapy for gastrointestinal tumors]. **2008**, 149, 2317-24

682 Molecular Neurooncology and Neoangiogenesis of Malignant Gliomas. **2009**, 23-55

681 Encyclopedia of Biometrics. **2009**, 28-35

1

680 A Case Report of Recurrent Glioblastoma treated with Bevacizumab and Irinotecan. **2009**, 18, 145-150

679 Molecular Imaging of Angiogenesis. **2009**, 52, 135

678 Immunohistochemical Detection of Erythropoietin, Platelet-Derived Growth Factor and Their Receptors in Ameloblastomas. **2009**, 18, 19-26

1

677 Molecular Mechanisms of Hepatocellular Carcinoma: Insights to Therapy. **2009**, 109-130

676 Angiopoietin-like 3 (ANGPTL3) Stimulates Human Umbilical Vein Endothelial Cell Tube Formation and Vascular Endothelial Growth Factor Production. **2009**, 30, 707-709

675 RAS Oncogenes and Tumor-Vascular Interface. **2010**, 133-165

1

674 von Hippel-Lindau Tumor Suppressor, Hypoxia-Inducible Factor-1, and Tumor Vascularization. **2010**, 119-132

673 Functional and molecular MR imaging in evaluating outcomes of tumor therapy. **2009**, 28, 979-983

672 A minibioreactor for developing perfused capillaries in cardiomyocyte aggregates. **2009**,

671 Aberrant Signalling Complexes in GBMs: Prognostic and Therapeutic Implications. **2010**, 95-129

670 Ω 3 PUFAs and Other Cancers. **2010**, 191-217

669 Cancer Therapy by Targeting Vascular Endothelial Cell Growth Factor- and Non-Vascular Endothelial Cell Growth Factor-Mediated Angiogenesis. **2010**, 95-113

668 S-Nitrosylation How Cancer Cells Say NO to Cell Death. **2010**, 85-102

667 Angiogenesis and Lymphangiogenesis in Colon Cancer Metastasis. **2010**, 243-287

1

666 Chapter 7: Mesenchymal Stromal/Stem Cells from Tissue Repair to Destruction of Tumor Cells. **2010**, 141-158

665 Advances in Radiation Therapy. **2010**, 313-334

664 Extravasale Proteolyse: Funktion und Interaktion der Faktoren des fibrinolytischen Systems. **2010**, 289-299

663 Invasiveness of and Drug Sensitivity to Various Anti-cancer Regimens in Five Colorectal Cancer Cell Lines. **2010**, 26, 98

662 Molecular Targeted Therapy. **2010**, 1523-1531

661 Cytotoxic and Protective Activity of Nitric Oxide in Cancers. **2010**, 103-132

660 Targets and Approaches for Cancer Drug Discovery. 1

659 Establishing the Tumor Microenvironment. 7-33

658 Role of Tumor-Associated Macrophages (TAM) in Cancer Related Inflammation. 77-98

657 Nanotechnologies for Cancer Sensing and Treatment. **2011**, 1-39

656 Regulation of Oxygen Homeostasis by Prolyl Hydroxylase Domains. **2011**, 419-436

655 Challenges and Successes in Developing Effective Anti-angiogenic Agents. **2011**, 347-401

654 Adrenomedullin administration alters vascular endothelial growth factor levels in rats in cold stress. **2010**, 4, 955-958

653 Role of CXC Chemokines and Receptors in Liver Metastasis – Impact on Liver Resection-Induced Engraftment and Tumor Growth. **2011**, 129-154

652 iTRAQ-Based LC-LC MALDI TOF/TOF MS Quantitative Analysis of Membrane Proteins from Human Glioma. **2011**, 127-143

651 The Cancer Stem Cell Paradigm. **2011**, 225-248

650 Biology and immunopathogenesis of vasculitis. **2011**, 1509-1521.e2

649 Selected Aspects of Angiogenesis in Haematological Malignancies. **2011**, 3, 17-39

648 Targeting angiogenesis in metastatic breast cancer. **2011**, 101-119

647 Microparticle Dissemination of Biological Activities: Implications for Cancer Biology. **2012**, 211-243

646 Anti-Angiogenesis Therapy for Melanoma. **2012**, 281-294

645 UPR Activation in Cancer Cells: A Double-Edged Sword. **2012**, 383-412

644 Targeted Therapies for Non-small-Cell Lung Cancer. **2012**, 93-114

643 Quantum Dots for Imaging of Angiogenesis. **2012**, 311-322

642 Blutversorgung, Physiologie und Neoangiogenese des inneren Genitales. **2012**, 269-279

641 Review of Graph Invariants for Quantitative Analysis of Structure Dynamics. **2012**, 325-343

640 Pharmacokinetic Analysis for Tumor Characterization Using MR-Guided Dynamic Contrast Enhanced Diffuse Optical Tomography. **2012**,

1

639 Pathophysiological Barriers Impeding the Delivery of Heat Shock Protein (HSP)-Based Macromolecules and Nanotherapeutics to Solid Tumors. **2012**, 185-199

638 Correlations of combined exercise-induced weight loss with cardiorespiratory fitness and angiogenesis factors.. **2012**, 21, 79-88

637 Influence of sera from interstitial lung disease patients on angiogenic activity of mononuclear cells. **2013**, 756, 139-45

636 Predictive Markers in Colon Cancer. **2013**, 1-23

635 Antiangiogenic Effects of Tocotrienol. **2012**, 79-88

634 Tocotrienols as Possible Treatments for Obesity. **2012**, 195-208

633 Cell Mechanobiology in Regenerative Medicine. **2012**, 1-16

632 Cancers of the Rectum and Anal Canal. **2013**, 141-171

631 Encyclopedia of Systems Biology. **2013**, 1507-1510

630 Insights into Roles of Immediate-Early Genes in Angiogenesis. **2013**, 145-162

629 Vascular Targeting of Adipose Tissue. **2013**, 381-400

628 and Investigations of the Microtubule Binding Drug Targetin on Angiogenesis. **2013**, 1, 41-47

627 Metastasis Initiation. **2013**, 445-469

626 RGD-Based Molecular Probes for Integrin $\alpha_5\beta_1$ Imaging. **2013**, 513-538

625 Bounded Stochastic Perturbations May Induce Nongenetic Resistance to Antitumor Chemotherapy. **2013**, 171-187

624 Association between Pretreatment Levels of Serum Vascular Endothelial Growth Factor (VEGF) and Survival Outcomes in Locally Advanced Cervical Cancer Patients. **2013**, 04, 1478-1484

623 Interactions of Normal Tissues and Systems with Metastatic Cells: Impact on Location, Survival and Growth. **2013**, 11-27

622 Multifunctional Polymeric Micelles for Drug Delivery and Therapeutics. 438-469

621 Shear Stress and Endothelial Cell Retention in Critical Lower Limb Ischemia. **2013**, 107-116

620 TGF- β Signaling in Physiological and Pathological Angiogenesis. **2013**, 323-348

619 Angiogenesis in Diseases and Therapy. **2013**, 3-16

618 Molecular Imaging of Inflammation and Intraplaque Vasa Vasorum. **2014**, 299-316

617 Endothelial Actin Cytoskeleton and Angiogenesis. **2013**,

616 Epigenetic Effects of Cigarette Smoke in Carcinogenesis. **2013**, 58, 167-170

1

615 Resistance to Antiangiogenic Treatments via Upregulation of Substitution Pathways. **2014**, 397-419

614 Liver and Bile Duct Cancer. **2014**, 1373-1396.e8

1

613 Essentials of Angiogenesis. **2014**, 1-34

1

612 Chemotherapeutic Engineering. **2014**, 21-80

- 611 Patient specific image driven evaluation of the aggressiveness of metastases to the lung. **2014**, 17, 553-60 1
- 610 Metronomic Chemotherapy in Gynecological Cancers. **2014**, 203-216
- 609 Cytosolic Phospholipase A2 and Autotaxin Inhibitors as Potential Radiosensitizers. **2014**, 159-176
- 608 Sesquiterpenes from Essential Oils with Promising Antitumor Properties. **2015**, 201-214
- 607 In Vitro Angiogenesis Assay: Endothelial Migration, Proliferation, and Tube Formation. **2015**, 3-12
- 606 Engineering Strategies to Recapitulate the Tumor Microenvironment. **2015**, 275-308
- 605 The Dark Chocolate against Angiogenesis?. **2015**, 2,
- 604 Nanocomposite Membranes in Water Treatment. **2015**, 134-181
- 603 CANCER CONUNDRUM. **2016**, 20, 5-8
- 602 Diagnostic Applications of Nuclear Medicine: Malignant Melanoma. **2016**, 1-39
- 601 Hepatic and Extrahepatic Malignancies in Alcoholic Liver Disease. **2016**, 249-269
- 600 Proangiogenic effect of newly synthesized compounds-analogue of inhibitors HIF-1. **2016**, 20, 85-89
- 599 Metabolic Syndrome and the Liver. **2016**, 149-177
- 598 Tumor Biology and Environmental Carcinogenesis. **2016**, 19-34
- 597 Hot Water Extract of *Scutellaria baicalensis* Inhibits Migration, Invasion and Tube Formation in a Human Umbilical Vein Endothelial Cell Model and a Rat Aortic Ring Sprouting Model. **2016**, 26, 91-100
- 596 Angiogenesis: Basics of Vascular Biology. **2016**, 1-29 0
- 595 An interesting case of angiogenesis in cavernous hemangioma. **2016**, 64, 783-785 1
- 594 Conjugates: Biosynthetic Synthetic Polymer Based. 2039-2060

- 593 DDA suppresses angiogenesis and tumor growth of colorectal cancer in vivo through decreasing VEGFR2 signaling. **2016**, 7, 63124-63137 4
- 592 Three Dimensional Porous Scaffolds: Mechanical and Biocompatibility Properties. **2017**, 353-384
- 591 Association Between microRNA-125a rs12976445 C>T Polymorphism and 18F-Fluorodeoxyglucose (18FDG) Uptake: Clinical and Metabolic Response in Patients with Non-Small Cell Lung Cancer. **2016**, 22, 4186-4192 1
- 590 Physiologic and Molecular Basis of PET in Cancer Imaging. **2017**, 399-427 0
- 589 Current Status and Characteristics of Cancer. **2017**, 1-5
- 588 [Vascular endothelial growth factor inhibitors in the treatment of neovascular age-related macular degeneration]. **2017**, 133, 125-129
- 587 Small Cell Lung Cancer and Molecular Targeted Therapy. **2017**, 139-154
- 586 Big Evolutionary Mechanisms of Network Robustness and Signaling Transductivity in Aging and Carcinogenic Process by System Modeling and Database Mining. **2017**, 527-669 1
- 585 Angiogenesis and Prostate Cancer: Friends or Foes. **2017**, 241-256
- 584 Endogenous Proteases in Tumoral Progression. **2017**, 119-145
- 583 Tissue Development. **2017**, 231-255
- 582 Diagnostic Applications of Nuclear Medicine: Malignant Melanoma. **2017**, 1065-1102
- 581 A coherent modeling procedure to describe cell activation in biological systems. **2017**, 8, 1-22 2
- 580 Secretogranin-II plays a critical role in zebrafish neurovascular modeling.
- 579 Anti-tumor effect of recombinant plasminogen kringle 1B in KB cells: Histological observation and immunoprecipitation-based high performance liquid chromatography. **2017**, 41, 45-54
- 578 Conjugates: Biosynthetic/Synthetic Polymer Based. **2017**, 340-361
- 577 Overleerde Anjiyogenezi Etkileyen Faktörler. **2017**, 26, 330-330
- 576 Blutversorgung, Physiologie und Neoangiogenese des inneren Genitales. **2018**, 317-328

575 The Present and Future of the Cancer Microenvironment Bioprinting. **2017**, 15, 103-110

574 Effect of Fucoïdan on Angiogenesis and Gene Expression in Human Umbilical Vein Endothelial Cells. **2017**, 49, 323-328

1

573 Applications. **2018**, 45-65

572 CRISPR engineering cardiometabolic disease models using human iPSC. **2018**, 2, 185-202

571 A commercialized photoacoustic microscopy system with switchable optical and acoustic resolutions. **2018**,

570 Scatterer density sensitive tomography utilizing light and ultrasound. **2018**,

569 Anti-angiogenic effects of VEGF stimulation on endothelium deficient in phosphoinositide recycling.

568 Gebelikte T_H1 DumanıMaruziyetinin Anne Sıın Akciıer Dokusunda Meydana Getirdiı Deıılikler İzerine Alfa Lipoik Asitin Etkilerinin İncelenmesi. 297-307

567 biodistribution of topical low molecular weight heparin-taurocholate in a neovascularized mouse cornea. **2018**, 11, 1435-1439

2

566 Molecular Target Therapy for Digestive Malignancy. **2018**, 14, 169-172

565 miR-425 suppresses EMT and inhibits the development of TNBC (triple-negative breast cancer) by targeting TGF-ı/SMD 3 signaling pathway.

564 On the impact of chemo-mechanically induced phenotypic transitions in gliomas.

563 Modern aspects of antiangiogenic therapy in ovarian cancer. **2018**, 17-21

562 Myeloid-derived Suppressor Cells in Cancer: A Review on the Pathogenesis and Therapeutic Potentials. **2018**, 7, 16-33

561 Breast Cancer Pain: A Review of Pathology and Interventional Techniques. **2019**, 63-83

560 Immunotherapy with Subcutaneous Injection of Immunomodulatory Agent (OK-432) Elicits Durable Response in Locally Advanced or Relapsed Cervical Cancer. **2019**, 8, 80-82

1

559 Immunomodulatory and Therapeutic Potential of Marine Flora Products in the Treatment of Cancer. **2019**, 139-166

0

558 Signaling Functions of Extracellular Hsp90 (eHsp90) in Cancer Metastasis. **2019**, 329-344

- 557 [Intraoperative vascular fluorescence in cerebral glioblastomas and vascular histological features]. **2019**, 83, 21-34 1
- 556 Vascularization in Oral and Maxillofacial Tissue Engineering. **2019**, 97-122
- 555 Notch signaling and taxis mechanisms regulate early stage angiogenesis: A mathematical and computational model.
- 554 Clinically-relevant cell type cross-talk identified from a human lung tumor microenvironment interactome. 1
- 553 2D or 3D? How in vitro cell motility is conserved across dimensions, and predicts in vivo invasion.
- 552 Molecular Design and Synthesis of New 3,4-Dihydropyrimidin-2(1H)-Ones as Potential Anticancer Agents with VEGFR-2 Inhibiting Activity. **2019**, 19, 310-322 0
- 551 Engineering Self-homing Circulating tumour cells as novel cancer theranostics. 1
- 550 Risk of breast cancer based on thermal tomography characteristics.. **2019**, 8, 1148-1157 0
- 549 Anti-angiogenic activities of the leaves of *Tapinanthus bangwensis* (Engl. and K. Krause) Danser Loranthaceae growing on three host trees in south-western Nigeria.
- 548 Apatinib for treatment of a pseudomyxoma peritonei patient after surgical treatment and hyperthermic intraperitoneal chemotherapy: A case report. **2019**, 7, 3881-3886 2
- 547 A mathematical dissection of the adaptation of cell populations to fluctuating oxygen levels. 0
- 546 Functional angiogenesis requires microenvironmental cues balancing endothelial cell migration and proliferation. 0
- 545 The application of methylene blue coloration technique in axillary lymph node dissection of breast cancer.. **2019**, 8, 2781-2790
- 544 An expanded analysis framework for multivariate GWAS connects inflammatory biomarkers to functional variants and disease.
- 543 The role of tumor-derived exosomes in tumor angiogenesis and tumor progression. **2019**, 32, 193-202 5
- 542 Effect of nanopolysaccharide (BSEPS) from *Bacillus subtilis* sp. on thioacetamide-induced liver fibrosis in rats. **2019**, 43,
- 541 Recent Development in the Biomarkers for the Gastric Cancer. **2020**, 115-138
- 540 Extracellular RNA in human health and disease. **2020**, 139-161

- 539 Efficient Synthesis of Marine Alkaloid Ageladine A and its Structural Modification for Exploring New Biological Activity. **2020**, 78, 51-59 0
- 538 Hypoxia induces tumor cell growth and angiogenesis in non-small cell lung carcinoma via the Akt-PDK1-HIF1 β -KLF4 pathway.. **2020**, 9, 2904-2918
- 537 Reoxygenation after Evofosfamide Treatment in Pancreatic Ductal Adenocarcinoma Xenografts is due to Decreased Oxygen Consumption and not Increased Oxygen Supply.
- 536 Light-controlled calcium signalling in prostate cancer and benign prostatic hyperplasia. **2020**, 6, 1
- 535 Live Impedance Measurements and Time-lapse Microscopy Observations of Cellular Adhesion, Proliferation and Migration after Ionizing Radiation. **2020**, 21, 642-652 1
- 534 Radioiodinated bicyclic RGD peptide for imaging integrin β_n cancers. **2020**, 528, 168-173 0
- 533 Growth of tumor emboli within a vessel model reveals dependence on the magnitude of mechanical constraint.
- 532 Abnormal angiogenesis of placenta in progranulin-deficient mice. **2020**, 22, 3482-3492 2
- 531 Microfluidic Device Setting by Coculturing Endothelial Cells and Mesenchymal Stem Cells. **2021**, 2206, 57-66
- 530 Studies on Anthrisci radix, Psoraleae semen Extract Based on Anti-angiogenic Effect. **2020**, 32, 899-910
- 529 Identification and verification of the prognostic value of the glutathione S-transferase Mu genes in gastric cancer. **2020**, 20, 100 1
- 528 Fusion of Deep Learning and Image Processing Techniques for Breast Cancer Diagnosis. **2021**, 1-25 1
- 527 Targeted Therapeutic Strategies for Triple-Negative Breast Cancer. **2021**, 11, 731535 6
- 526 Current role of systemic therapy in transarterial chemotherapy refractory hepatocellular carcinoma patients. **2021**, 10, 183-188
- 525 Angiogenesis Pathway in Kidney Renal Clear Cell Carcinoma and Its Prognostic Value for Cancer Risk Prediction. **2021**, 8, 731214 0
- 524 Bidirectional Mechanical Response Between Cells and Their Microenvironment. **2021**, 9, 1
- 523 Effect and mechanism of circRNAs in tumor angiogenesis and clinical application. **2021**, 1
- 522 Opioids and Breast Cancer Recurrence: A Systematic Review. **2021**, 13, 1

521	Role of Cytokines in Tumor Immunity and Immune Tolerance to Cancer. 2020 , 205-233	
520	Cyclical Changes in Ovarian Angiogenesis and Its Controls. 2020 , 14, 117-124	
519	Preoperative bevacizumab does not increase complications following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. 2020 , 15, e0243252	1
518	Radiolabeled Peptide Probes for Liver Cancer Imaging. 2020 , 27, 6968-6986	2
517	Minimal Residual Disease in Melanoma:molecular characterization of in transit cutaneous metastases and Circulating Melanoma Cells recognizes an expression panel potentially related to disease progression. 2020 , 25, 100262	0
516	Vascularization of 3D Engineered Tissues. 2020 , 1-18	
515	Agent-Based Modeling in Mathematical Biology: A Few Examples. 2020 , 273-298	
514	CHAPTER 11:Ultrashort Tetrameric Peptide Nanogels Support Tissue Graft Formation, Wound Healing and 3D Bioprinting. 2020 , 363-394	
513	ROS and Oxidative Stress in Cancer: Recent Advances. 2020 , 109-138	2
512	Vascularization of 3D Engineered Tissues. 2020 , 469-486	
511	Angiogenesis: A Therapeutic Target for Cancer. 2020 , 165-183	2
510	Pathophysiology of Angiogenesis and Its Role in Vascular Disease. 2020 , 89-116	
509	Single nucleotide polymorphism of transforming growth factor- β and interleukin-6 as risk factors for ovarian cancer. 2020 , 45, 267-275	3
508	A Non-Destructive Method for Quantifying Tissue Vascularity Using Quantitative Deep Learning Image Processing.	1
507	One-Pot Synthesis of Novel Furochromone and Oxazocine Derivatives as Promising Antitumor Agents with Their Molecular Docking Studies. 2020 , 2020, 1-16	
506	5-Fluorouracil and Simvastatin Loaded Solid Lipid Nanoparticles for Effective Treatment of Colorectal Cancer Cells. 2020 , 16, 205-213	2
505	Carbon Nanotubes: Current Perspectives on Diverse Applications in Targeted Drug Delivery and Therapies. 2021 , 14,	6
504	The Effect of Hypoxic and Normoxic Culturing Conditions in Different Breast Cancer 3D Model Systems. 2021 , 9, 711977	0

- 503 Engineered Nanoenzymes with Multifunctional Properties for Next-Generation Biological and Environmental Applications. 2108650 5
- 502 Prognostic Relevance of BRCA1 Expression in Survival of Patients With Cervical Cancer. **2021**, 11, 770103 0
- 501 The Protective Role of Prolyl Oligopeptidase (POP) Inhibition in Kidney Injury Induced by Renal Ischemia-Reperfusion. **2021**, 22, 2
- 500 PEDF is an endogenous inhibitor of VEGF-R2 angiogenesis signaling in endothelial cells. **2021**, 213, 108828 1
- 499 High expression of endothelial progenitor cell-induced angiogenic markers is associated with bile acid levels in HCC. **2020**, 20, 2729-2738 2
- 498 Atherosclerosis and Angiogenesis: Double Face of Neovascularization in Atherosclerotic Intima and Collateral Vessels in Ischemic Organs. **2008**, 374-386 1
- 497 Current and Future Therapeutic Targets of the Tumour-Host Microenvironment. **2005**, 345-367
- 496 Radiotherapy and Chemotherapy. **2005**, 155-166 2
- 495 Zellbiologie. **2006**, 454-470
- 494 Differenzierungs- und antiangiogene Therapie. **2006**, 613-619
- 493 Embolotherapy Applications in Gene Therapy. **2006**, 295-302
- 492 Combinations of Cytotoxic Drugs, Ionizing Radiation, and Angiogenesis Inhibitors. **2006**, 103-114
- 491 Hyperthermia and Angiogenesis. **2006**, 92-98 1
- 490 Morphology of Tumor Vasculature A Theoretical Model. **2007**, 226-238
- 489 Molecular Basis for Vascular Endothelial Growth Factor Expression in Tumor. **2008**, 79-124
- 488 The Plasticity of Melanoma Cells and Associated Clinical Implications. **2006**, 533-550
- 487 Tumor Endothelial Cell Abnormalities. **2008**, 73-84 2
- 486 Gene Therapy Targeted at Angiogenesis and Lymphangiogenesis for Cancer Treatment. **2007**, 301-330

- 485 Clinical Angioblast Therapy. **2007**, 245-258
- 484 Pleiotrophic Actions of Erythropoietin. **2003**, 7, 239-245
- 483 Endothelin-1-Promoting Actions in the Growth and Angiogenesis of Solid Cancers. **2008**, 187-196 1
- 482 Tumor Biology and Environmental Carcinogenesis. **2008**, 17-31
- 481 Molecular Imaging of Targets and Therapeutics in Tumour Angiogenesis. **2008**, 511-528
- 480 Imaging the Effect of Anti-Angiogenic Tumor Therapy in Clinical Studies. **2008**, 717-739
- 479 Combination Therapies for Choroidal Neovascularization. **2007**, 89-103
- 478 Blutversorgung, Physiologie und Neoangiogenese des inneren Genitales. **2008**, 237-246
- 477 3. Continuous and Pulsed Ultrasound. **2010**, 62, 13-25
- 476 Effect of Angiogenesis Related Growth Factors VEGF-a and FGF-1 on Osteosarcoma Cell Proliferation. 0
- 475 Chemotherapy response prediction with diffuser elapser network.
- 474 Novel pre-vascularized tissue-engineered dermis based on stem cell sheet technique used for dermis-defect healing. **2020**, 7, 627-638 0
- 473 Signaling in TNFSF15-mediated Suppression of VEGF Production in Endothelial Cells. **2021**, 2248, 1-18
- 472 Dynamic contrast-enhanced magnetic resonance imaging rapidly indicates vessel regression in human squamous cell carcinomas grown in nude mice caused by VEGF receptor 2 blockade with DC101. **2004**, 6, 213-23 26
- 471 Cancer stem cells, endothelial progenitors, and mesenchymal stem cells: "seed and soil" theory revisited. **2008**, 2, 169-74 11
- 470 Incorporation of biologic therapies in the management of gastroesophageal cancers. **2007**, 1, S22-9
- 469 Estradiol and nicotine exposure enhances A549 bronchioloalveolar carcinoma xenograft growth in mice through the stimulation of angiogenesis. **2006**, 28, 337-44 24
- 468 Occult thyroid carcinoma. **2009**, 29, 296-304 13

467	Bevacizumab: the evidence for its clinical potential in the treatment of nonsmall cell lung cancer. 2007 , 2, 31-49	3
466	Preclinical molecular imaging of tumor angiogenesis. 2010 , 54, 291-308	27
465	A robust model for simultaneously inducing corneal neovascularization and retinal gliosis in the mouse eye. 2011 , 17, 1901-8	17
464	Angiogenesis and melanoma - from basic science to clinical trials. 2011 , 1, 852-68	21
463	Antiangiogenic agents in advanced gastrointestinal malignancies: past, present and a novel future. 2010 , 1, 515-29	7
462	Vascular development in mouse lung metastases. 2012 , 2, 581-8	2
461	Angiogenesis in upper tract urothelial carcinoma associated with Balkan endemic nephropathy. 2012 , 5, 674-83	5
460	Dosage determination of ultrasmall particles of iron oxide for the delineation of microvasculature in the Wistar rat brain. 2005 , 40, 655-60	5
459	The relationship between inflammatory markers, angiogenesis, and obesity. 2013 , 9, 247-53	25
458	Increased production of soluble vascular endothelial growth factors receptor-1 in CHO-cell line by using new combination of chitosan-protein lipid nanoparticles. 2015 , 8, 1526-33	2
457	The role of MTDH/AEG-1 in the progression of cancer. 2015 , 8, 4795-807	39
456	Inhibitory effect of midkine-binding peptide on tumor proliferation and migration. 2015 , 8, 5387-94	4
455	Hypoxia inducible factor-1 alpha and multiple myeloma. 2016 , 4, 706-715	12
454	In vitro and in vivo antiangiogenic activity of desacetylvinblastine monohydrazone through inhibition of VEGFR2 and Axl pathways. 2016 , 6, 843-58	12
453	Paclitaxel targets VEGF-mediated angiogenesis in ovarian cancer treatment. 2016 , 6, 1624-35	9
452	Inhibition of AGS Cancer Cell Proliferation following siRNA-Mediated Downregulation of VEGFR2. 2016 , 18, 381-8	1
451	Revisiting the hallmarks of cancer. 2017 , 7, 1016-1036	267
450	Understanding tumor anabolism and patient catabolism in cancer-associated cachexia. 2017 , 7, 1107-1135	13

449	Overexpression of Antiangiogenic Vascular Endothelial Growth Factor Isoform and Splicing Regulatory Factors in Oral, Laryngeal and Pharyngeal Squamous Cell Carcinomas. 2017 , 18, 2171-2177	3
448	Poly-L-Lysine Inhibits Tumor Angiogenesis and Induces Apoptosis in Ehrlich Ascites Carcinoma and in Sarcoma S-180 Tumor. 2017 , 18, 2255-2268	9
447	[Application Progress of CRISPR/Cas9 System for Gene Editing in Tumor Research]. 2015 , 18, 571-9	
446	Significance of integrin-linked kinase (ILK) in tumorigenesis and its potential implication as a biomarker and therapeutic target for human cancer. 2019 , 9, 186-197	29
445	Key indexes and the emerging tool for tumor microenvironment editing. 2019 , 9, 1027-1042	2
444	TIMP-2: An Endogenous Angiogenesis Inhibitor with Distinct Antitumoral Properties. 2012 , 2, 31-35	1
443	Overexpression of ERBB3 promotes proliferation, migration, and angiogenesis in nasopharyngeal carcinoma. 2019 , 12, 2931-2940	1
442	CCL4 promotes the cell proliferation, invasion and migration of endometrial carcinoma by targeting the VEGF-A signal pathway. 2017 , 10, 11288-11299	8
441	Epigenetic mechanisms and the hallmarks of cancer: an intimate affair. 2020 , 10, 1954-1978	16
440	Integrin $\alpha 5 \beta 1$ /Akt/Sp1 pathway participates in matrix stiffness-mediated effects on VEGFR2 upregulation in vascular endothelial cells. 2020 , 10, 2635-2648	3
439	Safety of apatinib plus S-1 for advanced solid tumor as palliative treatment. 2021 , 21, 62	
438	[Research Progress of Anti-angiogenic Agents Combined with Immunotherapy in Patients with Advanced Non-small Cell Lung Cancer]. 2021 , 24, 196-203	
437	Monitoring cancer cell surface receptor expression during anti-angiogenesis therapy in vivo. 2021 , 11625,	
436	The Art of Oncoimmunovaccinomics. 2021 , 11, 50-66	0
435	Exosomal LBH inhibits epithelial-mesenchymal transition and angiogenesis in nasopharyngeal carcinoma via downregulating VEGFA signaling.. 2022 , 18, 242-260	1
434	Design, synthesis and evaluation of anticancer activity of new pyrazoline derivatives by down-regulation of VEGF: Molecular docking and apoptosis inducing activity. 2022 , 118, 105487	5
433	Qualitative and Quantitative Contrast-Enhanced Ultrasound Combined with Conventional Ultrasound for Predicting the Malignancy of Soft Tissue Tumors. 2021 ,	0
432	Targeting Tie2 in the Tumor Microenvironment: From Angiogenesis to Dissemination. 2021 , 13,	4

431	Polyacrylamide-Sodium Alginate Hydrogel Releasing Oxygen and Vitamin C Promotes Bone Regeneration in Rat Skull Defects. 2021 , 8,	1
430	Marine Bromophenol Bis(2,3,6-Tribromo-4,5-Dihydroxybenzyl)ether Inhibits Angiogenesis in Human Umbilical Vein Endothelial Cells and Reduces Vasculogenic Mimicry in Human Lung Cancer A549 Cells. 2021 , 19,	2
429	miR-335-laden B Cell-Derived Extracellular Vesicles Promote SOX4-Dependent Apoptosis in Human Multiple Myeloma Cells.. 2021 , 11,	0
428	PHD2 attenuates high-glucose-induced blood retinal barrier breakdown in human retinal microvascular endothelial cells by regulating the Hif-1 α /VEGF pathway. 2021 , 71, 69	0
427	Curcumin prevents As-induced carcinogenesis through regulation of GSK3 β /Nrf2. 2021 , 16, 116	3
426	Defining the Transcriptional and Epigenetic Basis of Organotypic Endothelial Diversity in the Developing and Adult Mouse.	1
425	Long noncoding RNA TUG1 upregulates VEGFA to enhance malignant behaviors in stomach adenocarcinoma by sponging miR-29c-3p. 2021 , 35, e24106	2
424	Cannabinoid Drugs-Related Neuroprotection as a Potential Therapeutic Tool Against Chemotherapy-Induced Cognitive Impairment. 2021 , 12, 734613	6
423	Current developments in modelling the tumour microenvironment in vitro: Incorporation of biochemical and physical gradients. 2021 , 3, 100012	1
422	Carotid Plaques From Symptomatic Patients With Mild Stenosis Is Associated With Intraplaque Hemorrhage. 2022 , 79, 271-282	1
421	Large Scale Tissues Bioprinting. 2022 , 257-280	
420	Microfiber-Based Organoids Bioprinting for In Vitro Model. 2022 , 237-256	
419	Contrast-Enhanced Ultrasound (CEUS). 2021 , 161-177	
418	The Characteristics of Tumor Microenvironment in Triple Negative Breast Cancer.. 2022 , 14, 1-17	4
417	A novel second near-infrared theranostic agent: a win-win strategy of tracing and blocking tumor-associated vessels for oral squamous cell carcinoma. 2022 , 17, 100172	3
416	Early Response Prediction of Multiparametric Functional MRI and F-FDG-PET in Patients with Head and Neck Squamous Cell Carcinoma Treated with (Chemo)Radiation.. 2022 , 14,	1
415	The notion of fractals in tumour angiogenic sprout initiation model based on cellular automata. 2022 , 155, 111717	1
414	Environmental dose of 16 priority-controlled PAHs mixture induce damages of vascular endothelial cells involved in oxidative stress and inflammation.. 2021 , 79, 105296	1

413	Buyang Huanwu Decoction promotes angiogenesis in myocardial infarction through suppression of PTEN and activation of the PI3K/Akt signalling pathway.. 2021 , 114929	0
412	Self-delivery nanomedicine for vascular disruption-supplemented chemo-photodynamic tumor therapy.. 2021 , 612, 562-571	2
411	Safety of apatinib plus S-1 for advanced solid tumor as palliative treatment. 2020 , 21, 62	
410	Imaging the host response to cancer. 2021 ,	
409	Transarterial Chemoembolization (TACE) Plus Sorafenib Compared to TACE Alone in Transplant Recipients with Hepatocellular Carcinoma: An Institution Experience.. 2022 , 14,	3
408	Copper-induced tumor cell death mechanisms and antitumor theragnostic applications of copper complexes.. 2022 ,	14
407	Negative Modulation of the Angiogenic Cascade Induced by Allosteric Kinesin Eg5 Inhibitors in a Gastric Adenocarcinoma In Vitro Model.. 2022 , 27,	1
406	Medical Imaging Biomarker Discovery and Integration Towards AI-Based Personalized Radiotherapy.. 2021 , 11, 764665	0
405	Using proteomimetics to switch angiogenic signaling.. 2022 , 12, 1534-1535	0
404	Chemotherapy response prediction with diffuser elapser network.. 2022 , 12, 1628	0
403	Robust Deep 3-D Blood Vessel Segmentation Using Structural Priors.. 2022 , PP,	
402	Introduction. 2022 , 1-28	
401	Critical Review of the simple theoretical models in Dynamic Imaging: Up-Slope Method and Graphical Analysis.. 2022 ,	
400	Advancements, Challenges, and Future Directions in Tackling Glioblastoma Resistance to Small Kinase Inhibitors.. 2022 , 14,	2
399	Angioprevention of Urologic Cancers by Plant-Derived Foods.. 2022 , 14,	0
398	Sheltered in Stromal Tissue Cells, Orchestrates Inflammatory Neovascularization via Activation of the Mast Cell Chymase Pathway.. 2022 , 11,	1
397	Safranal Inhibits Angiogenesis Targeting HIF-1 α /VEGF Machinery: and Insights.. 2021 , 11, 789172	6
396	Long non-coding RNAs involved in different steps of cancer metastasis.. 2022 , 1	0

395	Study of sacrificial ink-assisted embedded printing for 3D perfusable channel creation for biomedical applications.. 2022 , 9, 011408	2
394	Synthesis, bioactive properties, and biomedical applications of intrinsically therapeutic nanoparticles for disease treatment. 2022 , 435, 134970	10
393	Epigallocatechin 3-gallate: From green tea to cancer therapeutics.. 2022 , 379, 132135	16
392	Destruction of tumor vasculature by vascular disrupting agents in overcoming the limitation of EPR effect.. 2022 , 114138	1
391	Qiber3D-an open-source software package for the quantitative analysis of networks from 3D image stacks.. 2022 , 11,	2
390	Antitumor effect of isoquercetin on tissue vasohibin expression and colon cancer vasculature.. 2022 , 13, 307-318	1
389	Challenging the Paradigm: Anti-Inflammatory Interleukins and Angiogenesis.. 2022 , 11,	2
388	Combretastatin A4-loaded poly(lactic-co-glycolic acid)/soybean lecithin nanoparticles with enhanced drug dissolution rate and antiproliferation activity.. 2022 ,	
387	Shed syndecan-2 enhances colon cancer progression by increasing cooperative angiogenesis in the tumor microenvironment.. 2022 ,	1
386	Current nano-therapeutic approaches ameliorating inflammation in cancer progression.. 2022 ,	4
385	Suppression of tumor metastasis by a RECK-activating small molecule.. 2022 , 12, 2319	0
384	Angiogenic biomolecules specific nanobodies application in cancer imaging and therapy; review and updates.. 2022 , 105, 108585	0
383	The crosstalk between VEGF signaling pathway and long non-coding RNAs in neovascular retinal diseases: Implications for anti-VEGF therapy. 2022 , 27, 101541	
382	Modulating Angiogenesis by Proteomimetics of Vascular Endothelial Growth Factor.. 2021 ,	5
381	A microfluidic hanging drop-based spheroid co-culture platform for probing tumor angiogenesis.. 2022 ,	1
380	A 3D-printed biphasic calcium phosphate scaffold loaded with platelet lysate/gelatin methacrylate to promote vascularization.. 2022 ,	2
379	A Review on Ethnomedicinal, Phytochemistry and Pharmacological Activities of Rumex hastatus D. Don. 2022 , 205-248	
378	Confocal laser speckle autocorrelation imaging of dynamic flow in microvasculature. 2022 , 5, 210045-210045	1

- 377 Hypoxia Imaging. **2022**, 167-177
- 376 Assessing Tumour Haemodynamic Heterogeneity and Response to Choline Kinase Inhibition Using Clustered Dynamic Contrast Enhanced MRI Parameters in Rodent Models of Glioblastoma.. **2022**, 14, 0
- 375 Platinum Nanoparticles in Biomedicine: Preparation, Anti-Cancer Activity, and Drug Delivery Vehicles.. **2022**, 13, 797804 5
- 374 A multi-layered hybrid model for cancer cell invasion.. **2022**, 60, 1075
- 373 Radiomics Analysis of Multiparametric MRI for Prediction of Synchronous Lung Metastases in Osteosarcoma.. **2022**, 12, 802234 1
- 372 Diabetes and Its Cardiovascular Complications: Comprehensive Network and Systematic Analyses.. **2022**, 9, 841928 1
- 371 Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer: A Randomized Clinical Trial.. **2022**, 5, e2149040 4
- 370 Hypoxic response is driven by the BAF form of SWI/SNF. 0
- 369 A Mini-Review on Nanodelivery Systems as Therapeutics in Cancer. **2022**, 18,
- 368 Nanocarrier cancer therapeutics with functional stimuli-responsive mechanisms.. **2022**, 20, 152 0
- 367 Challenges of the Immunotherapy: Perspectives and Limitations of the Immune Checkpoint Inhibitor Treatment.. **2022**, 23, 2
- 366 Artificial Nanoplatelets Depend on Size for Precisely Inducing Thrombosis in Tumor Vessels.. **2022**, e2101474
- 365 Is Sphingosine-1-Phosphate a Regulator of Tumor Vascular Functionality?. **2022**, 14, 0
- 364 Engineering tumor constructs to study matrix-dependent angiogenic signaling of breast cancer cells.. **2022**, e3250
- 363 Pan-cancer Analyses reveal functional similarities of three lncRNAs across multiple tumors.
- 362 Transarterial Chemoembolization Combined With Tyrosine Kinase Inhibitors for Intermediate-Stage Hepatocellular Carcinoma, What Else Can We Do?. **2022**, 12, 824799 0
- 361 Angiogenesis Inhibitors and Immunomodulation in Renal Cell Cancers: The Past, Present, and Future.. **2022**, 14, 0
- 360 Apoplastic Production of Recombinant AntiVEGF Protein Using Plant-Virus Transient Expression Vector.. **2022**, 1 0

359 Applications of Polymer Bioconjugates. 1-47

358 Advanced Biomaterials for Cell-Specific Modulation and Restore of Cancer Immunotherapy.. **2022**, e2200027 3

357 Inverting angiogenesis with interstitial flow and chemokine matrix-binding affinity.. **2022**, 12, 4237

356 High-Throughput Production of Microsponges from Platelet Lysate for Tissue Engineering Applications.. **2022**, 1

355 Three Component One-Pot Synthesis of Novel 8-Benzyloxy-5-{2-[N[?]-(1,3-Diphenyl-1H-Pyrazol-4-Ylmethylene)-Hydrazino]-Thiazol-4-yl}-3,4-Dihydro-1H-Quinolin-2-Ones.

354 On-chip long-term perfusable microvascular network culture.

353 Bionanoparticles in cancer imaging, diagnosis, and treatment. 20200027 2

352 Intelligent Nanodelivery System-Generated O Mediates Tumor Vessel Normalization by Activating Endothelial TRPV4-eNOS Signaling.. **2022**, e2200038 0

351 Understanding the Molecular Mechanisms of Betel miRNAs on Human Health.. **2022**,

350 Pro-Calcific Environment Impairs Ischaemia-Driven Angiogenesis.. **2022**, 23,

349 ABSTRACTS (BY NUMBER). **2022**, 28, S-1-S-654

348 Propofol suppresses non-small cell lung cancer progression by modulating circ_0001727/miR-516b-5p/LRRC1 axis. **2022**, 65,

347 Understanding glioblastoma invasion using physically-guided neural networks with internal variables.. **2022**, 18, e1010019 1

346 Degradable Tumor-Responsive Iron-Doped Phosphate-Based Glass Nanozyme for HO Self-Supplying Cancer Therapy.. **2022**, 4

345 An intuitionistic fuzzy bireduct model and its application to cancer treatment. **2022**, 168, 108124 0

344 Natural products modulating interleukins and other inflammatory mediators in tumor-bearing animals: A systematic review.. **2022**, 100, 154038 1

343 Evolution of bone tissue based on angiogenesis as a crucial factor: New mathematical attempt. 108128652110489

342 Pixel Distribution Learning for Vessel Segmentation under Multiple Scales. **2021**, 2021, 2717-2721 1

341	Microvascular Experimentation in the Chick Chorioallantoic Membrane as a Model for Screening Angiogenic Agents including from Gene-Modified Cells.. 2021 , 23,	1
340	Diagnostic and Therapeutic Values of Angiogenic Factors in Endometrial Cancer.. 2021 , 12,	0
339	Frontiers in Anti-Cancer Drug Discovery: Challenges and Perspectives of Metformin as Anti-Angiogenic Add-On Therapy in Glioblastoma.. 2021 , 14,	2
338	A Gene-Based Machine Learning Classifier Associated to the Colorectal Adenoma-Carcinoma Sequence.. 2021 , 9,	
337	Association of pigment epithelium derived factor expression with cancer progression and prognosis: a meta-analysis study.. 2021 , 12, 61	
336	Capillary network formation and structure in a modified discrete mathematical model of angiogenesis. 2021 ,	3
335	Folate Transport and One-Carbon Metabolism in Targeted Therapies of Epithelial Ovarian Cancer.. 2021 , 14,	0
334	Low Inorganic Phosphate Stress Inhibits Liver Cancer Progression: from In Vivo to In Vitro. 2022 , 5, 2100224	2
333	Untangling Galectin-Mediated Circuits that Control Hypoxia-Driven Angiogenesis.. 2022 , 2442, 635-653	
332	P4HA1 Regulates CD31 COL6A1 in the Transition of Glioblastoma Stem-Like Cells to Tumor Endothelioid Cells.. 2022 , 12, 836511	0
331	CircRNAs: promising factors for regulating angiogenesis in colorectal cancer.. 2022 , 1	
330	Endothelial Cell Metabolism in Vascular Functions.. 2022 , 14,	1
329	Optical-force-controlled red-blood-cell microlenses for subwavelength trapping and imaging.	1
328	Image_1.TIFF. 2020 ,	
327	Image_2.TIFF. 2020 ,	
326	Image_3.TIFF. 2020 ,	
325	Table_1.DOCX. 2020 ,	
324	Table_1.docx. 2020 ,	

323 Image_1.pdf. 2020,

322 Data_Sheet_1.PDF. 2020,

321 DataSheet_1.pdf. 2020,

320 Table_1.docx. 2020,

319 Table_1.docx. 2020,

318 Table_1.docx. 2019,

317 Image_1.jpg. 2020,

316 DataSheet_1.docx. 2020,

315 Surufatinib plus toripalimab in patients with advanced solid tumors: a single-arm, open-label, phase 1 trial.. 2022, 1

o

314 Toward 3D-bioprinting of an endocrine pancreas: A building-block concept for bioartificial insulin-secreting tissue.. 2022, 13, 20417314221091033

o

313 Biodegradable Inks in Indirect Three-Dimensional Bioprinting for Tissue Vascularization.. 2022, 10, 856398

o

312 Effects of TGF- β and IL-6 on the Development and Metastasis of Gastric Cancer. 2022, 12, 65-71

311 Biofabricating the Vascular Tree in Engineered Bone Tissue.

310 CHAPTER 9. Quantum Dots in Biological Imaging. 2022, 278-321

o

309 In Vitro Effects of Papaverine on Cell Migration and Vascular Endothelial Growth Factor in Cancer Cell Lines.. 2022, 23,

1

308 EV (Extracellular Vesicle)-associated miRNAs as Biomarkers of Toxicity. 2022, 37-62

307 Depletion of T Cells Leads to Reduced Angiogenesis and Increased Infiltration of Inflammatory M1-like Macrophages in Ischemic Muscle Tissue.. 2022, 11,

o

306 Ultrasound high-definition microvasculature imaging with novel quantitative biomarkers improves breast cancer detection accuracy.. 2022, 1

1

305	Microvascular development in the rat arteriovenous loop model in vivo-A step by step intravital microscopy analysis.. 2022 ,	1
304	Structural Prior Models for 3-D Deep Vessel Segmentation. 2022 ,	
303	STAT6 Upregulates NRP1 Expression in Endothelial Cells and Promotes Angiogenesis. 2022 , 12,	
302	Extracellular vesicles rich in HAX1 promote angiogenesis by modulating ITGB6 translation.. 2022 , 11, e12221	0
301	Structural basis of human LRG1 recognition by Magacizumab, a humanized monoclonal antibody with therapeutic potential. 2022 , 78,	0
300	Tumor microenvironment heterogeneity an important mediator of prostate cancer progression and therapeutic resistance.. 2022 , 6, 31	2
299	Tumour Microenvironment-Immune Cell Interactions Influencing Breast Cancer Heterogeneity and Disease Progression. 2022 , 12,	0
298	Vocal fold fibroblasts promote angiogenesis in vocal fold leukoplakia by secreting pro-angiogenic factors.. 2022 ,	0
297	Identification of Angiogenesis-Related Prognostic Biomarkers Associated With Immune Cell Infiltration in Breast Cancer. 2022 , 10,	2
296	Enhancement of Farnesoid X Receptor Inhibits Migration, Adhesion and Angiogenesis through Proteasome Degradation and VEGF Reduction in Bladder Cancers.. 2022 , 23,	0
295	Virus-like siRNA construct dynamically responsive to sequential microenvironments for potent RNA interference.. 2022 , 622, 938-949	
294	Cold Atmospheric Plasma Reduces Vessel Density and Increases Vascular Permeability and Apoptotic Cell Death in Solid Tumors. 2022 , 14, 2432	1
293	Circ_0000274 contributes to renal cell carcinoma progression by regulating miR-338-3p/NUCB2 axis and JAK1/STAT3 pathway.. 2022 , 101626	
292	Nucleosomes Bind Fibroblast Growth Factor-2 for Increased Angiogenesis In vitro and In vivo. 2004 , 2, 281-288	5
291	Molecular Mechanism of Oxidative Stress in Cancer and Its Therapeutics. 2022 , 1-15	
290	Local and Regional Therapies for Hepatocellular Carcinoma and Future Combinations. 2022 , 14, 2469	1
289	Intra-tumoral angiogenesis correlates with immune features and prognosis in glioma.. 2022 , 14,	
288	Fast raster-scan optoacoustic mesoscopy enables assessment of human melanoma microvasculature in vivo.. 2022 , 13, 2803	0

- 287 Impact of lenvatinib on renal function compared to sorafenib for unresectable hepatocellular carcinoma.. **2022**, 101, e29289
- 286 Helical sulfono- α Apeptides with predictable functions in protein recognition.
- 285 Enabling CAR-T cells for solid tumors: Rage against the suppressive tumor microenvironment. **2022**, 3
- 284 Nanotechnology Perspective of Lung Cancer Imaging Diagnosis using Deep Learning Techniques. **2022**,
- 283 Contribution of the Tumor Microenvironment to Metabolic Changes Triggering Resistance of Multiple Myeloma to Proteasome Inhibitors. **2022**, 12, 1
- 282 Guiding cell migration in 3D with high-resolution photografting. **2022**, 12, 1
- 281 Indocyanine green fluorescence image processing techniques for breast cancer macroscopic demarcation. **2022**, 12, 0
- 280 Zebrafish: Promising Model for Cancer Research. **2022**, 197-213
- 279 The Preoperative Diagnostic Performance of Multi-Parametric Quantitative Assessment in Rectal Carcinoma: A Preliminary Study Using Synthetic Magnetic Resonance Imaging. **2022**, 12,
- 278 Contrast-enhanced mammography for the assessment of screening recalls: a two-centre study. 0
- 277 Comparison of diffusion kurtosis imaging and dynamic contrast enhanced MRI in prediction of prognostic factors and molecular subtypes in patients with breast cancer. **2022**, 110392
- 276 An overview of post transplantation events of decellularized scaffolds. **2022**, 101640 0
- 275 Spatially adaptive blind deconvolution methods for optical coherence tomography. **2022**, 147, 105650 1
- 274 3D Bioprinting of Prevascularized Full-Thickness Gelatin-Alginate Structures with Embedded Co-Cultures. **2022**, 9, 242 0
- 273 Cell motility in confluent tissues induced by substrate disorder. **2022**, 4,
- 272 Nano-Sonosensitized Sonodynamic Nanomedicine Augments Tumor-Selective Catalytic Tumor Eradication. 9, 1
- 271 Craniomaxillofacial derived bone marrow mesenchymal stem/stromal cells (BMSCs) for craniomaxillofacial bone tissue engineering: A literature review. **2022**, 0
- 270 Deepening the knowledge of rare diseases dependent on angiogenesis through semantic similarity clustering and network analysis.

269	Particle Hydrogels Decrease Cerebral Atrophy and Attenuate Astrocyte and Microglia/macrophage Reactivity After Stroke. 2200048	2
268	Targeting Tumour-Associated Fibroblasts in Cancers. 12,	2
267	Nanomedicine Penetration to Tumor: Challenges, and Advanced Strategies to Tackle This Issue. 2022 , 14, 2904	2
266	Inducible endothelial leakiness in nanotherapeutic applications. 2022 , 121640	1
265	Targeting signaling pathways in prostate cancer: mechanisms and clinical trials. 2022 , 7,	4
264	Case report study of thalidomide therapy in 18 patients with severe arteriovenous malformation s. 2022 , 1, 562-567	0
263	Blood vessel remodeling in late stage of vascular network reconstruction is essential for peripheral nerve regeneration.	1
262	A hierarchical vascularized engineered bone inspired by intramembranous ossification for mandibular regeneration. 2022 , 14,	0
261	Using pattern recognition and discriminant analysis of functional perfusion data to create Angioprints For normal and perturbed angiogenic microvascular networks. 2022 , 219-228	
260	VEGF Paradoxically Reduces Cerebral Blood Flow in Alzheimer Disease Mice. 2022 , 17, 263310552211092	0
259	Uncovering the limitation of nanodrug delivery system: Backdrop to the game changer. 2022 , 321-342	
258	Composites for angiogenesis induction. 2022 , 239-272	
257	Real World Study of Immune-Related Adverse Events Caused by PD-1 Inhibitors. 2022 , 12, 5913-5936	
256	The Role of the Microenvironment in Endometriosis: Parallels and Distinctions to Cancer. 2022 , 483-496	
255	Electrospun nanofibers for angiogenesis strategies. 2022 , 383-414	
254	Molecular Imaging of Tumor Progression and Angiogenesis by Dual Bioluminescence. 2022 , 457-469	
253	Tissue Architecture in Cancer Initiation and Progression. 2022 , 91-107	
252	Predictive value of intravoxel incoherent motion combined with diffusion kurtosis imaging for breast cancer axillary lymph node metastasis: a retrospective study. 028418512211076	

- 251 DNL-Net: deformed non-local neural network for blood vessel segmentation. **2022**, 22, 1
- 250 Crosstalk between angiogenesis and immune regulation in the tumor microenvironment. **2022**, 45, 401-416 1
- 249 Discovering Tuberosin and Villosol as Potent and Selective Inhibitors of AKT1 for Therapeutic Targeting of Oral Squamous Cell Carcinoma. **2022**, 12, 1083
- 248 Recombinant Bifidobacterium longum Carrying Endostatin Protein Alleviates Dextran Sodium Sulfate-Induced Colitis and Colon Cancer in Rats. 13, 1
- 247 Modelling human placental villous development: designing cultures that reflect anatomy. **2022**, 79, 0
- 246 Impact of VEGFA promoter polymorphisms on esophageal cancer risk in North-West Indians: a case-control study. **2022**, 44, 923-936 0
- 245 Diagnostic Value of AngioPLUS Microvascular Imaging in Thyroid Nodule Diagnosis Using Quantitative and Qualitative Vascularity Grading. **2022**, 10, 1554 1
- 244 Platycodin D Inhibits Vascular Endothelial Growth Factor-Induced Angiogenesis by Blocking the Activation of Mitogen-Activated Protein Kinases and the Production of Interleukin-8. 1-17 0
- 243 Integrated Transcriptome and Metabolomic Analysis Reveal Anti-Angiogenic Properties of Disarib, a Novel Bcl2-Specific Inhibitor. **2022**, 13, 1208
- 242 Connexin 43 overexpression induces lung cancer angiogenesis in vitro following phosphorylation at Ser279 in its C-terminus. **2022**, 24, 0
- 241 Transcutaneous Electrical Stimulation, Interferential Current and Photobiomodulation May Lead to the Recurrence of Breast Cancer in Rats?. **2022**, 68,
- 240 The novel transcriptomic signature of angiogenesis predicts clinical outcome, tumor microenvironment and treatment response for prostate adenocarcinoma. **2022**, 28, 0
- 239 Sound-based assembly of a microcapillary network in a saturn-like tumor model for drug testing. **2022**, 100357
- 238 Long-term cultured microvascular networks on chip for tumor vascularization research and drug testing. **2022**, 16, 044101
- 237 Statins and angiogenesis in non-cardiovascular diseases. **2022**, 2
- 236 Combining Mechanisms of Growth Arrest in Solid Tumours: A Mathematical Investigation. **2022**, 84,
- 235 Unraveling the Immune Microenvironment of Thymic Epithelial Tumors: Implications for Autoimmunity and Treatment. **2022**, 23, 7864 4
- 234 Progress and challenges on extrusion based three dimensional (3D) printing of biomaterials. **2022**, 27, e00223 0

233	A systematic comparison of anti-angiogenesis efficacy and cardiotoxicity of receptor tyrosine kinase inhibitors in zebrafish model. 2022 , 450, 116162	1
232	Thalidomide Radiosensitizes Tumors through Early Changes in the Tumor Microenvironment. 2005 , 11, 743-750	40
231	Antiangiogenic and Antitumor Activity of a Selective PDGFR Tyrosine Kinase Inhibitor, CP-673,451. 2005 , 65, 957-966	29
230	Vascularization of Melanoma by Mobilization and Remodeling of Preexisting Latent Vessels to Patency. 2005 , 65, 913-918	6
229	CXCL12 and Vascular Endothelial Growth Factor Synergistically Induce Neoangiogenesis in Human Ovarian Cancers. 2005 , 65, 465-472	127
228	Catulin reporter marks a heterogeneous population of invasive breast cancer cells with some demonstrating plasticity and participating in vascular mimicry. 2022 , 12,	0
227	Multi-scale modelling of nanoparticle delivery and heat transport in vascularised tumours.	0
226	Emerging Roles of Circ-ZNF609 in Multiple Human Diseases. 13,	0
225	Photoacoustic imaging for microcirculation.	0
224	Halogenated Flavonoid Derivatives Display Antiangiogenic Activity. 2022 , 27, 4757	1
223	Novel artemisinin derivative FO8643 with anti-angiogenic activity inhibits growth and migration of cancer cells via VEGFR2 signaling. 2022 , 175158	1
222	Effect of Tumor Host Microenvironment on Photodynamic Therapy in a Rat Prostate Tumor Model. 2005 , 11, 720-727	24
221	Nanovesicles for tumor-targeted drug delivery. 2022 , 219-244	
220	The pleiotropic role of galectin-3 in melanoma progression: Unraveling the enigma. 2022 ,	1
219	Diagnostic Performance of Superb Microvascular Imaging in Differentiating Benign and Malignant Axillary Lymph Nodes. Publish Ahead of Print,	
218	Tumor-on-a-chip model for advancement of anti-cancer nano drug delivery system. 2022 , 20,	1
217	Novel therapeutic combinations with PARP inhibitors for small cell lung cancer: A bench-to-bedside review. 2022 ,	0
216	Pleiotropic properties of statins via angiogenesis modulation in cardiovascular disease. 2022 , 103325	1

- 215 Copper (II) complexes based bis(pyrazolyl)borate derivatives as efficient anticancer agents: synthesis, characterization, X-ray structure, cytotoxicity, molecular docking and QSAR studies.
- 214 Spatiotemporal multi-scale modeling of radiopharmaceutical distributions in vascularized solid tumors. **2022**, 12, 1
- 213 Acute hypoxia promotes the liver angiogenesis of largemouth bass (*Micropterus salmoides*) by HIF - Dependent pathway. **2022**, 0
- 212 Transcatheter arterial chemoembolization plus atezolizumab and bevacizumab for unresectable hepatocellular carcinoma: a single-arm, phase 2 trial. 0
- 211 Effect of pulsed field ablation on solid tumor cells and microenvironment. 12,
- 210 Vascularization in Bioartificial Parenchymal Tissue: Bioink and Bioprinting Strategies. **2022**, 23, 8589 0
- 209 Advances of Epigenetic Biomarkers and Epigenome Editing for Early Diagnosis in Breast Cancer. **2022**, 23, 9521 2
- 208 Mechanical regulation of signal transduction in angiogenesis. 10, 1
- 207 The application of zebrafish patient-derived xenograft tumor models in the development of antitumor agents. 0
- 206 The Emerging Promise with O/C-Glycosides of Important Dietary Phenolic Compounds.
- 205 ADC and kinetic parameter of primary tumor: Surrogate imaging markers for fertility-sparing vaginal radical trachelectomy in patients with stage IB cervical cancer. **2022**, 155, 110467 0
- 204 Combination of apatinib with apo-IDO1 inhibitor for the treatment of colorectal cancer. **2022**, 112, 109233 0
- 203 Chemo-transport-mechanics in advecting membranes. **2022**, 181, 103746 0
- 202 Biomarkers, Prognosis, and Prediction Factors. **2023**, 49-70 0
- 201 Conventional Breast Imaging. **2023**, 18-39 0
- 200 Design, Synthesis and Biological Evaluation of Conformationally-Restricted Analogues of E7010 as Inhibitors of Tubulin Assembly (ITA) and Vascular Disrupting Agents (VDA). 0
- 199 Molecular Mechanism of Oxidative Stress in Cancer and Its Therapeutics. **2022**, 3401-3415 0
- 198 Antibody-drug conjugates for targeted delivery. **2022**, 377-419 0

- 197 Peptide nanogels as a scaffold for fabricating dermal grafts and 3D vascularized skin models. **2022**, 13, 204173142211118 1
- 196 Manufacturing functional hydrogels for inducing angiogenic osteogenic coupled progressions in hard tissue repairs: prospects and challenges. **2022**, 10, 5472-5497 0
- 195 The biology of cancer. **2023**, 35-45 0
- 194 Therapeutic Sources of Skeletal Muscle Regeneration from Volumetric Muscle Loss: A Narrative Review. **2022**, 31, 295-303 0
- 193 Biofabricating the vascular tree in engineered bone tissue. **2022**, 0
- 192 Metabolomics and Biomarkers in Retinal and Choroidal Vascular Diseases. **2022**, 12, 814 1
- 191 Emerging Role of microRNA Dysregulation in Diagnosis and Prognosis of Extrahepatic Cholangiocarcinoma. **2022**, 13, 1479 0
- 190 Tumor Distribution by Quantitative Mass Spectrometry Imaging of the Inhibitor of Apoptosis Protein Antagonist Xevinapant in Patients with Resectable Squamous Cell Carcinoma of the Head and Neck (EudraCT Number: 2014-004655-31). **2022**, 94, 12333-12341 1
- 189 Perfusion-Based Fluorescent Dye Labeling to Sort Cancer Cells Based on Their Distance from Blood Vessels. **2023**, 55-66 0
- 188 A novel hKDR mouse model depicts the anti-angiogenesis and apoptosis-promoting effects of neutralizing antibodies targeting VEGFR2. 0
- 187 Exploration of Site-Specific Drug Targeting: A Review on EPR-, Stimuli-, Chemical-, and Receptor-Based Approaches as Potential Drug Targeting Methods in Cancer Treatment. **2022**, 2022, 1-26 0
- 186 Molecular insight into pentraxin-3: update advances in innate immunity, inflammation, tissue remodeling, diseases, and drug role. **2022**, 113783 0
- 185 Retinal and Choroidal Neovascularization Antivascular Endothelial Growth Factor Treatments: The Role of Gene Therapy. 0
- 184 Phenformin suppresses angiogenesis through the regulation of exosomal microRNA-1246 and microRNA-205 levels derived from oral squamous cell carcinoma cells. 12, 0
- 183 All Roads Lead to Cathepsins: The Role of Cathepsins in Non-Alcoholic Steatohepatitis-Induced Hepatocellular Carcinoma. **2022**, 10, 2351 0
- 182 Tumor-derived exosomal lincRNA ROR promotes angiogenesis in nasopharyngeal carcinoma. **2022**, 101868 1
- 181 Metabolic Reprogramming in Tumor Endothelial Cells. **2022**, 23, 11052 3
- 180 Glioblastoma microenvironment and its reprogramming by oncolytic virotherapy. 16, 0

- 179 Paving the road to make chimeric antigen receptor-T-cell therapy effective against solid tumors. ○
- 178 TEM8 Tri-specific Killer Engager binds both tumor and tumor stroma to specifically engage natural killer cell anti-tumor activity. **2022**, 10, e004725 ○
- 177 Magnolol as a Potential Anticancer Agent: A Proposed Mechanistic Insight. **2022**, 27, 6441 ○
- 176 Efficacy of rechallenge transcatheter arterial chemoembolization after lenvatinib treatment for advanced hepatocellular carcinoma. ○
- 175 Nanoparticle-Based Drug Delivery Systems Targeting Tumor Microenvironment for Cancer Immunotherapy Resistance: Current Advances and Applications. **2022**, 14, 1990 1
- 174 Extracellular vesicles as central regulators of blood vessel function in cancer. **2022**, 15, 1
- 173 State-of-the-art Techniques for Imaging the Vascular Microenvironment in Craniofacial Bone Tissue Engineering Applications. ○
- 172 Pyrazolo[3,4- d]pyrimidine scaffold: A review on synthetic approaches and EGFR and VEGFR inhibitory activities. ○
- 171 Super-Resolution Ultrasound Localization Microscopy of Microvascular Structure and Flow for Distinguishing Metastatic Lymph Nodes [An Initial Human Study]. ○
- 170 Effects of acute exercise training on tumor outcomes in men with localized prostate cancer: A randomized controlled trial. **2022**, 10, ○
- 169 Deformable mirror-based photoacoustic remote sensing (PARS) microscopy for depth scanning. **2022**, 13, 5643 1
- 168 Characterization of the activity and the mechanism of action of a new toluquinol derivative with improved potential as an antiangiogenic drug. **2022**, 155, 113759 ○
- 167 Design, synthesis and biological evaluation of conformationally-restricted analogues of E7010 as inhibitors of tubulin assembly (ITA) and vascular disrupting agents (VDA). **2022**, 244, 114809 ○
- 166 Reprogramming Carbohydrate Metabolism in Cancer and Its Role in Regulating the Tumor Microenvironment. **2022**, 3-65 ○
- 165 Capturing the spatial and temporal dynamics of tumor stroma for on-chip optimization of microenvironmental targeting nanomedicine. ○
- 164 Protein and Peptide-Based Therapeutics for Cancer Imaging. **2022**, 441-471 ○
- 163 New Cu(i) square grid-type and Ni(ii) triangle-type complexes: synthesis and characterization of effective binders of DNA and serum albumins. **2022**, 51, 15648-15658 ○
- 162 Das Tumorstroma. **2022**, 851-860 ○

161	RUNX Family in Hypoxic Microenvironment and Angiogenesis in Cancers. 2022 , 11, 3098	0
160	Role of glucose metabolism in ocular angiogenesis (Review). 2022 , 26,	0
159	The Biological Relevance of Papaverine in Cancer Cells. 2022 , 11, 3385	1
158	Therapeutic potential of targeting mirnas to prostate cancer tumors: using psma as an active target. 2022 , 9,	0
157	Bioreaktoren für vaskularisiertes Knochen-Tissue-Engineering. 2022 , 28, 654-656	0
156	An immune evasion molecular subgroup predicts prognosis in lung adenocarcinoma.	0
155	The Frequency and Causes of Not-Detected Breast Malignancy in Dynamic Contrast-Enhanced MRI. 2022 , 12, 2575	1
154	Differential Expression of HIF1A, EPAS1, and VEGF Genes in Benign and Malignant Ovarian Neoplasia. 2022 , 14, 4899	0
153	Cancer Metabolism. 1-14	0
152	Diagnostic Value of Superb Microvascular Imaging in Differentiating Benign and Malignant Breast Tumors: A Systematic Review and Meta-Analysis. 2022 , 12, 2648	1
151	Mechanisms of Cancer Metastasis. 2022 ,	2
150	Revisiting the anticancer properties of phosphane(9-ribosylpurine-6-thiolato)gold(I) complexes and their 9H-purine precursors.	1
149	Angioside: The role of Angiogenesis and Hypoxia in Lung Neuroendocrine Tumours According to Primary Tumour Location in Left or Right Parenchyma. 2022 , 11, 5958	1
148	Geostatistical Modeling and Heterogeneity Analysis of Tumor Molecular Landscape. 2022 , 14, 5235	0
147	B-Mode and Contrast-Enhanced Ultrasonography Aspects of Benign and Malignant Superficial Neoplasms in Dogs: A Preliminary Study. 2022 , 12, 2765	1
146	In vitro vascularization of hydrogel-based tissue constructs via a combined approach of cell sheet engineering and dynamic perfusion cell culture. 2023 , 15, 015004	0
145	Tumor Angiogenesis. 1-30	0
144	Role of Nanotechnology in Overcoming the Multidrug Resistance in Cancer Therapy: A Review. 2022 , 27, 6608	0

- 143 ARL13B promotes angiogenesis and glioma growth by activating VEGFA-VEGFR2 signaling. ○
- 142 ER stress as a trigger of UPR and ER-phagy in cancer growth and spread. 12, ○
- 141 A Linkage between Angiogenesis and Inflammation in Neovascular Age-Related Macular Degeneration. **2022**, 11, 3453 1
- 140 Injectable rapidly dissolving needle-type gelatin implant capable of delivering high concentrations of H₂O₂ through intratumoral injection. **2022**, 156, 113910 ○
- 139 H₂O₂ self-sufficient nanoplatform based on CeO₂ QDs decorated MgO₂ nanosheet for amplified chemodynamic therapy. **2023**, 221, 112997 ○
- 138 Roles of TGF- β in cancer hallmarks and emerging onco-therapeutic design. 1-44 ○
- 137 MiR-29c-3p/C1QTNF6 Restrains the Angiogenesis and Cell Proliferation, Migration and Invasion in Head and Neck Squamous Cell Carcinoma. ○
- 136 Biomarkers for anti-vascular endothelial growth factor drugs. **2022**, 24, ○
- 135 Novel Retroperitoneal Neovascularity Scoring System in Renal Cell Carcinoma Tumor Staging. ○
- 134 From Macro to Micro: Comparison of Imaging Techniques to Detect Vascular Network Formation in Left Ventricle Decellularized Extracellular Matrix Hydrogels. **2022**, 8, 729 1
- 133 Gold nanoparticles as antiangiogenic and antimetastatic agents. **2022**, 103438 ○
- 132 Long-term effect of sodium selenite on the integrity and permeability of on-chip microvasculature. **2022**, 6, 046105 ○
- 131 Transient Receptor Potential (TRP) Channels in Tumor Vascularization. **2022**, 23, 14253 ○
- 130 Chapter 12. Imaging in Scaffolds. **2022**, 304-341 ○
- 129 Hypoxia alleviating platinum(IV)/chlorin e6-based combination chemotherapeutic-photodynamic nanomedicine for oropharyngeal carcinoma. **2023**, 238, 112627 ○
- 128 Polymersome-based protein drug delivery ¶quo vadis?. ○
- 127 Predicting axillary nodal metastasis based on the side of asymmetrical cortical thickening in breast cancer: Evaluation with grayscale and microvascular imaging findings. **2023**, 158, 110643 ○
- 126 Anisotropic dense collagen hydrogels with two ranges of porosity to mimic the skeletal muscle extracellular matrix. **2023**, 144, 213219 ○

- 125 Anticancer evaluation of new organometallic ruthenium(ii) flavone complexes. 1
- 124 A novel angiogenic effect of PCSK9- regulated genes. **2023**, 852, 147051 0
- 123 Stimulus-responsive strategy based on MnO₂ nanosheet-modified mesoporous silica nanoprobe for accurate multiple mRNAs detection. **2023**, 255, 124179 0
- 122 Fast and selective super-resolution ultrasound in vivo with acoustically activated nanodroplets. **2022**, 1-1 0
- 121 Perfusable cell-laden matrices to guide patterning of vascularization in vivo. 0
- 120 Selective delivery of pitavastatin-loaded nanoparticles induces arteriogenesis upon chronic myocardial ischemia. **2022**, 12, 1027-1032 0
- 119 Resveratrol suppresses serum-induced vasculogenic mimicry through impairing the EphA2/twist-VE-cadherin/AKT pathway in human prostate cancer PC-3 cells. **2022**, 12, 0
- 118 Characterization of TGF- β signaling in a human organotypic skin model reveals that loss of TGF- β II induces invasive tissue growth. **2022**, 15, 0
- 117 Evaluation of orbital lesions with DCE-MRI: a literature review. 1-9 0
- 116 Thienopyrimidine-based agents bearing diphenylurea: Design, synthesis, and evaluation of antiproliferative and antiangiogenic activity. 0
- 115 Functionally integrating nanoparticles alleviate deep vein thrombosis in pregnancy and rescue intrauterine growth restriction. **2022**, 13, 0
- 114 Models including preoperative plasma levels of angiogenic factors, leptin and IL-8 as potential biomarkers of endometrial cancer. 12, 0
- 113 Research progress on the circRNA-mediated regulation of tumor angiogenesis through ceRNA mechanisms (Review). **2022**, 49, 0
- 112 Tumor Microenvironment in Thymic Epithelial Tumors: A Narrative Review. **2022**, 14, 6082 1
- 111 The Biological Roles and Molecular Mechanisms of Long Non-Coding RNA MEG3 in the Hallmarks of Cancer. **2022**, 14, 6032 1
- 110 Preclinical Studies of Chiauranib Show It Inhibits Transformed Follicular Lymphoma through the VEGFR2/ERK/STAT3 Signaling Pathway. **2023**, 16, 15 1
- 109 Hypoxia-Inducible Factor-1: A Novel Therapeutic Target for the Management of Cancer, Drug Resistance, and Cancer-Related Pain. **2022**, 14, 6054 1
- 108 Clinical Effect of Lenvatinib Re-Administration after Transcatheter Arterial Chemoembolization in Patients with Intermediate Stage Hepatocellular Carcinoma. **2022**, 14, 6139 0

- 107 Molecular Features, Prognostic Value, and Cancer Immune Interactions of Angiogenesis-Related Genes in Ovarian Cancer. ○
- 106 Mechanical regulation of the early stages of angiogenesis. **2022**, 19, ○
- 105 ROS-responsive mechanically and electronically controllable conductive hydrogel sensor with NIR modulated photothermal therapy. **2022**, 140729 ○
- 104 Anticancer properties and mechanisms of botanical derivatives. **2022**, 100396 ○
- 103 Engineering chimeric antigen receptor T cells for solid tumour therapy. **2022**, 12, ○
- 102 Neomycin, but Not Neamine, Blocks Angiogenic Factor Induced Nitric Oxide Release through Inhibition of Akt Phosphorylation. **2022**, 23, 15277 ○
- 101 Resistance to Antiangiogenic Therapy in Hepatocellular Carcinoma: From Molecular Mechanisms to Clinical Impact. **2022**, 14, 6245 ○
- 100 Stromal cells in prostate cancer pathobiology: friends or foes? ○
- 99 Effects of second-generation H1-antihistamine drugs on angiogenesis in *in vivo* chick chorioallantoic membrane model. 1-4 ○
- 98 Prostate-specific membrane antigen expression predicts recurrence of papillary thyroid carcinoma after total thyroidectomy. **2022**, 22, ○
- 97 Hypoxia-responsive nanomaterials for tumor imaging and therapy. 12, ○
- 96 Head-up tilt does not enhance prostate tumor perfusion or oxygenation in young rats. **2022**, 10, ○
- 95 Nanoplatform for the Delivery of Topotecan in the Cancer Milieu: An Appraisal of its Therapeutic Efficacy. **2023**, 15, 65 ○
- 94 Constructing 3D In Vitro Models of Heterocellular Solid Tumors and Stromal Tissues Using Extrusion-Based Bioprinting. 1
- 93 Sesamin Attenuates VEGFA-Induced Angiogenesis via Inhibition of Src and FAK Signaling in Chick Chorioallantoic Membrane Model and Human Endothelial EA.hy926 Cells. **2023**, 11, 188 ○
- 92 Newly Emerging Concepts in Blood Vessel Growth: Recent Discovery of Endothelial Progenitor Cells and Their Function in Tissue Regeneration. **2003**, 51, 353-359 3
- 91 Investigation of the evolution of tumor-induced microvascular network under the inhibitory effect of anti-angiogenic factor, angiostatin: A mathematical study. **2023**, 20, 5448-5480 ○
- 90 Astrocytoma and IDH1-Wildtype Glioblastoma (GBM) Cells Colonize Tumor Vessels and Deploy Vascular Mimicry. ○

- 89 Robotic omentectomy in gynecologic oncology: surgical anatomy, indications, and a technical approach. ○
- 88 Genistein, a Soybean Isoflavone, Promotes Wound Healing by Enhancing Endothelial Progenitor Cell Mobilization in Rats with Hemorrhagic Shock. 2200236 ○
- 87 Negative impact of the microvascular area to tumor area ratio on the response to EGFR tyrosine kinase inhibitors in non-small cell lung cancer with EGFR mutation. ○
- 86 AngioMT: An in silico platform for digital sensing of oxygen transport through heterogenous microvascular networks. ○
- 85 Angiogenesis Invasion Assay to Study Endothelial Cell Invasion and Sprouting Behavior. **2023**, 345-364 ○
- 84 Tumor hypoxia: From basic knowledge to therapeutic implications. **2023**, 88, 172-186 ○
- 83 Isolation, Detection and Analysis of Circulating Tumour Cells: A Nanotechnological Bioscope. **2023**, 15, 280 ○
- 82 Targeting miR-5088-5p attenuates radioresistance by suppressing Slug. **2023**, 8, 164-173 ○
- 81 KPNA2 promotes angiogenesis by regulating STAT3 phosphorylation. **2022**, 20, ○
- 80 Theranostic Cancer Treatment Using Lentinan-Coated Selenium Nanoparticles and Label-Free CEST MRI. **2023**, 15, 120 ○
- 79 The Effects of Lapatinib and Trastuzumab in a Rat Model of Endometriosis. **2022**, 43, 556-563 ○
- 78 CURRENT STATE OF TECHNOLOGY FOR THERAPEUTIC TREATMENT OF BREAST CANCER. **2022**, 7-9 ○
- 77 Negative impact of the microvascular area to tumor area ratio on the response to EGFR-TKI in NSCLC with EGFR mutation. ○
- 76 Polymeric micelles-mediated photodynamic therapy. **2023**, 105-139 ○
- 75 Imaged-based modeling of vascular organization to evaluate anti-angiogenic therapy. ○
- 74 Exosomes as diagnostic and prognostic tools in prostate cancer. **2023**, 45-55 ○
- 73 Advances in cryostructures and their applications in biomedical and pharmaceutical products. ○
- 72 Biomaterials tools to modulate the tumour microenvironment in immunotherapy. 1

- 71 Antiangiogenic activity of the penicillin derivative TAP7f in melanoma. ○
- 70 Differential gene expression profiling in alveolar echinococcosis identifies potential biomarkers associated with angiogenesis. ○
- 69 Acrylate-based polymeric nanotheranostics. **2023**, 85-111 ○
- 68 Insight on the cellular and molecular basis of blood vessel formation: A specific focus on tumor targets and therapy. **2023**, 2, ○
- 67 The role of PLVAP in endothelial cells. ○
- 66 Vascular Progenitor Cells: From Cancer to Tissue Repair. **2023**, 12, 2399 1
- 65 Ten Years of Extracellular Matrix Proteomics: Accomplishments, Challenges, and Future Perspectives. **2023**, 22, 100528 1
- 64 Neo-vascularization-based therapeutic perspectives in advanced ovarian cancer. **2023**, 1878, 188888 ○
- 63 GPX4: The hub of lipid oxidation, ferroptosis, disease and treatment. **2023**, 1878, 188890 ○
- 62 Stimuli-responsive drug delivery systems triggered by intracellular or subcellular microenvironments. **2023**, 196, 114773 ○
- 61 Acute inflammatory reaction during anti-angiogenesis therapy combined with immunotherapy as a possible indicator of the therapeutic effect: Three case reports and literature review. 13, ○
- 60 From cells to organoids: The evolution of blood-brain barrier technology for modelling drug delivery in brain cancer. **2023**, 196, 114777 ○
- 59 Emergence of Nanohybrids in Hormonal Cancer-Targeted Therapy. **2022**, 71-88 ○
- 58 Long-term response to sintilimab, bevacizumab and chemotherapy in heavily pretreated microsatellite stable colon cancer. **2023**, 15, 127-133 ○
- 57 Intricate confrontation: Research progress and application potential of TRIM family proteins in tumor immune escape. **2023**, ○
- 56 Optical Coherence Tomography Structural and Functional Imaging. **2023**, 71-116 ○
- 55 Effective oxygen metabolism-based prognostic signature for colorectal cancer. 13, ○
- 54 Tumor microenvironment remodeling via targeted depletion of M2-like tumor-associated macrophages for cancer immunotherapy. **2023**, 160, 239-251 ○

- 53 Highly Porous Gas-Blown Hydrogels for Direct Cell Encapsulation with High Cell Viability. ○
- 52 Therapeutic Efficacy and Radiobiological Effects of Boric-Acid-Mediated BNCT in an Osteosarcoma-Bearing SD Rat Model. **2023**, 13, 514 ○
- 51 Fluorescence molecular optomic signatures improve identification of tumors in head and neck specimens. 5, ○
- 50 Cell Proteomic Footprinting: Advances in the Quality of Cellular and Cell-Derived Cancer Vaccines. **2023**, 15, 661 ○
- 49 Smart Thrombus-Self-Localizing UCST-Type Microcage. **2023**, 12, 320-324 ○
- 48 Expression profile of adrenomedullin and its specific receptors in liver tissues from patients with hepatocellular carcinoma and in tumorigenic cell line-secreted extracellular vesicles. **2023**, 243, 154383 ○
- 47 Self-organization of Long-lasting Human Endothelial Capillary Networks guided by DLP Bioprinting. ○
- 46 Advanced Biomaterials with Intrinsic Immunomodulation Effects for Cancer Immunotherapy. 2201404 ○
- 45 The Role of Reprogrammed Glucose Metabolism in Cancer. **2023**, 13, 345 1
- 44 The role of class IIa histone deacetylases in regulating endothelial function. 14, ○
- 43 Pan-Cancer Analysis Reveals Functional Similarity of Three lncRNAs across Multiple Tumors. **2023**, 24, 4796 ○
- 42 Development of a coupled modeling for tumor growth, angiogenesis, oxygen delivery, and phenotypic heterogeneity. ○
- 41 Antitumor Therapy Targeting the Tumor Microenvironment. **2023**, 2023, 1-16 ○
- 40 The implications and prospect of cuproptosis-related genes and copper transporters in cancer progression. 13, ○
- 39 Immune Compartments and Extracellular Matrix Crosstalk Involved in Tumor Dissemination. **2023**, 1-22 ○
- 38 Temporal phosphoproteomic analysis of VEGF-A signaling in HUVECs: an insight into early signaling events associated with angiogenesis. ○
- 37 The role of VEGF in cancer-induced angiogenesis and research progress of drugs targeting VEGF. **2023**, 175586 ○
- 36 Breast cancer (dual energy CT). ○

- 35 Dynamic image reconstruction to monitor tumor vascular perfusion in small animals using 3D photoacoustic computed-tomography imagers with rotating gantries. **2023**, ○
- 34 Chemokines and Chemokine Receptors in Cancer: An Update. **2023**, 1-30 ○
- 33 Angiogenesis Inhibitors in the Treatment of Cancer. **2023**, 1-33 ○
- 32 Cathepsin S Knockdown Suppresses Endothelial Inflammation, Angiogenesis, and Complement Protein Activity under Hyperglycemic Conditions In Vitro by Inhibiting NF- κ B Signaling. **2023**, 24, 5428 ○
- 31 The unfolding story of dying tumor cells during cancer treatment. 14, ○
- 30 Realizations of vascularized tissues: From in vitro platforms to in vivo grafts. **2023**, 4, 011308 ○
- 29 Image-based modeling of vascular organization to evaluate anti-angiogenic therapy. **2023**, 18, ○
- 28 Integration of pharmacoproteomic and computational approaches reveals the cellular signal transduction pathways affected by apatinib in gastric cancer cell lines. **2023**, 21, 2172-2187 ○
- 27 Correlation of fluorescence optomics method classification performance to varying expression level of epidermal growth factor receptor. **2023**, ○
- 26 Phthalides Isolated from the Endolichenic Arthrimum sp. EL000127 Exhibits Antiangiogenic Activity. **2023**, 8, 12548-12557 ○
- 25 Hydrogels: Promising Materials for 3D Printing Technology. **2023**, 9, 260 ○
- 24 The strange Microenvironment of Glioblastoma. **2023**, ○
- 23 The role of CXCL12 axis in pancreatic cancer: New biomarkers and potential targets. 13, ○
- 22 The diagnostic value of contrast-enhanced ultrasonography in breast ductal abnormalities. **2023**, 23, ○
- 21 Engineering Modular, Oxygen-Generating Microbeads for the In Situ Mitigation of Cellular Hypoxia. ○
- 20 Nanosecond Pulsed Electric Field Induces an Antitumor Effect in Triple-Negative Breast Cancer via CXCL9 Axis Dependence in Mice. **2023**, 15, 2076 ○
- 19 Transarterial chemoembolization (TACE) plus tyrosine kinase inhibitors versus TACE in patients with hepatocellular carcinoma: a systematic review and meta-analysis. **2023**, 21, ○
- 18 The participation of tumor residing pericytes in oral squamous cell carcinoma. **2023**, 13, ○

- 17 Nanostructures used in cancer imaging. **2023**, 169-191
- 16 Anticancer therapeutic potential of benzofuran scaffolds. **2023**, 13, 11096-11120
- 15 New Approaches and Recommendations for Risk-Adapted Breast Cancer Screening.
- 14 Molecular Ultrasound Imaging Depicts the Modulation of Tumor Angiogenesis by Acetylsalicylic Acid. **2023**, 24, 7060
- 13 Heparin Biofunctionalized Selenium Nanoparticles as Potential Antiangiogenic Chemotherapeutic Agents for Targeted Doxorubicin Delivery.
- 12 Novel strategies for cancer immunotherapy: counter-immunoediting therapy. **2023**, 16,
- 11 Hypoxia and Its Biological Implications for Cancer Therapy. **2023**, 1-18
- 10 Genetic Ablation and Pharmacological Blockade of Bradykinin B1 Receptor Unveiled a Detrimental Role for the Kinin System in Chagas Disease Cardiomyopathy. **2023**, 12, 2888
- 9 The generation, activation, and polarization of monocyte-derived macrophages in human malignancies. 14,
- 8 Intratumoral Microbiota-Host Interactions Shape the Variability of Lung Adenocarcinoma and Lung Squamous Cell Carcinoma in Recurrence and Metastasis.
- 7 A novel VEGFR inhibitor ZLF-095 with potent antitumor activity and low toxicity. **2023**, e15152
- 6 Basic Pathogenic Mechanisms and Epigenetic Players Promoted by Extracellular Vesicles in Vascular Damage. **2023**, 24, 7509
- 5 Combination of Two Photosensitisers in Anticancer, Antimicrobial and Upconversion Photodynamic Therapy. **2023**, 16, 613
- 4 Role of voltage-gated proton channel (Hv1) in cancer biology. 14,
- 3 Development and validation of an infrared-artificial intelligence software for breast cancer detection. 294-306
- 2 Perivascular localized cells commit erythropoiesis in PDGF-B-expressing solid tumors.
- 1 Danthron, an Anthraquinone Isolated from a Marine Fungus, Is a New Inhibitor of Angiogenesis Exhibiting Interesting Antitumor and Antioxidant Properties. **2023**, 12, 1101